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ABSTRACT 
 
DEVELOPMENT AND BIOAVAILABILITY/BIOEQUIVALENCE OF A FIXED-
DOSE COMBINATION ANTIRETROVIRAL RECONSTITUTABLE SUSPENSION 
INTENDED FOR PEDIATRICS 
 
 
By 
Fredrick Y. Esseku  
May 2011 
 
Dissertation supervised by Moji Christianah Adeyeye, Ph.D.  
This dissertation was designed to develop and assess bioavailability/ 
bioequivalence of age-appropriate fixed-dose combination granules of 
lamivudine/zidovudine/nevirapine as reconstitutable suspension for pediatrics for use in 
pediatric patients. The granules were developed via roller compaction process to improve 
granule flow characteristics, minimize segregation of the multi-component active 
pharmaceutical ingredients, and avoid introducing moisture into the formulation and 
thereby improve the stability of the product.  Optimization of the roller compaction 
process for the roll pressure and the ratio of the horizontal feed screw speed to the roll 
speed showed that these parameters had minimal effect on granule quality. Subsequently, 
a replicated 3
2 
factorial design was utilized to optimize the levels of the suspending agent 
 v 
(Avicel RC 591) and the anticaking agent (Aerosil 200). Modeling of the formulation 
viscosity through multiple regression analysis showed that the viscosity was a quadratic 
function of the concentration of Avicel RC 591.  An assessment of the stability of the 
granules for reconstitution under International Conference on Harmonization stability 
conditions at 40 
o
C/75 %RH and 30 
o
C/65 %RH indicated the granule formulation to be 
stable with an estimated shelf-life of not less than 6 months. Similarly, the evaluation of 
the chemical stability of the reconstituted suspension at 30 
o
C/65 %RH showed the 
suspension to be stable for several weeks. 
A clinical batch of the granules for reconstitution manufactured under Good 
Manufacturing Practices was tested for bioavailability and bioequivalence in a clinical 
study. A randomized single dose two-way complete crossover design in 24 healthy adult 
cohorts was performed, and the plasma samples from the subjects were analyzed by 
HPLC with UV detection. Non-compartmental pharmacokinetic analysis was performed 
to obtain the Cmax, AUCo-t, and AUCo-inf utilizing WinNonlin software. Analysis of 
variance of the formulation, period, sequence, and subject effects established the absence 
of any significant effects due to these parameters. Application of the two one-sided 
statistical tests using the Anderson-Hauck method showed that the 90 % confidence 
interval for the ratio of test/reference for various pharmacokinetic parameters was within 
82.6 – 124.5 % bioequivalence limits for all the three drugs. This confirms that the fixed-
dose combination granule for reconstitution was bioequivalent to the simultaneously 
administered single-entity reference products.  
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Chapter 1. Introduction 
 
1.1. Statement of the Problem 
The development of pediatric formulations is normally not a high priority during 
the development of new chemical entities into dosage forms for clinical use. This has 
resulted in a situation where there are several per oral formulations of drugs that can be 
used by the adult population for managing specific disease conditions without any 
corresponding age-appropriate formulations for pediatric patients. As a result of this, in 
some clinical settings, the adult formulations are extemporaneously reconstituted for 
administration to infants. This may take the form of breaking adult tablets or capsules and 
administering suitable fractions to the sick children. In addition, the solid oral dosage 
forms may be crushed and mixed with foods or dispersed in water and administered to 
children. This may result in inaccurate dosing manifested as over-dosing leading to 
severe toxicity. In contrast, children may be under-dosed when they do not receive the 
required amount of drug to effect the treatment. In the management of infectious diseases 
such as HIV/AIDS, malaria, and pneumonia, this could lead to worsening patient 
symptoms or the development of resistance by the pathogens. Age-appropriate pediatric 
formulations should be stable, palatable and be in a form that is convenient for 
administration to children. With a view to amend the Federal Food, Drug, and Cosmetic 
Act to improve the safety and efficacy of pharmaceuticals for children, the United States 
congress enacted the ―Best Pharmaceuticals for Children Act‖. Although the act has 
encouraged pharmaceutical manufacturers to develop more pediatric formulations, there 
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still remain a disproportionate number of adult formulations without the corresponding 
pediatric formulations.  
In the field on antiretroviral (ARV) therapy, several formulations are available for 
treating HIV/AIDS in adults without the age-appropriate formulations for pediatric 
patients. Effective treatment of HIV/AIDS requires highly active antiretroviral therapy 
(HAART). HAART consists of a combination of two or more drugs from at least two 
antiretroviral drug classes. The combination therapy provides adequate viral suppression 
in addition to providing mutational barrier to resistance, compared to monotherapy. Due 
to the advantages demonstrated by combination therapy, there has been a drive to 
formulate fixed-dose combination (FDC) therapies of drugs commonly co-administered 
together. The FDCs reduce the number and size of different formulations administered, 
reduce treatment cost, and improve compliance and treatment outcome. Furthermore, the 
Food and Drug Administration (FDA) recommends the development of FDCs where the 
evidence for safety and efficacy of the combined usage of the drugs in patients has been 
accumulated.  
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTI) 
which have been co-administered with nevirapine, a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) as combination therapy in HAART with demonstrated efficacy and 
safety. However, to date no per oral liquid formulation has been developed for use by 
children.  
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1.2. Hypothesis and Objectives 
 
It is hypothesized that a fixed-dose combination of lamivudine, zidovudine and 
nevirapine developed as granules for reconstitution will be stable under storage 
conditions recommended by the International Conference on Harmonization (ICH). 
Further, it is envisaged that the FDC developed will be bioequivalent to the 
simultaneously administered single-entity oral liquid reference products.  
Following from the hypothesis, the objectives for this dissertation are  
1. To develop a fixed-dose combination of lamivudine, zidovudine and nevirapine, 
formulated as granules for reconstitution, using dry granulation roller compaction 
technique. The granules for reconstitution formulation will be optimized and 
characterized.   
2. To evaluate the stability of the optimized formulation under accelerated and long-
term stability storage conditions.  
3. To conduct a pilot bioequivalence study between generic and reference products 
of lamivudine 150 mg/zidovudine 300 mg tablets. This will be done in order to 
determine the suitability of the international clinical site for further study. 
4. To perform bioavailability/bioequivalence (Phase I) studies on the developed 
granules for reconstitution in comparison to a combination of Epivir
®
 
(lamivudine) oral solution, Retrovir
®
 (zidovudine) syrup and Viramune
®
 
(nevirapine) suspension as reference products.   
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If successful, the fixed-dose combination formulation developed could be employed for 
the treatment of HIV/AIDS in treatment naïve children in resource poor settings. This 
could facilitate patient compliance with concomitant improved therapeutic outcome. 
 
 
1.3 Literature Review 
 
1.3.1 Antiretroviral Therapy  
1.3.1.1   Global AIDS 
Acquired immunodeficiency syndrome (AIDS) is caused by the human 
immunodeficiency virus (HIV). There are approximately a total of 33.4 million people 
living with HIV worldwide.
1
 Globally, the HIV epidemic seems to have stabilized around 
this number in the last couple of years. This is due to increased education about the 
epidemic and the implementation of intervention policies to prevent, test, treat and care 
for those affected by the disease. The World Health Organization (WHO) in recent times 
recommended that ―all adults and adolescents, including pregnant women, with HIV 
infection and a CD4 count of or below 350 cells/mm
3
 should be started on antiretroviral 
therapy, regardless of whether or not they have clinical symptoms‖.1 This has caused an 
apparent increase in the number of people living with HIV/AIDS who require treatment.  
In December 2009, it was estimated that antiretroviral therapy coverage among children 
less than 15 years of age was 28%.
1
 The majority of these children live in resource poor 
settings in sub-Saharan Africa. Previous pharmacokinetic studies by Ellis et al in 
Zambian and Malawi children on FDC adult ARV tablets demonstrated that some 
   5 
 
children do not achieve optimal concentration of nevirapine in plasma.
2
 Subsequent to 
this, Kashuba and Swanstrom also demonstrated lower lamivudine exposures and 
subtherapeutic nevirapine level in Malawian children receiving scored triple combination 
FDC ARV tablets.
3
 There is thus a need to provide age-appropriate formulations of 
antiretroviral drugs to enhance access to treatment, particularly for use in infants and 
young children. The United States President’s Emergency Plan for AIDS Relief 
(PEPFAR), is providing funding for the scale-up of HIV/AIDS services worldwide to the 
tune of $5.5 billion annually.
1, 4
  This fund could be accessed for providing antiretroviral 
therapy for resource poor settings.  
 
1.3.1.2 Life Cycle of HIV  
The life cycle of HIV occurs in the body of the infected host. The envelope 
protein gp160 regulates the tropism
5
 of HIV-1 and gp41 controls fusion of the virus lipid 
bi-layer with that of the host cell. The virus binds to CD4 receptors on macrophages and 
lymphocytes, and also binds to CCR5 or CXCR4 co-receptors on macrophages and T-
lymphocytes (Figure 1.1). Upon fusion of the virus with the host cell, viral RNA is 
released into the host cytoplasm and undergoes replication to form RNA-DNA duplex. 
This duplex is short lived as viral RNA is degraded by RNase H to allow the formation of 
full length double stranded DNA copy of the virus, a process catalyzed by reverse 
transcriptase. The DNA of the virus is transported into the nucleus where it is integrated 
into host chromosome by viral integrase in a random location. Viral RNA and structural 
proteins are formed in the cytoplasm. The structural proteins assemble around viral RNA 
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to form a nucleocapsid. Reverse transcriptase enzyme, other proteins, and cell membrane 
are assembled and bud to form a new enveloped HIV particle.  
The currently available drugs for treating HIV infection target potential sites for 
disruption of the life cycle to inhibit replication including 1. site of attachment to 
receptors and fusion with host cell, 2. reverse transcription, 3. integration, 4. 
transcription, 5. translation and 6. release of the viral particle (Fig 1.1). The antiretroviral 
agents co-administered in HAART are selected from these drug classes. 
 
 
 
Fig 1.1 The life cycle of HIV.
6
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1.3.1.3 Rationale for Selecting the Antiretroviral Drug Combination 
There are about 25 antiretroviral compounds licensed by the FDA for the 
treatment of HIV/AIDS. These approved drugs belong to the following classes: CCR-5 
co-receptor antagonist, fusion inhibitors, nucleoside reverse transcriptase inhibitors 
(NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase strand 
transfer inhibitors and protease inhibitors (PI).
7
 The use of antiretrovirals in pediatric 
patients is a rapidly evolving science, with frequent changes in the composition of the 
main first-line and second-line antiretroviral therapy. The backbone of antiretroviral 
regimen in treatment naïve children is 2 NRTIs plus 1 NNRTI or 2 NRTIs plus 1 protease 
inhibitor.
8, 9
 The combination of AZT plus 3TC plus Nev (2 NRTIs +1 NNRTI) has been 
extensively used in adults and children and can be administered to children below 3 years 
of age.
10-13
  
In vitro studies of the three-drug combination in peripheral blood mononuclear 
cells (PBMC) utilizing isobologram and the median-effect equation has been used to 
calculate the combination index for AZT/3TC/Nev.
14
  The combination index method 
developed by Chou and Talalay, based on the median-effect principle of the law of mass-
action, may be used to quantitate synergistic, antagonistic and additive effect for a drug 
combination.
15
 Combination indices of <1, 1 and >1, indicate synergism, additive effect, 
and antagonism respectively. The combination index of percent of HIV-1 inhibition by 
AZT/3TC/Nev was less than 1, indicating synergistic activity.
14
  Moreover, transmitted 
HIV drug resistance is low which makes these older drugs still effective in the treatment 
naïve children:
1
  in children, HIV/AIDS infection is primarily due to mother-to-child 
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transmission. Furthermore, the Pediatric Antiretroviral Working Group (PAWG) of 
World Health Organization has recommended the combination regimen of AZT plus 3TC 
plus Nev [60 + 30 + 50 mg] as one of several ideal dosing strengths for priority 
antiretroviral products.
16 
 The combination regimen of AZT plus 3TC plus Nev [60 + 30 
+ 50 mg] was thus selected for development into the granules for reconstitution. It is 
expected that as pharmacokinetic studies of newer antiretroviral drugs are performed in 
children, the availability of clinical data will facilitate the formulation of new pediatric 
FDCs. See page 158 for further discussion. 
 
 
1.3.1.4 Biopharmaceutics of the Antiretroviral Drugs 
Lamivudine A (Fig. 1.2) is the (-)-enantiomer of 2’3’-dideoxy-3’-thiocytidine 
(3TC), a cytosine analog acting as a nucleoside reverse transcriptase inhibitor. The 2R 
cis(-)-enantiomer of 3TC is more potent and less toxic than the racemic mixture and it is 
the active pharmaceutical ingredient in drug products. Following oral administration, it is 
rapidly absorbed with an oral bioavailability of 86% (Table 1.1) and has a low plasma 
protein binding affinity. The phosphorylated (-)-enantiomer is more resistant to cleavage 
from nascent RNA/DNA duplexes by cellular 3’-5’ exonucleases than the (+)-enantiomer 
and may explain the higher potency.
5
 Upon entering cells by passive diffusion, 3TC is 
phosphorylated by deoxycytidine kinase to the monophosphate and subsequently by 
deoxycytidine monophosphate kinase and nucleoside diphosphate kinase to form 
lamivudine 5’-triphosphate. The intracellular half-life of lamivudine 5’-triphosphate is 12 
to 18 hours.  When the active anabolite is incorporated into HIV DNA, it acts as a 
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competitive inhibitor of reverse transcriptase to cause chain termination. Lamivudine is 
eliminated primarily as the unchanged drug in the urine. Lamivudine shows low affinity 
for human DNA polymerases, and thus has low toxicity to humans. Severe side effects 
associated with 3TC use are lactic acidosis and severe hepatomegaly.  
 
 
 
Fig.1.2 Chemical Structures of Lamivudine (A), Zidovudine (B) and Nevirapine (C). 
 
Zidovudine B is 3-azido-2,3-dideoxythymidine (AZT), a thymidine analog. 
Intracellular zidovudine is phosphorylated by thymidine kinase to zidovudine 5’-
monophosphate, which in turn is phosphorylated by thymidylate kinase to the 
diphosphate and by nucleoside diphosphate kinase to zidovudine 5’-triphosphate, the 
active form with intracellular half of 3 to 4 hours.  Because the triphosphate lacks a 3’-
hydroxyl group, incorporation by reverse transcriptase into nascent DNA terminates the 
proviral DNA chain. Zidovudine undergoes rapid first pass metabolism to form 5’-
glucuronyl zidovudine and bioavailability is about 64% with plasma protein binding of 
approximately 25 %. The absorption is slowed by the presence of food, but there is no 
alteration in the area under the curve (AUC).
17
 The penetration of zidovudine into the 
cerebrospinal fluid is a slow process and reaches an AUC of about 75% of the plasma 
         A            B        C 
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level.
18
 Zidovudine is mainly excreted in the urine as 14 – 20 % of the unchanged drug 
and 74% of the glucuronide metabolite: less than 1% of an administered dose is 
internalized in cells as the active triphosphate.
19
 Side effects associated with zidovudine 
use are neutropenia, anemia, myopathy, lactic acidosis and hepatomegaly.  
 
Table 1.1. Pharmacokinetic parameters in adults 
Parameter  Lam Zid Nev 
Oral bioavailability (%) 86±16 64±10 >90 
App. vol. distribution (L/kg) 1.3±0.4 1.6±0.6 1.21±0.09 
Plasma protein binding (%)  <36 <38 60 
Elimination half-life (hr) 5 – 7  0.5 – 3  25 – 30  
Food effect no no no 
 
The chemical name of nevirapine C is 11-cyclopropyl-4-methyl-5,11-dihydro-6H-
dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one. Nevirapine, an NNRTI is a non-competitive 
inhibitor that binds to an allosteric site on the HIV-1 to induce a conformational change 
at the active site and disrupt catalytic activity. Nevirapine is active against HIV-1 but not 
HIV-2 and resistance to the drug develops rapidly because its site of action is not 
essential for enzymatic action. It is rapidly absorbed; oral bioavailability is 90 % with no 
food effect. Nevirapine induces cytochrome CYP3A4 enzyme, a member of the 
cytochrome P450 mixed-function oxidase system, and a major enzyme in oxidation of 
xenobiotics in the body.
5
  The autoinduction of CYP3A4 enzyme in turn results in 
induction of nevirapine metabolism thus reducing elimination half-life from 45 hours to 
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25-30 hours after two weeks. It is eliminated primarily by oxidative metabolism by 
cytochrome CYP3A4 and CYP2B6 enzymes.
20
  Less than 3% of parent drug is 
eliminated unchanged in the urine. In animal studies, the hydroxylated metabolites 
formed were 2-, 3-, 8-, and 12-hydroxynevirapine.
21
 4-carboxynevirapine, formed by 
secondary oxidation of 12-hydroxynevirapine, was a major urinary metabolite. 
Nevirapine has been linked with hypersensitivity reactions which present 
clinically as severe and life threatening idiosyncratic skin rash. This dose-dependent rash 
is more common in females than males. Shenton et al. have observed similar 
characteristic rashes in rats and humans suggesting a common mechanistic pathway.
22-24
 
Immunohistochemistry analysis showed macrophage infiltration and ICAM-1 expression 
in the ears of treated rats as early as day 7 of treatment.
25
 Investigations are underway to 
determine whether nevirapine or its reactive quinone methide metabolite (Fig 1.3) is 
responsible for the idiosyncrasy.
25, 26
 The quinone methide is reactive because breaking of 
the double bond at C9 and formation of the double in the pyridine ring restores 
aromaticity and stability to the structure. 
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Fig 1.3 Postulated mechanism for formation of reactive nevirapine metabolite 
implicated in rash formation due to hypersensitivity reaction.
26
  
 
In humans, the rash may develop 2-3 weeks after initiating nevirapine therapy. Further, 
CD4
+
 T cells are essential to the development of the rash, and their depletion confers 
partial protective status to the patient. The low CD4
+
 T cells protective effect is of 
interest in HIV/AIDS patients who typically present with depleted CD4
+
 T cells levels. 
Pruritus may accompany the skin rash. Nevirapine may also cause hepatotoxicity when 
administered under normal prescribing conditions. Even though these severe reactions are 
rare, there is a need to exercise extreme caution in initiating therapy with nevirapine. Due 
to the hypersensitivity reaction, nevirapine therapy is initiated by a lead-in dose daily for 
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two weeks to trigger the development of tolerance in patients and thus minimize the risk 
of the idiosyncratic rash. 
 
1.3.1.5 Fixed-Dose Combination Formulation 
The high pill burden, frequency of administration, and co-administration of other 
medications for opportunistic infections do not encourage drug intake by people living 
with HIV/AIDS. For instance, lamivudine solution, zidovudine syrup and nevirapine 
suspension are given to children with HIV, and this makes the volume of the doses 
administered large.  There are no fixed-dose combinations available for pediatrics. Fixed-
dose combination (FDC) therapy may enhance the therapeutic outcome of antiretroviral 
therapy through a combination of factors. The FDC reduces the number and size of 
different formulations administered with a resultant reduction in the cost of the drugs 
administered. In addition, FDCs reduce the propensity for drug-excipient incompatibility 
and thereby enhance compliance and success of therapy. The FDA released a Guidance 
document on fixed dose combination and co-packaged products to promote the 
development of FDCs.
27
 A major provision of this document was the waiver to conduct 
clinical studies for safety and efficacy for the FDCs since the clinical evidence for the 
safety and efficacy of the specific combination is available prior to the FDC formulation 
development. However, there is a requirement to perform bioequivalence studies to 
determine the bioavailability of the FDC product. 
Fixed-dose combinations have some limitations due to the fixed ratio of the drugs. 
FDCs cannot be used for individualized dosing. For instance, where individuals or sub-
populations show higher or lower nevirapine metabolism due to varying CYP3A4 or 
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CYP2B6 levels, the dose of nevirapine cannot be adjusted.  Consequently, prior to start 
of FDC, patients are usually given two-weeks of nevirapine lead-in dose to minimize the 
risk of developing hypersensitivity reaction, but the FDC product cannot be used for that 
purpose. Correcting for the dose of nevirapine for the lead-in period may result in under-
dosing of the other drugs in the combination. 
 
 
1.3.2 Granules for Reconstitution into Suspension 
The goal of the project is to formulate a fixed-dose combination granule for 
reconstitution into suspension which contains lamivudine/zidovudine/nevirapine 30 
mg/60 mg/50 mg per 5 mL.  The rationale for the choice of dosage form is to facilitate 
the titration of doses to meet individual pediatric patient requirements. Unlike oral solid 
dosage forms, the dose of oral liquid dosage forms can be tailored to meet the needs of 
patients, particularly children. Granule for reconstitution into suspension form is a type of 
oral liquid dosage form containing a coarse dispersion of the API in aqueous medium. 
The particle size range of the APIs is greater than 0.5 μm.28 This formulation may be 
employed when the API has poor solubility or stability in water. Some desirable 
properties of a reconstitutable suspension are a fast and simple reconstitution, slow 
sedimentation rate to ensure uniform dose dispensing, an appropriate viscosity for easy 
pouring and redispersion and a flocculated system to ensure ease of redispersion. The 
suspending agent used should be hydrated quickly by hand shaking to ensure rapid 
reconstitution.
29, 30
 The granules for reconstitution could be made by roller compaction 
process to prevent the segregation of the drugs from the excipients. In addition, the roller 
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compaction process will avoid the introduction of moisture into the product: moisture 
could compromise the stability of the formulation. 
 
 
1.3.2.1 Physicochemical Properties of the Drugs  
The physicochemical properties of the drug substances essential to formulation 
are solubility, dissolution, partition coefficient and pKa. The varied physicochemical 
properties (Table 1.2) could pose challenges in a fixed dose combination product.  
 
Table 1.2 Physicochemical properties of the drug substances
31
 
 
 Parameter  Lamivudine  Zidovudine Nevirapine  
Empirical formula C8H11N3O3S C10H13N5O4 C15H14N4O 
  CAS Number 134678-17-4 30516-87-1 129618-40-2 
Molecular weight 229.26 267.2 266.3 
Melting temp (
o
C) 178 122 247 
Aqueous Solubility (mg/mL) 70 20 0.1 
  pKa 4.3 9.68 2.8  
  Log P 0.06 0.09 2.05 
 
Lamivudine and zidovudine are biopharmaceutics classification system (BCS) 
Class 1 compounds with high solubility and high permeability whereas nevirapine is a 
BCS class II compound with low solubility but high permeability.
31
 Zidovudine which 
exists as anhydrous crystals has a solubility of 20 mg/mL. This solubility exceeds the 12 
mg/mL of drug present in the proposed formulation. Therefore zidovudine will be 
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completely dissolved in solution in the reconstituted suspension. Lamivudine anhydrous, 
hemihydrate and 0.2 hydrate have been reported in the literature. The 0.2 hydrate has one 
mole of water per five moles of lamivudine.
32-34
 The proposed dose of 6 mg/mL of 
lamivudine is far below the solubility (70 mg/mL) of the anhydrous and hydrated forms 
of the drug
33
 and thus the drug will be in solution in the reconstituted product. However, 
there is a need to characterize and control the physical form of the drug in the granules 
for reconstitution.
35
  
Nevirapine presents as anhydrous and pseudo-polymorphic hemihydrate forms. 
The two forms have different solubility, dissolution rates and stability.
36, 37
 The 
anhydrous nevirapine has higher solubility in water than the hemihydrate. Marketed 
nevirapine (Viramune®) tablets contain the anhydrous crystals while nevirapine 
(Viramune®) suspension contains the hemihydrate crystals. Angel et al. reported that the 
when the anhydrous form was formulated as aqueous suspension, it was converted into 
the micrometer-sized hemihydrate crystals. The degree of conversion and the rate of 
growth of the hemihydrate crystals were dependent on the temperature and time.
38
 
Interestingly, the hemihydrate crystals could not be detected by optical microscopy or 
Fourier transform infrared (FT-IR) spectroscopy but by low voltage scanning electron 
microscopy (LVSEM) as a surface catalyzed nucleation. Due to the lower solubility of 
the hemihydrate crystals, the dissolution rate of the suspension was negatively impacted. 
Further, crystal growth in a suspension promotes sedimentation and may result in caking 
to form a non-redispersible sediment.
39
 This is an unacceptable phenomenon as it leads to 
an untoward physical appearance. However, formulating the anhydrous nevirapine as 
granules for reconstitution significantly reduces the contact time in aqueous medium and 
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the probability of conversion to the hydrate. In addition, the presence of polyhydric 
alcohols (polyols) in the medium could adsorb onto the surfaces of crystals to prevent 
nucleation and the conversion of the crystal into hydrates.
40, 41
  Polyols commonly used as 
excipients in suspensions such as xylitol, mannitol and sorbitol have been shown to 
possess the ability to inhibit recrystallization. Furthermore, the presence of polymers 
which adsorb to the crystal surface by specific interaction with the functional groups can 
inhibit crystal growth. For example, Ziller and Rupprecht successfully inhibited the 
growth of acetaminophen suspension by incorporating a small quantity of 
polyvinylpyrrolidone (PVP).
39
 Thus, formulation strategies could be adopted to eliminate 
or minimize recrystallization and crystal growth. 
Compounds are generally more chemically stable in water as dispersed solid 
particles than when dissolved. The high solubility of lamivudine and zidovudine could 
lead to a faster rate of degradation in solution since all the three drugs are susceptible to 
hydrolysis. By and large, these challenges could adversely impact the safety, efficacy, 
performance and stability of the drug product.  
 
 1.3.2.2 Drug Substance and Excipient Interaction 
In multi-component systems such as fixed dose combination (FDC) drug 
formulations, the presence of drug substances and several excipients within the same 
formulation enhances contact among the different components and increase the 
propensity for interactions, which could lead to incompatibility. Primarily, scientific 
evaluation of the chemistry and physical properties of formulation components provides 
the most efficient tool in selecting compatible formulation components to prevent 
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incompatibility.  In addition, drug-drug and drug-excipient compatibility testing, another 
tool for selecting compatible formulation components can reveal potential problems 
which otherwise may not be predicted during initial physicochemical evaluation.
42, 43
  For 
example, the presence of unknown residues (impurities) in drug substances and 
excipients may cause interactions that may be detected by compatibility testing but 
otherwise couldn’t have been predicted by basic structure-related scientific evaluation. 
Consequently, formulation development requires systematic solid-state or liquid-state 
characterization during preformulation to allow specifications to be set for the 
formulation components in line with International Conference on Harmonization (ICH) 
tripartite guideline Q6A ―Specifications: Test Procedures and Acceptance Criteria for 
New Drug Substances and New Drug Products: Chemical Substances‖.35  The goal is to 
ensure the safety, efficacy, performance, and stability of the drug product. 
Drug-drug, drug-excipient, or excipient-excipient interactions could impact 
material properties including hydration, dehydration, crystal growth, dispersibility, 
dissolution, powder flow, physical appearance of the dosage form and chemical 
degradation.
44, 45
 Consequently, the drug substance and excipients are characterized for 
melting temperature, solubility, pKa, particle size, particle morphology, polymorphism, 
and hydration state.
46, 47
  
Residual moisture can compromise stability of the formulation by facilitating 
molecular mobility and reactivity. However, in the solid state, the bipyramidal 
lamivudine anhydrous did not transform into acicular lamivudine hydrate when exposed 
up to 95 % relative humidity.
33
 A similar observation has been made for nevirapine 
anhydrous in the solid state.  The temperature and time for the drug-excipient study are 
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also critical as they influence the rate and extent of reactivity of the components. In 
addition, roller compaction and milling processes could induce dehydration or 
polymorphic phase conversions. This could mean that when hygroscopic excipients 
mixed with these drugs absorb atmospheric moisture, the minimal water absorbed may 
not cause the drugs to become hydrates.  
Lamivudine, a primary amine, may undergo Maillard reaction. The Maillard 
reaction occurs between primary or secondary amines and the carbonyl groups on 
reducing carbohydrates.
48
  The implication is that bulk sweeteners such as maltose which 
are reducing carbohydrates cannot be used to formulate lamivudine reconstitutable 
suspension.    To date, no interactions have been reported between lamivudine, nevirapine 
and zidovudine in FDC formulations. Interestingly, acesulfame potassium, employed as 
sweetening agent in AZT/3TC/Nev tablets reacted with AZT to form  1-[5-
hydroxymethyl-4-(5-methyl-2,3-dihydro-[1,2,3]triazole-1-yl)-tetrahydrofuran-2-yl]-5-
methyl-1 H-pyrimidine-2,4-(1H,3H)dione.
49
 Hence, drug-excipient interaction studies 
would be performed to determine the compatibility of the formulation components. 
 
1.3.2.3 Solid State Characterization  
Powder X-ray diffractometry, Fourier transform infrared spectroscopy, 
differential scanning calorimetry and thermogravimetry are some analytical techniques 
used for solid state characterization of drug-excipient interaction studies and stability 
testing of the formulation.
50-54
 These analytical techniques are used to characterize 
starting materials in order to determine the polymorphic or hydration form as well as 
determine whether there are any solid state transformations due to processing. The 
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techniques are also used to rule out drug-excipient incompatibility or for excipients 
screening. The impact of the interaction on compatibility and stability could be evaluated 
by potency and dissolution testing using HPLC.  
 
1.3.2.3.1 Powder X-ray Diffraction (PXRD)   
 The different crystal forms of the drugs have different degrees of solubility and 
this could result in varying dissolution rates with unpredictable bioavailability profiles. 
This requires the characterization of the drug substances and the drug product to be able 
to relate the dissolution and bioavailability to the physical form of the drug.  Hence, the 
solid-state characterization techniques employed should be applicable to the analysis of 
the drugs in pure form and in the presence of other formulation components. That is, the 
method(s) employed should have the selectivity to identify the crystal form in a mixture 
and the sensitivity to detect varying levels of the drug. Powder X-ray diffractometry 
(PXRD) is a solid-state analytical technique that meets these requirements.  
Powder X-ray diffractometry provides diffraction patterns unique to the crystal 
structure of the molecule.  
 
   21 
 
 
 
Fig 1.4 Diffraction of light by an optical grating 
 
 
A crystal may be considered as being made of planes of unit cells (Fig 1.4) and the planes 
diffract x-rays according to Bragg’s law (Eq. 1.1) which is defined as  
2dsinθ = nλ     (Eq. 1.1) 
            where  θ = Bragg angle 
λ = wavelength  
d = distance between adjacent planes 
n = integer 
When Bragg’s law is fulfilled, the diffracted rays are in phase and there is constructive 
interference. The size and shape of the unit cell determine the d-space while the position 
of the various atoms in the cell and their atomic number determine the scattering power. 
These properties define the powder diffraction pattern of a crystalline material.
55
 Thus 
peak position and peak intensity are used to characterize crystals.  In a solid mixture, the 
powder diffraction pattern of each crystalline phase is produced independently. This 
implies that in a mixture of powders, the powder diffraction patterns of the individual 
components will be summed up in the diffraction pattern obtained. The peak intensities 
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and positions and any changes thereof may be used for substance identification, 
polymorphic phase identification and transformations, and to study interactions. For 
instance, PXRD may be used to analyze ribbons or granules produced by roller 
compaction to determine whether the mechanical stress applied by the rolls induced any 
phase changes. 
 
1.3.2.3.2 Fourier Transform Infrared Spectroscopy 
 Molecular species may undergo transitions from one rotational or vibrational 
energy level to another by absorbing infrared (IR) radiation. Vibration motions are of two 
types: bending and stretching.  Bending vibrations involve a change in the angle between 
two bonds whereas stretching vibrations involve changes in the interatomic distances 
along the axis of the bond between atoms.
56
 In heteronuclear molecules, the vibrations or 
rotations results in fluctuating dipole moment. When the vibration frequency matches the 
frequency of the IR radiation, the IR radiation is absorbed and the amplitude of molecular 
vibration changes. Thus the molecule can absorb the IR radiation only if there is a net 
change in the dipole moment as it rotates or vibrates.
56
 Hence, the IR absorption spectrum 
of a molecule is unique to the molecular structure and the environment in which it occurs, 
making it a useful tool for the identification of compounds.  
The mid-IR spectral region of wavenumbers 4000 to 200 cm
-1
 is applied in 
Fourier-Transform infrared (FTIR) spectroscopy instruments in the identification of 
pharmaceutical compounds. The FTIR instruments provide (i) greater signal-to-noise 
ratio due to a large radiant power reaching the detector, (ii) high resolving power and 
wavelength reproducibility, and (iii) short data acquisition times since all signals reach 
   23 
 
the detector simultaneously.
56
 The IR spectrum consists of two major regions: the group 
frequency region and the fingerprint region. The group frequency region (3600 to 1250 
cm
-1
) represents the approximate frequency of the functional groups in a molecule. The 
fingerprint region (120 to 600 cm
-1
) represents the general absorption maxima of the 
compound. By combining the data from the two regions, the general structure and 
functional groups in a compound can be identified.  Frequently, the absorption spectrum 
of the unknown sample is compared to the spectra of the reference sample or a reference 
chart.  
 
1.3.2.3.3     Differential Scanning Calorimetry (DSC)   
Thermal analytical techniques provide yet another means of measuring the 
physical properties of pharmaceutical substances. Of particular interest in the analysis of 
small sample quantities is differential scanning calorimetry. Differential scanning 
calorimetry is the measurement of difference in energy input to a sample and a reference 
to keep them at the same temperature as a function of time and temperature. This may be 
used to obtain the melting temperature, glass transition temperature, and enthalpy of 
fusion or crystallization.
57
 These parameters can contribute towards the determination of 
the drug substance’s purity and the extent of solid-solid interaction.  
At constant pressure, the energy exchanged between a system and its environment 
is the enthalpy change (dH) given by  
          VPUH     (Eq. 1.2) 
For solids and liquids, the volume change is negligible and dV approximates to zero. 
Thus         pqpUH  )(         (Eq. 1.3) 
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where dU is sum of internal energy of the system, PdV is change in amount of work and 
dq is heat flow. For temperature change from T1 to T2, the heat exchange entering or 
leaving the system is equal to enthalpy change: 
 
          (Eq. 1.4) 
 
where H is enthalpy (J mol
-1
), Cp is the heat capacity (JK
-1
 mol
-1
), T is temperature (K) 
and t is time. Thus the total heat flow in the DSC is the sum of that related to the heat 
capacity and the kinetic response f(T,t) of the system.
56
 The heat capacity is the amount 
of energy required to raise the temperature of a material by 1
o
C.
58
 For a mixture of 
substances, the melting point of each substance and enthalpy of fusion are usually 
depressed due to the fact that melting process is a colligative property.  Thus the enthalpy 
of fusion of the mixture may approximate the sum of the fusion enthalpies of the 
individual components. Some authors have used the differences between the 
experimental and predicted enthalpies of fusion (corrected for temperature) to describe 
the extent of interaction,
59
 with the assumption that the observed differences are due to 
non-bonded interactions.  
 
1.3.2.4 Preparation of Reconstitutable Suspension 
 Multiparticulate solids for reconstitution into oral suspension typically come as a 
finished formulation (powder or granules) requiring only the addition of water and 
agitation prior to dispensing. The solids may consists of the active pharmaceutical 
 tTf
dt
dT
C
dt
dH
p ,
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ingredient(s); a suspending agent to keep the insoluble drug particles suspended; 
anticaking agent to prevent the granules from forming aggregates; preservatives to 
maintain the microbial integrity of the product; sweetening and flavoring agents to 
enhance the taste and flavor of the reconstituted product. The granules may be prepared 
by direct blending, wet granulation or dry granulation (roller compaction or slugging) 
processes depending on the bulk properties of the formulation components. 
 
 
1.3.2.5 Dry Granulation Processing – Roller Compaction 
 Roller compaction is a dry granulation technology employed to improve flow 
characteristics, minimize segregation of components, increase particle size and bulk 
density of powders. The product contacting parts of the roller compactor are the feed 
hopper, feed screws (horizontal, vertical, tapered, angular), and the rolls. As the powder 
from the hopper is conveyed by the feed screw mechanism to the slip zone, the powder 
slips onto the roll surface (Fig. 1.5) where the material may experience deaeration and 
elastic deformation.
60
 Rotation of the rolls transfers the material to the nip zone. In this 
region, the powder particles undergo rearrangement, densification and plastic 
deformation.
61
 The material moves at the same speed as the rolls and as it passes through 
the region of maximum pressure between the rolls, it is compacted into a sheet called a 
ribbon or briquette. The nip angle is a function of both the powder properties such as 
compressibility and flow as well as the instrument parameters including feeding 
mechanism, roll dimensions and surface. As the compacted sheet enters the release zone, 
it may expand due to elastic recovery. The extent of elastic recovery is determined by the 
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material properties, deaeration, roll diameter and speed. Recent experiments to validate 
the Johanson
62
 rolling theory of granular solids showed that the theory predicted well the 
effect of material properties on peak pressure and nip angle.
63
 However, at higher roll 
speed, the model could not adequately predict due to air entrainment. 
Milling of the sheets leads to the formation of more uniformly sized granules with 
improved flow properties.
64
 Furthermore, the granules are composites of the individual 
powders constituting the powder blend and this minimizes or prevents segregation. 
Ribbons or the granules made from the ribbons may be characterized by porosity, particle 
size, tensile strength, density and solid fraction.
65, 66
 Dry granulation by roller compaction 
is thus a useful process for making granules for reconstitution into suspension. 
 
 
 
Fig 1.5 The zones in a roller compactor. Adapted from reference 
67
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The instrument parameters manipulated to produce variable ribbon properties are 
roll pressure, roll speed, feed screw speed, roll gap and dwell time. By modeling the 
friability of lactose ribbons formed under variable instrument parameters, it was 
established that the relative importance of these parameters in decreasing order was roll 
pressure, roll speed and horizontal screw speed.
68
 Higher roll pressures produce dense 
compacts and larger granules due to stronger interparticle bonding during compaction. 
The roll speed is inversely related to the dwell time, the dwell time being the period 
required for particle rearrangement and bonding. By reducing the roll speed, the dwell 
time increases for stronger bonding to occur leading to stronger compacts.  The roll gap 
determines the thickness of the compacted sheets. For a given roll pressure and speed, 
low feed rate forms thinner ribbons while high feed rates form thicker ribbons. Finally, 
the ratio of the feeding screw speed to roller speed determines the material throughput. 
The feeding screw transfers materials to the slip zone whereas the rollers transport the 
powder material from the slip zone to the nip zone. Therefore the ratio of roller speed to 
feed screw speed is critical in forming ribbons of uniform density. The flow of the 
granules and the distribution of the APIs in the granules may be assessed to establish 
whether the roller compaction process achieved the stated objectives. 
 
1.3.2.6 Reconstitution of Granules for Coarse Suspension and Considerations 
The final blend of the granules for reconstitution is usually dispersed in water to 
form a coarse suspension prior to dispensing to the patient. Dispersed particles in a 
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suspension, may experience diffusion via Brownian motion if the particle sizes are in the 
colloidal and molecular size ranges.   
Brownian Motion: Brownian motion can affect the reconstitution and sedimentation rate 
of suspensions. Diffusion is dependent on Brownian motion, and diffusion coefficient has 
an inverse relationship with the radius of the particle. Thus, Brownian motion and 
convective currents can cause small particles (less than 0.5 μm) to remain dispersed 
continuously. The Einstein equation (Eq. 1.5) for translational Brownian motion 
28
 is 
given as 
 
                   Dtx 2                    Eq. 1.5  
where x is the mean displacement in direction x in time t and D is the diffusion 
coefficient. The diffusion coefficient, D (cm
2
/s) given by the Stokes-Einstein equation 
(Eq. 1.6) is a measure of the mobility of a molecule or particle in a liquid.
28
  
 
                            
rN
RT
D
6
                       Eq. 1.6 
R is gas constant, T is absolute temperature (K), r is the radius of a spherical particle 
(cm), N is the Avogadro’s number, and  is the viscosity of the medium (Poise). As the 
particle size becomes greater than 0.5 μm, as in coarse suspensions, Brownian motion is 
no longer able to keep the particles suspended and the particles sediment to obey Stokes’ 
law (Eq. 1.7).    
Sedimentation Velocity: Stokes’ law28 describes the velocity of sedimentation of spherical 
particles in dilute suspensions as 
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         (Eq. 1.7) 
υ = velocity (cm/sec) 
∂ = diameter of particles (cm) 
η = viscosity of dispersion medium (Poise) 
ρs = density of dispersed phase (g/cm
3
) 
ρo = density of dispersion medium (g/cm
3
) 
g = acceleration due to gravity (cm/sec
2
) 
 
Stokes’ law assumes that there are no interactions between the dispersed particles, there 
are no interactions between the dispersion medium and the dispersed particles, and the 
particles are spherical. By reducing the sedimentation velocity, the dispersed API 
particles can remain suspended long enough for uniform doses to be dispensed. Hence 
small particle size, high viscosity of dispersion medium and minimum difference in 
densities between the dispersed and dispersion phases reduce the sedimentation velocity. 
Most dispersed particles in pharmaceutical suspensions are anything but spherical. To 
account for the variable size and shapes of the API particles, the velocity may be adjusted 
by a porosity term. 
Finely dispersed particles can associate through particle-particle interaction via 
Van der Waals forces to form loose aggregates with entrapped dispersion medium called 
flocs. The flocs settle quickly but can be redispersed easily due to the weak interactions 
holding the particles together. By adjusting the viscosity of the suspension, the 
sedimentation volume, redispersibility and flow of the suspension will be suitable for 
everyday manipulation by patients. 



18
)(2 gos 
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Sedimentation Volume: The sedimentation volume of a suspension is defined by the 
relationship  
 
  
         (Eq. 1.8) 
where Vu is the  volume of sediment and Vo is the initial volume of suspension. As F 
approximates 1, sedimentation is minimum and the product appears elegant. An accurate 
approach to assess uniform drug dispersion is to sample and analyze the top layer of the 
suspension for potency. In addition, the rheological properties, chemical stability of the 
drug substance, and acceptable taste, odor and color form essential components of 
formulation design and development.  
 
Rheology of Suspensions: The rheological properties of a suspension can facilitate 
suspending the drug particles for a period of time and assure the measurement of an 
accurate dose. The Stokes’ law provides a tool for manipulating the viscosity. Added to 
this, the viscosity could influence the dissolution mechanisms for suspensions by 
impacting mass transport phenomena such as shear at the particle surface, hydrodynamic 
and diffusion boundary layer thickness.
69
 The viscosity is expected to remain constant 
throughout the shelf-life of the product as changes may lead to physical instability and 
inaccuracies in the dispensed dose. The effect of formulation components on viscosity 
may also be determined as an aid to excipient selection.  
      Rotational rheometer may be used to determine the rheological properties of non-
Newtonian fluids such as suspensions. Accurate measurements of shear rate and shear 
stress of non-Newtonian fluids can be made on a cone and plate geometry (Fig. 1.6) of a 
o
u
V
V
F 
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rotational rheometer. At shear rates where laminar flow exists, the layers of the fluid 
move in concentric circles. The rheometer measures the torque required to rotate the cone 
as it causes the layers of the fluid to move. The cone is attached to a calibrated spring and 
as it rotates in the fluid, the resistance of the fluid to the movement (viscosity) causes a 
deflection of the spring which is displayed on a digital display. The physical variables 
obtained by direct measurement are the torque M (dyne-cm), the angular velocity  of 
the cone (rad/sec), the cone angle θ (degrees) and the radius r (cm) of the cone.70   
    
Fig 1.6 Geometry of a cone and plate rheometer.
70
 
 
The relationship between shear rate (γ), shear stress (), viscosity () and the physical 
variables are as follows:  
Shear rate (sec
-1
)           



sin
    (Eq. 1.9) 
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Shear stress (dynes/cm
2
) 







3
2 3r
M

   (Eq. 1.10) 
 
Viscosity (poise)         


      (Eq. 1.11) 
The viscosity of a system is dependent on temperature, pressure, shear rate, time, and 
history of the system. Most pharmaceutical suspensions intended for per oral 
administration are non-Newtonian exhibiting thixotropic flow behavior. Thixotropic 
systems display a reduction in viscosity with time when subjected to a constant shear 
rate.
71
 When shear rate increasing at a constant rate is applied to a thixotropic system up 
to a point, and then reduced at the same rate, a plot of shear stress versus shear rate shows 
the downcurve displaced to the right of the upcurve (hysteresis) due to a decrease in 
viscosity (Fig. 1.7). The viscosity of the system decreases because the molecules in the 
system require time to reform the cohesive interactions which were disrupted due to 
shearing. Thixotropy is essential to pharmaceutical suspensions since the higher viscosity 
on storage could retard settling while the lower viscosity on agitation could facilitate 
pouring of a dose.  
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Fig. 1.7 Plot of shear rate vs. shear stress showing thixotropy. 
 
 Several models have been used to describe the flow properties of non-Newtonian 
systems. Two of these are the Casson and the Herschel-Bulkley models.
72, 73
 
  
 Casson model:    o   (Eq. 1.12) 
  
            Herschel-Bulkley model: 
n
o k    (Eq. 1.13) 
where γ = shear rate 
           = shear stress 
          = viscosity 
        o = yield stress 
          k = consistency index 
           n = flow index 
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The Casson model may be suitable for describing dispersions with high solid content.  
The yield stress and plastic viscosity obtained from the Casson model can be readily 
related to the desirable attributes of a suspension.  The Herschel-Bulkley model may be 
used to describe the general flow of non-Newtonian liquids, particularly where the fluid 
exhibits a spectrum of rheological behavior under different conditions. The Herschel-
Bulkley model defines the rheological properties of shear thinning systems as consistency 
index, k>0 and the flow index, 0<n<1; and n > 1 corresponds to yield-dilatant 
behavior.
72, 73
 The consistency index indicates flow behavior at low shear rate. 
 
1.3.2.7 Chemical Stability of Granules and Suspensions  
The chemical kinetics of drugs in a fixed-dose combination of granules for 
reconstitution into a suspension could be complex. The API in the granules (solid state) 
could have kinetic rates and pathways different from those of the drug in solution or the 
suspended drug particles. The mechanisms of degradation of drugs in pharmaceutical 
dosage forms usually follow zero-order, first-order or pseudo-first order kinetics. The 
linearized form of the zero-order rate equation (Eq. 1.14) is defined as  
 
tKCC oot    (Eq. 1.14) 
where Co and Ct are the drug concentrations at initial time and at time t. Ko is the zero-
order rate constant, the quantity of drug degraded in a unit time. A plot of Ct vs. time 
yields a straight with the slope equal to Ko. The slope is negative since the concentration 
decreases with time. Shelf-life, the time for 10% of drug to degrade is  
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oK
C
t 090
1.0
     (Eq. 1.15) 
The reaction rate of zero-order reaction is independent of concentration but affected by 
other parameters such as pH. 
In suspensions, as the dissolved drug degrades in solution, more of the suspended 
drug dissolves to replace the degraded amount thus keeping the amount of drug in 
solution constant. Under such conditions, the degradation kinetics appears to be 
independent of concentration of the drug and the reaction rate is described as apparent-
zero-order kinetics.
74, 75
  The zero-order rate (Ko) constant becomes equal to the product 
of the first-order rate constant (K) and the solubility of the drug (Cs) at the specific 
temperature (Eq. 1.16). When the drug reservoir is depleted, the suspension system 
behaves like a solution, following first-order kinetics. 
 
tKCCC sot )(   (Eq. 1.16) 
 
   
For a first-order reaction, the reaction rate depends on the first power of concentration of 
one reactant. The linearized first-order reaction equation (Eq. 1.17) is 
 
KtCC ot  lnln     (Eq. 1.17) 
where K is the first-order rate constant. The shelf-life equation is  
 
K
t
105.0
90       (Eq. 1.18) 
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When the reaction rate depends on two reactants but one reactant is in excess and the 
apparent concentration does not change, the reaction is described as a pseudo-first-order 
reaction. The mathematical treatment is similar for a first-order reaction. The hydrolysis 
of drugs in aqueous solution is an example of pseudo-first order kinetics. This is due to 
the fact that in a solution, the solvent is in a large excess and thus the concentration of the 
solvent will not change significantly during the course of the reaction. The decomposition 
of drugs in solid dosage forms is frequently zero-order or first-order kinetics. 
      The ICH guidance document Q1A(R2) prescribes conditions for testing the 
stability of drug substances and drug products.  The climatic conditions in Nigeria, the 
intended market, are hot and humid (zone IVA).
76, 77
 Accelerated stability conditions are 
40 
o
C / 75 % RH for 6 months and long-term stability conditions are 30 
o
C / 65 % RH for 
a minimum of 12 months.
78
  The stability of reconstituted suspension may be evaluated 
for the duration of use,
75
 while the powder is evaluated for the period stipulated for all 
dosage forms. Potency tests, dissolution tests and degradation products are usually 
assessed at well defined sampling time points during stability studies. 
 
 
1.3.3 Bioavailability and Bioequivalence Studies 
1.3.3.1 Bioavailability  
The biological availability or bioavailability of a new per oral drug product is 
assessed to determine the release of the drug substance from the drug product and the 
absorption of the drug substance into the systemic circulation. The systemic exposure 
profile obtained is utilized to establish a therapeutic dosage regimen. Bioavailability is 
   37 
 
defined in 21 CFR 320.1 as the rate and extent to which the active ingredient or active 
moiety is absorbed from a drug product and becomes available at the site of action. For 
drug products that are not intended to be absorbed into the bloodstream, bioavailability 
may be assessed by measurements intended to reflect the rate and extent to which the 
active ingredient or active moiety becomes available at the site of action.
79
 The 
bioavailability is obtained from the plasma drug concentration versus time profile.  The 
pharmacokinetic (PK) parameters used to characterize bioavailability include (i) the area 
under the plasma concentration-time curve (AUC) which is a measure of the extent of 
drug absorption; (ii) the maximum plasma concentration (Cmax) which is a measure of the 
rate of drug absorption; (iii) the time required to reach the maximum plasma 
concentration (tmax).  Other PK parameters of interest are the elimination half-life and 
terminal disposition rate constant, which is often assumed to follow first order kinetics. 
The Cmax and tmax are obtained directly from the plasma-concentration time profile.  
Non-compartmental analysis: The non-compartmental (NCA) pharmacokinetic analysis 
is frequently used to derive the pharmacokinetic parameters in bioavailability studies. In 
NCA, the body is assumed to consist of a system within which there is an accessible pool 
for sampling and measuring drug concentration.
80
 Measurement of the drug concentration 
in the accessible pool yields information for calculating the pharmacokinetic parameters. 
The NCA model presents several advantages for pharmacokinetic analysis. First, NCA 
requires fewer assumptions than that which is necessary with compartmental analysis. 
Secondly, numerous concentration points are obtained which reduce the uncertainty and 
make the measurements more robust.
81
  Plotting this large number of point makes the 
AUC less prone to variability due to experimental errors.  
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The AUC from time zero to time t may be calculated by the trapezoidal rule (Eq. 
1.19), while the AUC from time zero to infinity is obtained according to Eq. 1.20 where 
Ck is the last measurable concentration and λ is the terminal elimination rate constant.  
 
        (Eq. 1.19) 
 
 
        (Eq. 1.20) 
 
Relative bioavailability (f) is the ratio of the AUC of a drug from a test product to 
the AUC of the reference product in the same dosage form and given by the same route 
of administration.
82
 When the doses of the test and reference products are the same,  
  
reference
test
AUC
AUC
f      (Eq. 1.21) 
The relative bioavailability (Eq. 1.21) describes the fraction of the dose of the test 
product administered per orally that is absorbed and becomes systemically available for 
pharmacologic activity as compared to the reference product. When a generic (test) and 
an innovator (reference) show comparable AUC, the two products are accepted as 
bioequivalent.  
 
1.3.3.2 Bioequivalence 
Bioequivalence is defined in 21 CFR 320.1 as the absence of a significant 
difference in the rate and extent to which the active ingredient or active moiety in 
pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of 
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drug action when administered at the same molar dose under similar conditions in an 
appropriately designed study.
79
  Pharmaceutical alternative refers to products that are 
different dosage forms, different strengths or different crystal forms of the active 
moiety.
82
  On the other hand, pharmaceutical equivalent refers to products containing the 
same active ingredient, in the same strength and dosage form and are intended for the 
same route of administration.  The two bioequivalent products are fundamentally 
assumed to offer therapeutic equivalence in terms of formulation performance, efficacy 
and safety.
81
  
The statistical criterion for bioequivalence as issued by the Food and Drug 
Administration requires that the 90 % confidence interval of the ratio of the average 
response for test to reference of AUC and Cmax on a log-transformed scale should fall 
within 80 % to 125%.
79, 83
 The log-transformation normalizes the distribution of the data: 
that is there is the assumption of log-normality for intersubject and intrasubject 
variabilities in the bioequivalence studies.
84
   In other words, intrasubject variability is 
assumed to be the same for each subject and for each formulation. The log transformation 
further reduces the skewedness of the otherwise positively skewed data. The statistical 
test for the determination of the 90 % confidence interval is two one-sided t-tests. The 
two one-side t-test assesses whether (i) the test product is significantly less bioavailable 
compared to the reference listed product and (ii) the reference product is significantly less 
bioavailable compared to the test product. 
81
 Within the 80 % to 125% log-transformed 
interval, any observed differences between the test and reference products do not 
manifest in clinically significant effects. This is referred to as the 80/125 rule.  
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Fig. 1.8 Possible outcome of bioequivalence (BE) studies showing the 90 confidence 
intervals of log-transformed data (BIE – bioinequivalence, T – test, R – reference). 
Adapted from reference. 
81
  
 
The concept of bioinequivalence (Fig 1.8) is demonstrated when the ratio of the mean 
response for test/reference of AUC and Cmax on a log-transformed scale lies within the 80 
% to 125% band, but the range overlaps the confidence interval.
81, 84
  The results of 
bioinequivalence may be due to poor performance of the formulation, excessive 
variability in product characteristics, sample size, or improper study design.  
Bioinequivalence may occur when the sample size is small, but the intrasubject 
variability is high resulting in a high total variance between the two study products.
85
 In 
addition, if the plasma sampling intervals do not accurately capture the Cmax, all the three 
pharmacokinetic parameters will be affected. The inability to capture the true Cmax leads 
to decreased AUC. Finally, when the generic product shows a lot of variability in product 
performance attributes such as dissolution, it could lead to big differences or outliers 
T/R (%) 80% 125% 
Demonstrate BE 
    Demonstrate  BIE 
    Demonstrate  BIE 
Failed BE   Failed  BE 
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when the pharmacokinetic parameters for each individual is compared across products. 
When both the mean ratios and the range lie outside the confidence interval, the product 
is said to have failed bioequivalence. The outcome of the bioequivalence test determines 
whether the product may be approved for marketing and clinical use by the regulatory 
authorities.  
 
1.3.3.3 Sample Size 
Another rule, the 80/20 rule, is employed to calculate the power for sample size 
determination prior to the bioequivalence study. The 80/20 rule requires that the number 
of subjects involved in the trial should be large enough to provide at least 80 % chance of 
detecting a 20 % difference in the average bioavailability.  The sample size per sequence 
(ne) is given by Eq. 1.22 where  is the level of significance,  is the probability of type 
II error and CV is the quotient of the square root of mean square error divided by the 
mean AUC of the reference product.
84
 The CV may be obtained from published 
literature.     
   
         (Eq. 1.22) 
 
A type I error occurs if truly non-equivalent products are declared to be bioequivalent 
(risk to patient) and type II error occurs if true equivalent products are declared as not 
bioequivalent (manufacturer’s risk). Generally, small samples sizes (20 to 30 subjects) 
are used in bioequivalence studies which limit the power of the study if the intrasubject 
variance is large. 
86
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1.3.3.4 Design of Bioequivalence Studies 
For the in vivo measurement of the active moiety in bioequivalence studies, the 
parallel design, the crossover design and the balanced incomplete block designs are used. 
Parallel design: In this design, each group of subjects receives only one drug instead of 
being dosed with both drugs at different periods. Parallel designs are useful when (i) the 
drugs are very toxic such that it is unethical to expose the subjects to both products; (ii) 
the study medications have very long elimination half-lives; and (iii) the study population 
consists of very ill subjects. The variations observed in bioequivalence studies are due to 
formulation, intersubject and intrasubject variabilities.
84
 However, parallel designs are 
unable to identify and separate out intrasubject and intersubject variabilities. In addition, 
parallel designs require a larger number of subjects to provide valid statistical inference. 
Hence parallel designs are not commonly used for bioequivalence studies.  
Crossover designs:  These are most commonly used in bioequivalence studies. In this 
design, each group of subjects receives more than one drug product at different time 
periods. Each group of subjects called a block receives a different sequence of drug 
products. The assumptions in a crossover design are that the absorption, distribution, 
biotransformation, and elimination in a subject are less variable from one time to the next 
time of study, compared to the variability in the product performance. The crossover 
design presents the following advantages: (i) Each subject serves as his control and 
allows the use of a smaller number of subjects to provide precise statistical inference; (ii) 
intrasubject comparison of formulations can be obtained while the intersubject variability 
between formulations is eliminated; and (iii) provides the best unbiased estimate of 
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variance between the study products. However, crossover designs are not suitable for 
bioequivalence studies in which clinical outcome is the study endpoint or for drugs with 
very long elimination half-life since the long half-life will prolong the washout period. 
Extended washout period could cause the study subjects to drop out. To prevent the 
interference of drug carryover to subsequent treatment periods in crossover designs, 
which may bias any inferences drawn, a suitable washout period is built into the design. 
 
1.3.3.5 Carryover Effects and Washout Period in Crossover Design  
Carryover effect refers to residual concentration of drug in the plasma persisting 
after the end of a dosing period and into the subsequent dosing period. The washout 
period is the time between two treatment periods where no drug is administered and the 
residual concentration from the dose administered in the prior period does not carryover 
to the subsequent period. The washout period should be long enough for the effect of the 
drug to wear off.
83
 In the case of immediate release oral suspension, this may be a few 
hours or days. A more stringent requirement is for the washout out period to be at least 
five-and-half times the elimination half-life of the drug.
82
 This ensures that at least 95.5 
% of the parent compound is eliminated. For products with active metabolites that have 
long half-life, the metabolites should be taken into account in establishing the washout 
period. To verify the absence of first order carryover effects, the biological fluid such as 
plasma collected before dosing should be analyzed for drug or metabolite content as 
appropriate. A practical limitation to this approach may be the sensitivity of the analytical 
method employed for analyzing the biological fluid. When carryover effects are 
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determined to be absent, the carryover term can be eliminated from the statistical model 
defining the pharmacokinetic parameter. 
 
1.3.3.6 Blocking and Randomization 
Subject characteristics including age, gender and weight could contribute to the 
variance observed in a bioequivalence study. Such variability or noise tends to confound 
the comparison between the test and reference formulations.  Blocking out the noise due 
to these factors serves to control their effect on the response variables.
87
 The principle of 
blocking matches the input variables pertaining to the subjects such that the effect of 
these variables is eliminated from the measured variables of primary interest. To form 
randomized blocks, the heterogeneous cohort (Fig. 1.9a) is grouped into homogeneous 
units or blocks (Fig. 1.9b) to represent a combination of gender, age, and weight. The 
treatments are assigned randomly to the blocks formed (Fig. 1.9c).  It is desirable to form 
equal treatment group sizes with comparable group attributes to facilitate data analysis 
and interpretation.
84, 87
 The randomization of the subjects in blocks ensures a balanced 
design. Randomized blocks may be analyzed statistically by the confidence interval 
approach or the analysis of variance approach. 
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Fig. 1.9 Steps in blocking and randomization 
87
 
 
Randomization and blinding are the two major design techniques for avoiding 
possible bias in clinical studies. Randomization involves the probabilistic assignment of 
subjects to treatment groups to remove the predictability of treatment assignment.
88
  By 
introducing the element of chance into the treatment assignment, there is less likelihood 
of the subject characteristics influencing the outcome of the study. The stakeholders in a 
clinical study are the subjects, investigators (physicians, nurses, pharmacists, laboratory 
analysts, clinical coordinator) and the sponsor. These stakeholders can consciously or 
unconsciously by commission or omission negatively bias the primary study endpoints. 
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To avoid this, treatments may be masked (blinded), if the dosage form lends itself to that. 
Blinding is performed to make the test and reference products look similar so that the 
subjects and the investigators are unable to differentiate between the test and reference 
(placebo) products. Comparing the different dosage forms, tablets are the easiest to blind. 
The techniques for blinding tablets include overencapsulation (Appendix 2), film coating, 
and manufacturing matching placebos. For liquid and powder products, blinding may 
require repackaging the formulations in identical packaging containers or applying 
identical labels. As part of the blinding process, the products should be adequately coded 
to facilitate unblinding, subsequent to the dosing and samples. 
 
1.3.3.7 Statistical Methods for Average Bioequivalence 
The data captured from the study should be evaluated for outliers before breaking 
the blind to ensure bias is not introduced into the analysis. The data exclusion criteria 
should be defined prior to the commencement of the study and justified. In a trial, all 
subjects enrolled and randomized into the planned treatment regimen groups are 
described as the intent to treat set.
88
 However, often times, not all subjects in the intent to 
treat category follow the study protocol to the end and may drop out due to various 
reasons. The group of subjects who meet the entry criteria and follow the treatment 
protocol to completion form the protocol compliant set. The protocol compliant set 
typically receives the treatment, provides samples for measurements and does not violate 
the provisions of the protocol. Hence, full analysis set for the intent to treat subjects and 
per protocol analysis set for the protocol compliant subjects are compared to determine 
whether the inferences drawn from the two analysis sets are similar.
83, 88
 Appropriate 
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statistical methods are applied to the two data sets. The confidence interval approach is 
considered an appropriate statistical method for assessing average bioequivalence. Added 
to this, the analysis of variance approach is applied to statistical inferences for the 
intersubject (carryover) effects and intrasubject (drug and period) effects.
84
 
In a two-treatment two-sequence (2 X 2) randomized crossover design, the 
statistical model
84
 for an observed pharmacokinetic response is given by   
 
     ijkkjkjikijk eQFPSY      Eq. 1.23 
 
where Yijk = pharmacokinetic response of the ith subject in the kth sequence at the jth  
period 
μ = overall mean 
Sik = random effect of the ith subject in kth sequence; i=1,2, ...nk and k=1,2 
Pj = fixed effect of the jth period; j=1,2 
Fjk = direct fixed effect of formulation in the kth sequence which is administered 
at the jth period 
Qk = fixed effect of the sequence, k=1,2  
eijk = the within subject random error in observing Yijk 
 
The analysis of variance (ANOVA) of the formulation, period, sequence, and 
subject effects are determined prior to establishing bioequivalence (Table 1.3). The 
absence of any of these effects is necessary to show that the assessment of bioequivalence 
is purely due to the formulation differences between the two products. 
86
 The statistical 
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assumptions of the ANOVA are (i) randomization of the subjects to the sequences; (ii) 
the variance associated with the sequence and treatments should be homogeneous; (iii) 
the main effects model for subject, period, formulation, and sequence should be additive 
without any interactions;  and (iv) the residuals of the model should be normally 
distributed and independent.
86
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Table 1.3. Analysis of variance table for 2 x 2 crossover design
84
  
Source of variation df SS MS=SS/df E(MS) F 
Intersubjects       
      Sequence  1 SScarry SScarry 
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Fc=MScarry/MSinter 
      Residuals  n1+ n2 - 2  SSinter SSinter/n1+ n2 - 2 222 es    Fv=MSinter/MSintra 
Intrasubjects       
      Formulation 1 SSformulation SSformulation 
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Fd=MSdrug/MSintra 
      Period 1 SSperiod  SSperiod  
  221
21
212
ePP
nn
nn


 
Fp=MSperiod/MSintra 
      Residuals n1+ n2 - 2 SSintra SSintra/n1+ n2 - 2 2
e   
Total 2(n1+ n2) -1     
Footnotes: Fd is valid if CR=CT,  n is the number of subjects in a treatment group, 
2
e  is intrasubject variability,
2
s is intersubject 
variability 
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1.3.3.8 Principles of Good Clinical Practice  
Good Clinical Practice (GCP): It provides quality standards for ethical and scientific 
means of conducting clinical studies in human subjects. To ensure the safety, rights and 
well-being of human subjects, clinical trials should be performed according to the ethical 
principles emanating from the Helsinki Declaration.
89
 In this regard, the study protocol 
should comply with all regulatory requirements including approval by a competent 
Institutional Review Board (IRB) or Ethics Committee (IEC). Generally, the benefits of a 
clinical trial should outweigh the associated risks.
90
 The goals of clinical trial may be 
therapeutic or non-therapeutic trial such as pharmacokinetic or safety evaluation. The 
components of the ethical principles include subject recruitment, consent, and safety.  
 
Recruitment of Subjects: The recruitment of subjects should consider the rights of study 
participants and steps should be taken to protect them from unnecessary risk. Subjects 
should be educated about their rights and responsibilities to ensure that both the subjects 
and the sponsor achieve the best possible outcome of the study. Further, subjects should 
not be coerced or induced by excessive monetary rewards or any other form of 
compensation to participate. This prevents a situation where the economically challenged 
find themselves exposed repeatedly to experimental medicines. The payments to the 
subjects should be prorated so that in case subjects withdraw before completing the study, 
the compensation will be commensurate to the individual participation. In addition, 
subjects recruited for a study should include individuals representing the demographics of 
the region and the disease being studied.
90, 91
 This ensures the data generated from the 
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study will be relevant to the target population in which the product is intended to be used. 
However, the pediatric population represents a vulnerable subgroup and therefore initial 
evaluation of pediatric medicines could be performed in the adult population to obtain an 
indication of the safety parameters.
91
 
 
Informed Consent: This should be obtained from all the study participants. The 
requirements of the study should be communicated to the participants in a language that 
they can understand, including the written informed consent document. The adult 
participants capable of sound decision making should provide consent by personally 
signing and dating the written informed consent form.
90
 Participants should be made 
aware of their rights to decline to participate or to withdraw from the study at any time 
without any punitive consequences. 
 
Risks: Efforts should be made to minimize the risk and distress that participants are 
subjected to. To be able to adequately appreciate the intricacies and the risks associated 
with the study, all the investigators conducting the study should have suitable training 
and skills to perform the assigned tasks and avoid hazards. Procedures and practices 
employed in the trials should be designed to minimize risk.
91
 For instance, indwelling 
catheters could be used in place of repeated venipunctures for drawing blood samples, 
where applicable. The number of venipunctures, the volume of blood draws and the 
frequency of sample collection should be clearly stated at the onset of the study. Hence, a 
qualified physician should be enrolled in the study to be responsible for medical 
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decisions including the management of any adverse drug effects the subjects may 
experience.  
 
Confidentiality: The records of all participants should be managed such that individual 
identities are not disclosed. This information should not be shared with the other 
volunteers engaged in the study. In addition, the study investigators should not be privy 
to this information, unless their assignments require them to know the information. 
Furthermore, the participant identifying information may not be associated with any of 
the research instruments or any publications made from the study. Thus, the privacy of 
the subjects is paramount.  
 
Regulatory Approval: As part of GCP, an Investigational New Drug Application (INDA) 
should be submitted to the FDA for approval prior to the administration of any 
investigational products to humans. Although various products containing lamivudine, 
zidovudine, and nevirapine have been approved by the FDA, the granules for 
reconstitution is a ―new product‖ without a prior marketing authorization and thus subject 
to INDA (21 CRF 312.40). To comply with this requirement, Form FDA 1571 should be 
completed and submitted to the FDA for approval. In addition, regulatory submission and 
approval is required by the National Agency for Food and Drug Administration and 
Control (NAFDAC), Nigeria, the country for the clinical site location.  
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1.3.3.9 Clinical Batch Manufacturing and Regulatory Considerations 
 In the clinical investigation of generic products, adequate safety and efficacy data 
from other existing clinical trials in humans can guide subsequent selection of the dose, 
the dosage form and the route of administration. To comply with the GCP standards
90
, the 
test and reference products to be investigated in a clinical study should be manufactured, 
handled, and stored in accordance with Good Manufacturing Practice (GMP) as defined 
in the 21CFR 312. This responsibility rests with the sponsor of the study. Upon the 
successful development and complete characterization of the test product, the technology 
should be transferred to a GMP certified site for the manufacture, labeling and storage of 
the clinical batch. This implies that all the product components (active ingredients, 
excipients and packaging) should meet GMP standards. In view of the fact that a major 
cause of the failure of a generic product to achieve bioequivalence with the reference 
listed product is the variability in the test product, the need for complete characterization 
of the clinical batch cannot be overemphasized. Hence the manufacturing and the 
packaging batch records should be designed to capture the test procedures for product 
characterization. In addition, the certificate of analysis and the GMP certificate of 
compliance should be summarized in the investigator’s brochure specific for the study. 
The investigator’s brochure should also define the steps for reconciling the handling, use, 
and disposition of any unused products. 
 The GCP documentation requirements should meet both international and local 
regulatory requirements.
90
 Some of the essential documents required for a clinical study 
are:  
 Investigator’s Brochure  
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 Protocol  
 Case Report Form (CRF) 
 Advertisement For Subject Recruitment  
 Informed Consent Form  
 Approval of Institutional Review Board (IRB)  
 Regulatory Authority(ies) Authorization   
 Medical/Laboratory/Technical Procedures /Tests  
 Certificate(s) of Analysis of Investigational Product(s)  
 Master Randomization List  
 Monitoring Visit Reports  
 
 As previously discussed, the identity of the human subjects should not be disclosed in 
any clinical study reports. The subjects should report any events (such as accidents or 
illness unrelated to drugs used in the study or study protocol) or adverse drug reactions to 
the qualified physician engaged in the study for treatment and monitoring. Finally, the 
investigator should report any serious and unexpected adverse drug reactions to the IRB 
and the regulatory authorities.  
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Chapter 2.  Development of Fixed-Dose Combination of 
Lamivudine, Zidovudine and Nevirapine, Formulated as Granules 
for Reconstitution 
 
2.1 Introduction 
Role of Physical-Chemical Properties:  Oral liquid dosage forms facilitate the titration of 
doses to meet individual pediatric patient requirements. The choice between solution and 
suspension depends on factors such as the solubility of the drug, moisture content, crystal 
state of the actives and organoleptic properties.  
Solubility: Lamivudine and zidovudine are soluble in water and could be formulated as 
solution. On the other hand, nevirapine has very low solubility and relating dose size to 
its solubility precludes nevirapine from being formulated as a solution. Formulating a 
suspension could overcome the low solubility challenge.  
Moisture and Influence on Crystal State:  The absence of water in dry powder 
formulations makes powders more stable than liquid formulations.  Furthermore, dry 
powder formulation minimizes the probability of converting nevirapine anhydrous into 
nevirapine hemihydrate. Thus the formulation of granules for reconstitution into 
suspension could extend the shelf-life of the product. In addition, changes in the 
crystallinity of the API could be due to indirect incompatibility or to the introduction of 
moisture by one of the excipients.   The objective of this step of the project was to 
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formulate a fixed-dose combination granule for reconstitution into suspension containing 
lamivudine/zidovudine/nevirapine 30 mg/60 mg/50 mg per 5 mL. 
Segregation of the granule powder: The granules for reconstitution could be made by 
roller compaction process not just to avoid moisture but also to prevent the segregation of 
the drugs from the excipients. In a multi-drug formulation, segregation could be a real 
challenge and adequate steps should be taken during the manufacturing process to 
prevent segregation. By compacting the drugs into ribbons, dry granulation by roller 
compaction process lends itself to addressing this challenge. The probability of moisture 
causing unexpected interaction or reaction is also avoided by the roller compaction 
process. 
Organoleptic properties: Drug-drug, drug-excipient, and excipient-excipient  
incompatibility [which could be established by isothermal stress testing (IST)] could 
affect the organoleptic properties such as color. Solid-state characterization and solution-
state analysis may be used to assess the absence of interactions using techniques such as 
IST. Color changes in the mixture after IST or changes in the viscosity of the suspending 
agent could be used as indicators of incompatibility in the dosage form.   
The taste of per oral pediatric formulations is critical as children are particularly 
averse to bitter taste. To enhance the taste, bulk sweeteners such as xylitol may be used. 
Xylitol is a non-cariogenic natural constituent of fruits and vegetables with sweetness 
equal to that of sucrose. Xylitol is a non-reactive crystalline material, stable to heat and 
air but moderately hygroscopic.
101
 Compared to equivalent concentration of sucrose, it 
has a reduced tendency to cap-lock, has lower water activity and a higher osmotic 
pressure which enhances product microbial stability and freshness.
92
 In addition, the 
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xylitol product literature states that ―a 40 %w/w xylitol solution passes the BP 
preservative efficacy test‖.92 Hence xylitol was selected as the bulk sweetener.  
Xylitol has low specific surface area and exhibits brittle fragmentation.
93
 
Therefore, when xylitol is used as diluent in tablet formulations, it results in the 
formation of tablets with weak crushing strength.
94
 The weak compaction properties of 
xylitol may be desirable in the formulation of granules for reconstitution.  The roller 
compacted ribbons which have relatively weak strength and weaker granule strength 
would form granules that could be easily dispersed in water to form a suspension. Thus 
the compaction properties of xylitol make it a potential candidate for formulating 
granules for reconstitution by roller compaction.  
In addition, roller compaction and milling processes can cause significant particle 
size reduction resulting in increased surface area and faster dissolution rate as described 
by the Noyes-Whitney
95
 equation (Eq 2.1) below: 
 CC
h
DS
dt
dM
s      Eq. 2.1 
dM/dt is the mass rate of dissolution, D is the diffusion coefficient of the solute in 
solution, S is the surface area of the particle, h is the thickness of the diffusion layer, Cs 
is the solubility of the solid, and C is the concentration of the dissolved drug in the bulk 
fluid at time t. The increased dissolution rate may be particularly beneficial to the 
dissolution of nevirapine, a BCS class II compound with low aqueous solubility. 
High Intensity Sweeteners: High intensity sweeteners are often used in low amounts to 
supplement bulk sweeteners in formulations and minimize the physical size of the dose as 
well as enhance the flavor of the formulation. Sucralose, neotame, and saccharin are 
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some of the sweeteners in FDA approved products (Fig 2.1). However, the choice of high 
intensity sweetener will depend on compatibility with the other formulation components.  
Preservatives: Considering antimicrobials for oral liquid formulations, the parabens have 
been shown to exhibit synergistic antimicrobial activity in a wide pH range. Hence the 
combination of methylparaben and propylparaben is frequently used in oral suspensions 
to maintain the microbial integrity of formulations. 
Hydration Tendency of Suspending Agent:  Furthermore, the granules for reconstitution 
into suspension are reconstituted by simple hand agitation prior to dispensing. This 
requires that the suspending agent selected should hydrate rapidly when water is added to 
be effective at suspending the dispersed drug particles. Avicel RC 591 has been shown to 
be an effective suspending agent in reconstitutable suspension.
96
 Considering the 
tendency of one component, xylitol, to adsorb moisture, the incorporation of an anti-
caking agent such as Aerosil 200 colloidal silicon dioxide to prevent the formation of 
lumps in the granules could be essential. Aerosil 200 has high porosity and preferentially  
absorbs moisture to keep the granules dry and free and flowing. 
 
         
            Sucralose    Neotame     Saccharin 
Fig. 2.1 Structures of high intensity sweeteners 
 
   59 
 
Hence, it is hypothesized that fixed-dose combination of lamivudine, zidovudine 
and nevirapine formulated as granules for reconstitution can be developed using roller 
compaction process. Granulation by roller compaction process will eliminate the 
introduction of water into the formulation and thereby improve product stability. 
Furthermore, the formulated granules for reconstitution will be stable under ICH 
recommended stability testing conditions for tropical climate. The specific aims are (i) to 
develop FDC granules for reconstitution by roller compaction, and (ii) to characterize the 
formulation. 
 
2.2 Experimental 
2.2.1 Materials 
Lamivudine, zidovudine and nevirapine reference standards (United States 
Pharmacopoeia, Rockville, MD); acetonitrile HPLC grade, ammonium acetate (Fisher 
Scientific, Hanover Park, IL); formulation components are listed in Table 2.1; all other 
reagents were of analytical grade.  
 
2.2.2   Validation of Gradient HPLC method 
2.2.2.1 Chromatographic Conditions for Gradient HPLC method   
A gradient HPLC method was developed for the evaluation of the FDC granules 
for reconstitution. The chromatographic system consisted of Waters 2695 Separations 
module, 996 PDA detector, and Empower 2 chromatographic software (Waters 
Corporation, Milford, MA). The absorbance was monitored at 265 nm.  The mobile phase 
was made of 50 mM ammonium acetate buffer pH 6.8 and acetonitrile. The mobile phase 
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was filtered and degassed before use.  The gradient was from 5 to 55 % v/v acetonitrile 
over 26 min at a flow rate 1 ml/min. Column used was Luna-C18 5μm 250 x 4.6 mm 
column (Phenomenex, Torrance, CA).  
    
2.2.2.2   Preparation of Standard Solutions  
Solutions containing 10 mg/mL of the lamivudine, zidovudine, cytosine and 
thymine were prepared in Millipore water. 10 mg/mL stock solutions of nevirapine, 
methylparaben and propylparaben were prepared in acetonitrile/water 40 % v/v.  Further 
dilutions were made using 30 % v/v acetonitrile/water solution. Quality control samples 
were similarly prepared. 
 
2.2.2.3 Linearity and Range  
To establish the linearity and the range, six concentrations in triplicate were used 
to construct the calibration curve. The range was calculated based on the estimated 
maximum amount of drug dissolved in 900 mL of dissolution medium. Linearity was 
examined over the following concentration ranges: lamivudine (20-80µg/mL), 
zidovudine (20-100µg/mL), nevirapine (20-80µg/mL), methylparaben (2-20µg/mL), 
propylparaben (0.8-10µg/mL), cytosine (0.8-10µg/mL) and thymine (0.8-10µg/mL).  The 
six analyte solutions were mixed together in the same vials and analyzed. The data was 
fitted using the least sum of squares method. 
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2.2.2.4 Precision and Accuracy  
Precision and accuracy were determined as 20%, 50% and 100% of the calibration 
curve range. Triplicate samples were analyzed at each level. Precision was computed as 
percent relative standard deviation (RSD) and accuracy was computed as percent relative 
recovery.  Inter-day reproducibility was examined by repeating the procedure using 
independent samples on three separate days. The data was analyzed using two-way 
ANOVA. 
 
Table 2.1. Components of Reconstitutable Granule Formulation  
Ingredients 
CAS 
Registry # 
Manufacturer Category 
Percent 
w/w 
Zidovudine USP 30516-87-1 
Dayang 
Chemical 
Active  2.58 
Lamivudine USP 134678-17-4 
Dayang 
Chemical 
Active 1.29 
Nevirapine anhydrous 
USP 
129618-40-2 
Dayang 
Chemical 
Active 2.15 
Avicel RC 591 
(microcrystalline 
cellulose/ sodium 
carboxymethylcellulose) 
9004-34-6 
9004-32-4 
FMC 
Biopolymer  
Suspending 
agent 
4.30 
Sucralose NF 56038-13-2 Tate & Lyle 
Sweetening 
agent 
0.43 
Xylitol NF 87-99-0 
Roquette 
America Inc. 
Sweetening 
agent 
86.00 
Aerosil 200 (Colloidal 
Silicon Dioxide USP) 
7631-86-9 Degussa 
Anticaking 
agent 
1.98 
Magnesium stearate USP 557-04-0 
Spectrum 
Chemical 
Lubricant 0.90 
Methylparaben NF 99-76-3 
Spectrum 
Chemical  
Preservative 0.32 
Propylparaben NF 94-13-3 
Spectrum 
Chemical 
Preservative 0.03 
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2.2.3 Formulation of Reconstitutable Granule Formulation 
 The components of the granules for reconstitution are listed in table 2.1. In view 
of the fact that the developed formulation will be tested in humans for bioavailability and 
bioequivalence, only excipients listed in the Food and Drug Administration’s ―Inactive 
Ingredients in Approved Products Database‖ were selected to avoid safety issues. The 
GMP batch for the clinical trials was manufactured at a GMP contract manufacturing site 
using GMP grades of the same formulation and packaging components. In addition, the 
formulation components were selected after preformulation studies using IST, solid state 
characterization techniques, and other screening methods described in the sections below. 
 
2.2.3.1 Isothermal Stress Testing  
Drug-drug and drug-excipient interactions were evaluated using isothermal stress 
testing (IST). Nevirapine, lamivudine and zidovudine powders were prepared singly and 
as mixtures in fixed ratios with 5 %w/w of water and stored in closed vials at 50
o
C for 
three weeks. 
42
 Similarly, identical dry blends were processed and stored at 50
o
C and at 
room temperature and used as controls. At the end of the storage period, the samples 
were visually inspected for organoleptic change. Powder x-ray diffraction (PXRD) 
characterization of the samples was performed to establish no changes in crystal form of 
the drugs. The validated HPLC-UV method was used to evaluate chemical changes. 
 
2.2.3.2 Powder X-Ray Diffraction  
Powder X-Ray Diffraction (PXRD) analysis was carried out to identify the 
polymorphic forms of the bulk drug substances. Isothermally stressed drug-drug mixtures 
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were also analyzed by PXRD. The powder samples were loaded unto the sample holder 
and tapped with the block gently to produce a smooth surface that flushes with the rim of 
the sample holder (back loading technique). The X’Pert Pro MPD diffracting system 
(PANalytical BV, Almelo, Holland) was used at the following settings: generator setting 
40mA, 45 kV; anode Cu K-α1, K-α2, scan step size 0.017 degree 2θ, scan step time 75s, 
scan range from 3-50 degree 2θ.  
 
2.2.3.3 Fourier Transform Infrared Spectroscopy  
The Fourier Transform IR spectrometer was used to collect the spectra of the bulk 
APIs for identification purposes. Isothermally stressed drug-drug mixtures were also 
analyzed by FT-IR. NICOLET 380 FT-IR instrument and Omnic software (Thermo 
Electron Corporation, Madison, WI) were used for data collection. The scan range was 
500-4000cm
-1
, the data was averaged over 32 scans at a sensitivity of 50 and resolution of 
4cm
-1
.  
 
2.2.3.4 Liquid State Characterization and Screening of Excipients   
 To choose between three high intensity sweeteners, (saccharin, neotame, and 
sucralose), 0.2% w/w of the sweeteners was added to different beakers containing 2% 
w/w Avicel RC591 (microcrystalline cellulose/sodium carboxymethylcellulose) in 
deionized water. The rheological properties of the suspension were measured on 
Brookfield LV DV-III Ultra rheometer using cone and plate geometry with spindle CP51 
and electronic gap of 500 nm. The rheological properties were measured at a shear rate of 
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1 to 96 s
-1
. The data was captured and analyzed using the Rheocalc software. The pH of 
the suspension was measured using a pH meter. 
 
2.2.4 Manufacturing Process and Formulation Optimization 
2.2.4.1 Manufacturing Process 
Initial attempts to assess the compaction properties of binary mixtures of the three 
drugs and magnesium stearate formed weak ribbons that fragmented easily. The drugs 
constituted 99 % by weight fraction of the blend. Therefore, if the drugs had good 
compaction properties, the ribbons formed would have been strong. That the ribbons 
formed were weak was an indication that the drugs had poor compactibility. 
Unfortunately, the determination of the specific causes of the poor compactibility of the 
drugs was beyond the scope of this project. On the other hand, the binary mixture of 
xylitol and magnesium stearate formed relatively strong ribbons. Since xylitol constitutes 
greater than 80 % w/w of the final blend, the strength of the ribbons formed will be 
expected to parallel that of xylitol.  
The granules were manufactured by screening through a 20 mesh screen, weighed 
quantities of lamivudine, zidovudine, nevirapine, xylitol, and magnesium stearate. The 
screened components were blended for 5 min utilizing a twin-shell V-blender (Patterson-
Kelley Co. Stroudsburg, PA). The blend was roller compacted on a Fitzpatrick IR 220 
chilsonator (The Fitzpatrick Co., Elmhurst, IL) followed by milling the ribbons on Fitz-
mill communitor (The Fitzpatrick Co., Elmhurst, IL) at 1500 rpm screen size. The roller 
compaction parameters are described under the section for roller compaction optimization 
below. The granules produced were blended in a V-blender together with the other 
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screened formulation components for 5 min. This final blend was packaged into amber 
plastic bottles for storage before further characterization.  
 
2.2.4.2 Optimization of Roller Compaction Parameters 
  Based on literature, the initial roll pressure ranged 145 to 2900 psi.  Analysis of 
the ribbon strength on a beam bending test was used to reduce the limits of the roll 
pressure to 1300 to 1800 psi. The ratio of the horizontal feed screw speed to the roll 
speed was similarly selected. A 2 x 3 factorial design (Table 2.2) with two factors [roll 
pressure and the ratio of the horizontal feed screw speed to the roll speed] at three levels 
[low, medium, high] was used to optimize the roller compaction parameters. It is 
predicted that the roll pressure and the ratio of the horizontal feed screw speed to the roll 
speed could influence the break force of the ribbons formed.
68
 The response variables 
were (a) the force required to break the ribbons, and (b) the fraction of granules less than 
250 microns. Xylitol, the major component of the granules is brittle and thus the break 
force was more appropriate than indentation testing that is more suitable for testing the 
tensile strength of plastic deforming materials.  The mean diameter of the suspending 
agent was 250 microns and therefore a similar mean particle diameter was applied to the 
granules made from the roller compacted ribbons. The experimental design and the 
statistical analysis of the response were performed using JMP statistical software, version 
4 (SAS Institute Inc, Cary, NC).   
Break Force: The three point bend rig method was used to measure the average force 
required to break the ribbons.  The measurements were made on a TAXTplus texture 
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analyzer and Texture exponent 32 software was used for data acquisition (Texture 
Technologies Corp, Scarsdale, NY).  
Particle Size Distribution: Dry sieve analysis was performed to determine the particle 
size distribution. The details of the method are described in section 2.2.5.1.  
 
Table 2.2 Design of experiment for optimizing the roller compaction parameters. Vertical 
screw speed = 100 rpm, roller gap = 2 mm, RS =  roll speed, HS = horizontal screw 
speed.  
Run  Roll Pressure (psi) HS/RS 
A 1300 15/3 
B 1300 15/4 
C 1300 20/5 
D 1550 15/3 
E 1550 15/4 
F 1550 20/5 
G 1800 15/3 
H 1800 15/4 
K 1800 20/5 
 
 
2.2.4.3 Suspension Formulation Optimization  
A replicated 3
2 
factorial design (Table 2.3) was utilized to optimize the levels of 
the suspending agent (Avicel RC 591) and the anticaking agent (Aerosil 200), each at 
three coded levels (-1, 0, 1). The anticaking agent inhibits settling and flocculation 
whereas the suspending agent influences the viscosity and the sedimentation rate of the 
reconstituted suspension. Aerosil 200 has also been shown to have effect on viscosity. 
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The hypothesis was that the suspending agent can suspend the drug particles long enough 
for a uniform dose to be measured. The response variables were (a) Viscosity: High at 
high level of Avicel RC 591 and (b) Sedimentation volume (F): F is closer to 1 at high 
level of Avicel RC 591. Least squares regression model was used to fit the viscosity data 
and the variance in the mean values were tested with ANOVA (p < 0.05), utilizing using 
JMP statistical software.  It was also hypothesized that the presence of Aerosil 200 in the 
suspension could prevent the caking of the drug particles. The response variable was the 
absence of cakes in the suspension. 
 
Table 2.3 Randomized 3
2
 full factorial design matrix for formulation optimization. Avicel 
RC 591 [-1=1.0%, 0=2.0%, 1=3.0%], Aerosil 200 [-1=1.00%, 0=1.25%, 1=1.50%], all 
levels represent %w/v. The levels of the other formulation components were fixed as 
indicated in table 2.1.   
Formulation # Avicel RC 591 Aerosil 
1 -1 -1 
2 1 1 
3 1 0 
4 -1 1 
5 0 -1 
6 0 0 
7 1 -1 
8 0 1 
9 -1 0 
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2.2.5 Characterization of Development Batch of Granules  
Based on the results of the suspension optimization, the granules were 
manufactured and characterized for the relevant product attributes. The stability of both 
the granules and the reconstituted suspension including dissolution and potency are 
discussed under chapter 3. 
 
Moisture Content: 5 g of sample was weighed and dried at 80 
o
C to constant weight. The 
loss in weight was computed as a percentage of the initial weight.  
 
Density: A weighed quantity of granules was placed in a graduated cylinder and 
repeatedly tapped 200 times. The initial and final volumes of the powder in the cylinder 
were recorded. The bulk density, tapped density, and the compressibility index were 
calculated. This information was useful in selecting the bottle for packaging. 
 
Particle Size Distribution: A quantity of granules was placed on a nest of standard USP 
sieves arranged in decreasing size down on Performer III sieve shaker (Cole-Parmer, 
Vernon Hills, IL). The sieves were agitated for 5 min and the weight of granules on each 
sieve determined. The geometric mean diameter and geometric standard deviation were 
computed. 
 
Content Uniformity: The quantity (2.33 g) of granules equivalent to 5mL dose was 
weighed into a 200 mL flask. 100 mL of 40 % v/v acetonitrile/water solution was added 
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and sonicated for 30 min. 1 mL of this solution was diluted with 5 mL of 30 % v/v 
acetonitrile/water. The solution was filtered through 0.45 micron nylon filter and 
analyzed on HPLC in triplicate.  The potency and the antimicrobial preservative content 
were determined from the peak area response from the chromatogram. Six separate 
measurements were made and the following computed:      
(a) Amount of drug (mg)/ 5 ml 
(b) Percent Potency (%) = Amount recovered x 100 % / Theoretical amount 
(c) Acceptance Value ksXM      Eq. 2.2 
where X = mean content, M = reference value, k=acceptability constant, and s =standard 
deviation.  Measured volumes (5 mL) of the reference products (Epivir solution 
(lamivudine), Retrovir syrup (zidovudine), and Viramune suspension (nevirapine) were 
similarly analyzed.    
 
Dissolution: Weighed sample (2.33 g) of granules was added to each of six dissolution 
vessels containing deaerated 0.01N HCl at 37 
o
C. The USP apparatus II (paddle method) 
was run at 100 rpm for 60 minutes. Samples were collected at 0, 5, 10, 15, 30, 45 and 60 
min, filtered through 0.45 micron nylon filter and analyzed on HPLC.   
 
2.2.6 Clinical Batch Manufacturing and Characterization 
Identification and Testing of Excipient: The excipients were identified using Fourier 
Transform Infrared (FTIR) spectroscopy and chemical tests at a contract research 
analytical testing facility. The FTIR spectra were collected using NICOLET 380 FT-IR 
instrument and Omnic software (Thermo Electron Corporation, Madison, WI). The scan 
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range was 500-4000cm
-1
, the data was averaged over 32 scans at a sensitivity of 50 and 
resolution of 4cm
-1
.  
 
Manufacturing and Packaging:  To manufacture the clinical batch of granules for 
reconstitution under current Good Manufacturing Practices (cGMP), the lab developed 
technology was transferred to a GMP contract research manufacturing facility. The 
manufacturing and packaging batch records were transferred together with the product 
specifications. The batch was scaled-up to twice size of the laboratory batch. Following 
successful manufacturing of the demonstration batch, the GMP (clinical) batch was 
manufactured using similar parameters. The clinical batch was packaged into amber 
plastic bottles and appropriately labeled and stored. The batch was sampled and 
characterized for potency and dissolution. The batch was also evaluated for stability 
under long term-storage conditions. 
 
2.3 Results and Discussions 
2.3.1 HPLC method validation 
The ICH guideline ―Q2 (R1) Validation of Analytical Procedures: Text and 
Methodology‖ recommends validating analytical methods prior to employing the method 
for routine analysis. The HPLC method developed was validated according to this 
guidance document. The chromatogram (Fig. 2.2) shows well resolved peaks indicating 
the specificity of the method.  The calibration curves were fitted by the least squares 
regression model. The intermediate precision was evaluated by means of two-way 
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analysis of variance (ANOVA).  A p-value> 0.05 and Fcal < Fcrit indicates non 
significant differences in the results between days or between levels.  
 
 
Fig 2.2 Chromatogram of granules for reconstitution showing resolved peaks for 
lamivudine (3TC), zidovudine (AZT), nevirapine (NEV), methylparaben (MP), and 
Propylparaben (PP).  
 
All the analytes showed strong linear relationship between analyte concentration 
and the peak area within the range evaluated (Table 2.4). The intraday accuracy for the 
drugs ranged 99.15% to 100.12% while the precision ranged 0.17% to 1.32%. The 
interday accuracy for the drugs was 99.02% to 100.20% with intermediate precision of 
0.97% to 1.78%. The accuracy and precision for the preservatives were 99.10% to 
103.46% and 1.49 to 3.35% respectively. The interday accuracy and intermediate 
precision for the preservatives were 99.00% to 102.87% and 3.03% to 4.19% 
respectively. The lower precision and accuracy of the preservatives compared to the 
drugs was probably due to the lower concentration range tested. The ANOVA showed 
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that there were no significant differences (p>0.05 and Fcal < Fcrit) in accuracy or 
precision between the different concentrations examined within day or between days. 
Thus the validated HPLC method had the level of accuracy and precision required for 
analysis of the formulation samples.
97
 
   
7
3
 
 
Table 2.4 HPLC-UV method validation. ANOVA (p > 0.05 and Fcal< Fcrit, for all samples) 
Parameter Lamivudine Zidovudine Nevirapine Methylparaben Propylparaben 
Linear range (µg/mL) 20-80 20-100 20-80 2-20 0.8-10 
R
2
  0.9958±0.0050 0.9954±0.0032 0.9992±0.0014 0.9941±0.0037 0.9903±0.0064 
Intraday      
Accuracy (%) 100.12 99.15 100.01 103.46 99.10 
Repeatability (%) 0.17 0.77 1.32 3.35 1.49 
Interday      
Accuracy (%) 99.02 99.81 100.20 102.87 99.00 
Lower 95% CI 98.36 99.14 99.83 101.7 97.51 
Upper 95% CI 99.69 100.47 100.56 104.05 100.48 
Stdev 1.76 1.76 0.97 3.12 4.14 
Intermediate precision (%) 1.78 1.76 0.97 3.03 4.19 
 
 
   74 
 
 
2.3.2 Isothermal Stress Testing  
Drug-drug interactions: Previous studies showed that lamivudine anhydrous was 
converted to the hydrate form in the presence of zidovudine and water at elevated 
temperature, although that did not affect the chemical stability of the drugs.
98
 This was 
consistent with the fact that commercially available fixed-dose combination tablets 
containing lamivudine and zidovudine are stable under ICH stability storage conditions. 
This underscores the fact that the process for manufacturing the granules for 
reconstitution should be devoid of the addition of water to the product. HPLC analysis 
(Table 2.5) and solid state characterization using PXRD showed that there were no 
interactions between lamivudine and nevirapine or zidovudine and nevirapine.  
 
Table 2.5 Recoveries of drugs from isothermally stressed samples. The physical blends of 
the drugs were stored under different conditions for 3 weeks. 
  Drug Recovery (SD) %         
Sample # Condition (3 weeks storage) 3TC AZT Nev 
1 Room Temp 99.04 (0.20) 101.28(0.15) 94.70 (0.16) 
2 50 
o
C 96.24 (0.32) 100.11(0.31) 91.32 (0.27) 
3 50 
o
C/5% water 101.51(0.75) 98.87 (0.35) 97.75 (0.18) 
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Drug-excipient interactions: Wet drug-sucralose mixtures stored at 50
o
C showed brown 
discoloration but, samples stored at 40 
o
C/75 % RH for three weeks did not produce any 
discoloration. Neotame-drug samples showed pale yellow discoloration at both 
temperatures. However, the recoveries of the drugs from drug-sucralose or drug-neotame 
mixtures were not affected. Stressed individual samples of neotame and sucralose showed 
similar discoloration. Neotame undergoes hydrolysis of the methyl ester moiety to form 
de-esterified neotame.
99
 Sucralose (Fig. 2.1) also undergoes hydrolysis to form 4-chloro-
4-deoxy-galactose (4-CG) and 1,6-dicholoro-1,6-dideoxyfructose (1,6-DCF).
100
 
Sucralose is listed as a component of a powder for oral suspension product in the Food 
and Drug Administration’s ―Inactive Ingredients in Approved Products Database‖, which 
indicates that the excipient is stable for use in the granules for reconstitution. Similarly, 
as at the end of January 2011, neotame was listed in the same database as a component of 
an oral spray. Saccharin, the other sweetener evaluated did not produce color changes in 
the samples. Thus all three high intensity sweeteners could potentially be used to 
formulate the granules for reconstitution. Furthermore, there were no observed color 
changes or significant degradation (less than 10%) of drugs recovered from the stressed 
mixtures of the drugs and the other formulation components (Table 2.6).  
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Table 2.6. Recoveries of 3TC/AZT/Nev mixture stressed with individual formulation 
components containing 5 % moisture stored at 50 
o
C for 3 weeks 
 
            Drug Recovery (SD) % 
Excipient 3TC AZT Nev  
Avicel RC591 97.82 (0.18)  97.52 (0.46) 92.35 (1.21) 
Xylitol 102.87(0.14) 102.61 (0.09) 94.69 (0.11) 
Sucralose 101.00 (0.19) 100.63 (0.18) 95.15 (0.16) 
Aerosil 200 99.59 (0.51) 98.77 (0.05) 94.96 (0.18) 
Methylparaben 97.76 (0.30) 96.42 (0.29) 90.98 (0.28) 
Propylparaben 97.95 (0.47) 98.62 (0.56) 90.35 (0.13) 
Magnesium Stearate 98.63 (1.01) 97.98 (0.12) 99.63 (0.21) 
 
 
2.3.3 Liquid State Characterization and Screening of Excipients   
ANOVA of mean pH and viscosities of the suspensions containing high intensity 
sweeteners and Avicel RC 591 were significantly different, each with p-value<0.0001. 
Suspensions containing saccharin had acidic pH < 3 (Table 2.7), and Avicel RC 591, a 
water-dispersible hydrocolloid was flocculated reducing the apparent viscosity to 
approximately 1 cP at a shear rate of 57 s
-1
. This shear rate is similar to that encountered 
in pharmaceutical suspension during pouring.
72
 Saccharin, pKa of 1.6 produces protons in 
aqueous solution that react with the negatively charged carboxymethylcellulose anion 
leading to precipitation. The suspension formulated with both saccharin and Avicel RC 
591 cannot suspend the drug for a uniform dose to be dispensed. Contrary to Avicel RC 
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591 technical literature that suggests the suspending agent to be stable at pH 3.5-11, the 
viscosifying property was markedly reduced below pH 5. Suspensions containing 
neotame (pH = 6.02) had no negative effect on the viscosity (Fig 2.3). Neotame has a 
pKa of 3.01 and the concentration of protons produced in the aqueous suspension was not 
high enough to precipitate the carboxymethylcellulose anion.  On the other hand, 
sucralose is nonionic and had no effect on carboxymethylcellulose anion and thus no 
negative effect on the viscosity of the suspension (Fig 2.3). The pH of suspension 
containing sucralose was 6.08.  Sucralose (Fig. 2.1) lacks UV/VIS absorption due to the 
absence of chromophores in the molecule. This deficiency is an advantage in HPLC-UV 
analysis, since it does not interfere with the API peaks. On the other hand, neotame has 
chromophores with UV/VIS absorption and could interfere with the selectivity of the 
HPLC-UV analysis for a multicomponent formulation sample. Hence, sucralose was 
selected instead of neotame for further studies. 
 
Table 2.7 The pH of Avicel RC 591 and high intensity sweetener in deionized water 
Sample pH 
Avicel RC 591 6.12 
Neotame + Avicel RC 591 6.02 
Sucralose + Avicel RC 591 6.08 
Saccharin + Avicel RC 591 2.44 
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Fig 2.3 Viscosity of Avicel RC591 alone and in the presence of Neotame (A), Sucralose 
(B) and Saccharin (C). 
 
 
 
 
   79 
 
2.3.4 Powder X-Ray Diffraction 
Effect of Roller Compaction on Crystallinity of the Drugs:  To determine whether the 
roller compaction process induced any polymorphic changes in the three drugs, the 
PXRD patterns before and after roller compaction were compared using granule samples. 
There were no differences in the diffraction patterns of lamivudine (Fig 2.4), zidovudine 
(Fig 2.5), and nevirapine (Fig 2.6) before and after roller compaction, indicating the 
absence of any polymorphic transformations. Further, samples of the roller compacted 
drugs stored at 40 
o
C/75 %RH for six months did not show any new peaks indicating the 
drugs were stable under the processing conditions. 
 
 
Fig 2.4 PXRD patterns of lamivudine powder before roller compaction (red) and granules 
after roller compaction (blue) 
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Fig 2.5 PXRD patterns of zidovudine powder before roller compaction (red) and granules 
after roller compaction (blue) 
 
 
Fig 2.6 PXRD patterns of nevirapine powder before roller compaction (red) and granules 
after roller compaction (blue) 
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Crystallinity of Nevirapine and Lamivudine in Granules: In order to distinguish between 
the two crystal forms of nevirapine during stability studies on the granules, the powder 
X-ray diffraction (PXRD) patterns of nevirapine anhydrous and the recrystallized 
nevirapine hemihydrate were obtained and compared (Fig 2.7). The nevirapine 
hemihydrate had characteristic peaks at 5, 10.5, 11.5 and 14 deg 2θ which could 
potentially be used for distinguishing between the two crystal forms. Similarly, 
lamivudine 0.2 hydrate was also recrystallized and the PXRD pattern (Fig 2.8) compared 
with that of lamivudine anhydrous. The two forms of lamivudine have characteristic 
peaks suitable for identification of the two crystal forms. 
 
 
Fig. 2.7 PXRD patterns of nevirapine anhydrous (blue) and nevirapine hemihydrate (red) 
powder after recrystallization. 
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Fig. 2.8 PXRD patterns of lamivudine anhydrous (red) and lamivudine 0.2 hydrate (blue) 
powder after recrystallization. 
 
Despite the characteristic peaks of the different crystal species of nevirapine, 
diffraction patterns obtained in the PXRD analysis could not be used to distinguish 
between granules containing nevirapine anhydrous or hemihydrate (Fig 2.9).  This is due 
to the large mass fraction of xylitol in the blend compared to nevirapine. Xylitol 
suppressed the peaks of nevirapine in the diffraction pattern.  The only different peaks 
that do not belong to xylitol are at 20.7
o
 and 21.5
o
 2θ. These two peaks are common to 
lamivudine, zidovudine, nevirapine anhydrous and hemihydrate. Similarly, the 
characteristic peaks of lamivudine in the PXRD pattern were also suppressed by xylitol.  
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Fig 2.9 Diffraction patterns of pure xylitol (black), granules blend containing nevirapine 
hemihydrate (blue) and granules blend containing nevirapine anhydrous (red). 
 
Dissolution of Different Species of Drugs: In view of the fact that PXRD could not 
distinguish between granules containing nevirapine anhydrous and hemihydrate, 
dissolution of the granules was evaluated as a means of distinguishing between the two 
crystal forms. The following test conditions were evaluated for the dissolution of the 
drugs: (a) 0.1 N HCl dissolution medium and USP apparatus II at 100 rpm could not 
discriminate between nevirapine anhydrous and the hemihydrate (Fig 2.10A). (b) When 
0.01 N HCl dissolution medium and USP apparatus II at 50 rpm was employed, the 
granules formed a cone at the bottom of the vessel and the dissolution of the more soluble 
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drugs (lamivudine and zidovudine) was limited. (c) 0.01 N HCl dissolution medium and 
USP apparatus II at 100 rpm could discriminate between formulations containing 
nevirapine anhydrous and the hemihydrate (Fig 2.10B). Hence test conditions (c) were 
adopted for the analysis of the FDC granules. Moreover, lamivudine and zidovudine have 
high solubility and would be soluble in 0.01 N HCl dissolution medium. 
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Fig 2.10 Dissolution of granule blend showing the profiles of nevirapine anhydrous and 
hemihydrate in (A) 0.1 N HCl dissolution medium and USP apparatus II at 100 rpm (B) 
0.01 N HCl dissolution medium and USP apparatus II at 100 rpm. 
 
 
2.3.5 Fourier Transform Infrared Spectra 
 The reflectance spectra of the bulk drugs and the USP reference standards of the 
drugs were obtained and compared. The overlay of the respective bulk and reference 
spectra of lamivudine (Fig 2.11), zidovudine (Fig 2.12) and nevirapine (Fig 2.13) did not 
reveal any differences confirming the identities of the active pharmaceutical ingredients. 
Analysis of isothermally stressed drug mixtures and physical mixtures of the similar 
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composition did not show any differences in the spectra indicating the absence of 
molecular interactions.  
 
 
Fig 2.11 FT-IR spectra of lamivudine bulk and USP reference standard 
 
 
 
Fig 2.12 FT-IR spectra of zidovudine bulk and USP reference standard 
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Fig 2.13 FT-IR spectra of nevirapine bulk and USP reference standard 
 
 
2.3.6 Optimization of Roller Compaction Parameters  
 The average force required to break the ribbons ranged from 1182.51g to 
2208.65g. The percent fraction of the granules made from the same ribbons of mean size 
less than 250 microns varied from 55.45 to 76.91 %. The results are summarized in Table 
2.8. The data was subjected to multiple regression analysis using JMP software v4. The 
break force was fitted according to Eq. 2.2 
 
 21322110 XXXXY       Eq. 2.2 
where X1 = roll pressure and X2 = speed ratio. 
The R
2
 was 0.3163 and the ANOVA p-value = 0.7710 indicated that the model could not 
adequately describe the observed data. Furthermore, from the effects table, the p-values 
were all greater than 0.5, an indication that the roll pressure, the speed ratio, and the 
interaction between the two terms could not adequately account for the variance in the 
observed data. Thus there was a weak relationship between the input variables and the 
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break force. This could be due to the fact that the mechanical properties of the blend 
components (dependent on the large amount of xylitol) have a strong influence on the 
ribbon quality as explained below. However, this blend component was kept constant and 
was not included in the model (Eq 2.2). In addition, the same screen size was used to mill 
all the different ribbons. Since the screen size determines the particle size of the granules, 
the properties of the granules such as Carr’s compressibility index which are related to 
the size of the granules were similar. Thus there was an absence of trends between 
average break force, fraction less than 250 microns and the compressibility of the 
granules. In particular, the hardness of the ribbons did not correlate with the particle size 
of the granules.  
Xylitol, the major component of the blend consolidates by brittle fragmentation. 
The low specific surface area of xylitol minimizes the surface area available for 
interparticle bonding and this contributed to the ribbons which were not very hard.
93, 94
 
However, that property could be used to advantage in this formulation since hard 
granules for reconstitution could slow down the granule reconstitution process. Hence the 
quality of the granules obtained after milling the ribbons was suitable for the intended 
use. 
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Table 2.8 Optimization of the roller compaction parameters. RS = roll speed, HS = 
horizontal screw speed.  
Run  
Parameters 
Roll Pressure 
(psi) HS/RS 
Ave. Break 
Force** (g) 
% Fraction less 
250 microns 
Ave Compressibility* 
(%) 
A 1300 15/5 1682 (24.1) 55.45 27.13 (1.53) 
B 1300 15/4 1182 (23.9) 75.86 27.85 (0.46) 
C 1300 20/5 1895 (23.6) 76.91 27.37 (0.86) 
D 1500 15/5 1529 (27.1) 73.61 28.11 (0.83) 
E 1500 15/4 2038 (44.1) 75.96 28.33 (0.00) 
F 1500 20/5 2098 (25.3) 75.27 26.92 (0.85) 
G 1800 15/5 2208 (22.1) 74.32 28.65 (0.82) 
H 1800 15/4 1778 (29.3) 76.19 28.11 (0.83) 
K 1800 20/5 1829 (39.0) 73.06 28.11 (0.83) 
    ** % RSD,  * SD 
 
The Carr’s compressibility index is an indication of the flowability of a powder, 
with lower numbers representing better flow properties. USP <1174> on powder flow 
defines Carr’s compressibility index of 21 – 25 % as passable and 26 – 31 % as poor. The 
Carr’s index obtained ranged from 26.92 – 28.65 % (n=3). It is expected that by adding 
Aerosil 200, a glidant, to the final granule blend, the flow will improve from poor to 
passable or better.  Run F formed strong ribbons, had the best flow property, and greater 
than 75 % of the granules was less than 250 microns. Therefore, the parameters for run F 
(roll pressure of 1500 psi and ratio of the horizontal screw speed to the roll speed of 20/5) 
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were selected as the optimum roller compaction parameters. All the subsequent 
formulations were roller compacted using these parameters. 
 
Initial Granule Formulation: After selecting sucralose as the sweetener of choice, the 
level of Aerosil 200 in the formulation was varied to select the concentration that will 
prevent lump formation in the granules.  After four weeks storage of the granules at 40 
o
C/75 % RH, visual inspection of all the samples showed the absence of lumps and the 
granules were free flowing. This was an indication that all the levels of Aerosil 200 
studied were effective at preventing the granules from lumping together.  The colloidal 
sized Aerosil 200 formed films around the granule particles to prevent lump formation. 
The moisture uptake during that period was less than 0.4 %w/w. The minimal moisture 
uptake could be due to the fact the amber plastic bottles provided effective packaging 
barrier to water vapor. In particular, the packaging minimized the water uptake by the 
moderately hygroscopic xylitol.  
 
2.3.7 Suspension Formulation Optimization  
Suspension Sedimentation and Viscosity: Sedimentation was observed in samples 
containing the lowest levels of the independent variables together (-1, -1). That is, low 
Avicel RC591 and low Aerosil 200 concentrations were associated with sedimentation of 
the suspended drug particle. The formulations containing the other levels of Avicel 
RC591 and low Aerosil 200 did not show any sign of sedimentation. The observed pH of 
the formulations was independent of the concentration of the input variables.  
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The viscosity data was fitted by multiple regression analysis according to Eq. 2.3 
using JMP software v4.  
 
 225
2
1421322110 XXXXXXY       Eq. 2.3 
 
where X1 = concentration of Avicel RC591 and X2 = concentration of Aerosil 200. The 
adequacy of the fitted model was checked by ANOVA and the variables which were not 
statistically significant were removed from the model. The square term of X2 was not 
significant (p=0.0803) and was removed from the model. The final model (Eq. 2.4) was  
 
2
12121 69.12090.5290.39045.43684.681 XXXXXY   Eq. 2.4 
 
 
 
Table 2.9 Effect of optimization factors on viscosity modeled utilizing least squares 
regression model (r
2
= 0.9654, n= 27).  
 
Source Nparm DF Sum of Squares F Ratio Prob > F  
X1 1 1 3422434.4 588.5315 <.0001  
X2 1 1 28662.6 4.9289 0.0370  
X1*X2 1 1 33579.9 5.7745 0.0251  
X1*X1 1 1 87394.0 15.0285 0.0008  
 
Both Avicel RC591 and Aerosil had significant effects (p<0.05) on viscosity of 
the suspension. Also the interaction between Aerosil 200 and Avicel RC 591 and the 
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square term of Avicel RC591 had significant effects on viscosity (Table 2.9). However, 
the viscosity of the samples containing high levels of both components (1,1) was too high 
(> 1000 cP) to be utilized as an oral suspension.  The residual plot (Fig. 2.14A) for 
viscosity did not show any pattern indicating the model assumptions were not violated. 
The surface plot (Fig. 2.14B) showed a curvature typical of a quadratic function. That is, 
the relationship between the concentration of Avicel RC 591 and the viscosity of the 
suspension was not linear. The increase in viscosity was a quadratic function of the 
Avicel RC 591 concentration.  
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Fig. 2.14 The residual plot (A) of viscosity and the surface plot (B) showing effect of 
Avicel RC 591 (X1) and Aerosil 200 (X2) on viscosity. 
 
Due to the fact low levels of Avicel RC591 and Aerosil 200 resulted in particle 
sedimentation and high levels of Avicel RC591 resulted in suspensions with excessive 
viscosity, the mid range concentration of these components were selected as the optimum 
concentrations of the two ingredients. Hence, 2% w/v of Avicel RC591 and 1 %w/v of 
Aerosil 200 were employed in the subsequent formulations.  
A B 
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2.3.8 Characterization of Granules (Development Batches)   
Three development batches (1, 2, and 3) of the optimized formulation (Table 2.1) 
were manufactured, packaged and characterized.  The particle size distribution, moisture 
content, flowability (indicated by Carr’s index), content uniformity and dissolution were 
characterized. 
 
Particle Size Distribution:   The size distribution of the final granule blend for the three 
batches was determined by sieve shaking method. The mean particle diameter, d50, was 
150 µm for all the three batches. The percent fraction less than 250 microns for batches 
S1, S2, and S3 were 80.00%, 76.91%, and 77.99% respectively. The fine particle size 
facilitates both reconstituting with water and suspending the drug particles since 
sedimentation rate is inversely related to particle size, according to Stokes’ law. 
 
Moisture Content: The initial moisture content of the granules was 0.3 %w/w, 0.3 %w/w 
and 0.2 %w/w for batches 1, 2 and 3. The low moisture content was important to 
maintain the granules in a free flowing state. 
 
Flowability or Carr Compressibility Index: The compressibility indices for batches S1, 
S2, and S3 were 24.99±0.65, 24.76±0.98%, and 25.46±0.65% respectively. The 
compressibility indices were passable, and the flow of the final granule blend was better 
than the granules obtained after milling the roller compacted ribbons. The improved flow 
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was probably due to the addition of Aerosil, a glidant, which serves to reduce 
interparticle friction between the granules and thus improved flowability.  
 
Content Uniformity of Granules:   The mean content of the drugs ranged from 
101.84±0.03% to 105.78±2.33% while the mean content of the preservatives ranged from 
96.55±3.39% to 102.95±1.38% (Table 2.10).   The acceptance values for the analytes 
were calculated using Eq. 2.1. The USP33 <905> on uniformity of dosage units states 
that the maximum allowed acceptance value L1 (maximum range for deviation), for solid 
and liquid dosage forms of 10 dosage units is 15%.  The maximum acceptance values 
calculated for the analytes was less than 10% (Table 2.10) indicating the five analytes 
passed the acceptance criteria for the uniformity of content. Thus the granules for 
reconstitution meet the specification for content uniformity. The clinical batch of 
granules had similar potency for lamivudine (97.49±0.46 %), zidovudine (101.55±0.56 
%), and nevirapine (100.82±0.54 %). 
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Table 2.10 Content uniformity of granules. 
  Batch S1 
 
Batch S2 
 
Batch S3 
 
Acceptance value  
Analyte Ave (%) SD Ave (%) SD Ave (%) SD (%) 
Lamivudine 102.85 1.35 102.45 0.56 104.28 0.21 9.87 
Zidovudine 102.03 1.00 104.00 1.24 101.12 0.21 6.40 
Nevirapine 103.12 1.72 101.31 3.33 101.84 0.03 7.79 
Methylparaben 102.95 1.38 102.88 1.12 102.64 1.70 4.77 
Propylparaben 102.81 0.82 101.17 1.53 96.55 3.39 6.19 
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Dissolution of Granules: Typical dissolution profiles of the three development batches 
performed using 0.01 N HCl dissolution medium and USP apparatus II at 100 rpm is 
represented in Fig 2.15. The drug release, corrected for potency, was rapid for all the 
three drugs. Lamivudine and zidovudine are BCS class I drugs that show rapid 
dissolution. For all the three batches, more than 80 % of lamivudine and zidovudine were 
released in 10 min which met the USP criterion of not less than 80 % dissolved in 30 
min.  
Similarly, more than 80 % of nevirapine was released within 10 min from all 
three batches which satisfied the USP criteria of not less than 75 % dissolved in 60 min.   
Nevirapine, a BCS class II drug showed rapid drug release than would be expected from 
this class of compounds. During the roller compaction, the pressure exerted by the rollers 
could have caused a reduction in the particle size distribution of nevirapine. In addition, 
milling the ribbons on the FitzMill would have further reduced the size distribution of the 
nevirapine particles. The reduction in particle size is inversely related to the surface area 
of the particles. The Noyes-Whitney equation (Eq. 2.1) shows that the mass rate of 
dissolution is directly related to the surface area of the particles. Thus as the size of the 
particles was reduced, the surface area increased resulting in increased dissolution rate. 
Furthermore, xylitol, a hydrophilic diluent was intimately mixed with nevirapine. 
Wetting of xylitol could have imparted faster wetting to the nevirapine particles to result 
in rapid dissolution. Finally, the dissolution profile of the clinical batch (discussed below) 
was similar to the profile of the development batch. 
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Fig. 2.15 Typical dissolution of development batch of granules in 0.01N HCl showing 
profiles lamivudine (lam), zidovudine (zid), and nevirapine (nev). 
 
Dissolution of Clinical Batch:  The dissolution profile (corrected for potency) of the 
clinical batch was determined under similar conditions. The profiles obtained for 
lamivudine and zidovudine showed that more than 80 % was dissolved in 5 min (Fig 
2.16), which satisfied the dissolution requirement of not less than 80 % dissolved in 30 
min. In the case of nevirapine, the criterion is not less than 75 % should be dissolved in 
60 min and the observed profile showed more than 80 % dissolved in 10 min, fulfilling 
the USP requirement. Hence the dissolution profiles of the three drugs in the clinical 
batch met the USP specifications and the batch was suitable for the intended purpose.  
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Fig 2.16 Dissolution of the clinical batch showing the profiles of lamivudine (lam), 
zidovudine (zid) and nevirapine (nev). The clinical batch contains nevirapine anhydrous. 
 
 
2.4 Conclusions 
 The gradient high performance liquid chromatography method was validated for 
the drugs and the preservatives in the formulation. The method was suitable for the 
analysis of the fixed-dose combination granules and suspension without any interference 
from the formulation matrix.  
There were no drug-drug interactions among the drugs and there were no drug-
excipient interactions. Sucralose, the high intensity sweetener was preferred to neotame 
due to the lack of chromophores in the molecule and thus non-interference in HPLC-UV 
analysis.  Furthermore, sucralose was stable and compatible with the drug and suspending 
agent; therefore it could be used as high-intensity sweetener in oral powders for 
reconstitution into suspension.                         
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 The roller compaction process was suitable for producing granules of uniform 
potency as indicated by the results of content uniformity. Powder X-ray diffraction 
analysis showed that the roller compaction process did not induce any polymorphic 
transformations in the drugs. The roller compaction process parameters were optimized 
for ribbon strength, particle size distribution and granule flow. In addition, the 
formulation optimization revealed that the Avicel RC591 and Aerosil 200 were important 
determinants of the viscosity of the suspension and the sedimentation rate.  
 The drugs and preservatives met the acceptance criteria for potency, and the 
granules had the desirable product characteristics. Dissolution conditions of 0.01N HCL 
medium and USP apparatus II at 100 rpm were identified to be discriminatory between 
granule formulations containing nevirapine anhydrous or nevirapine hemihydrate.  The 
percent drug released for lamivudine, zidovudine, and nevirapine from all the three 
development batches and the clinical batch met the USP specifications for dissolution. 
The development batches and the GMP batch had the requisite potency and dissolution 
profiles. 
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Chapter 3.  Evaluation of the Stability of Fixed-Dose Combination 
Granules for Reconstitution Formulation and the Reconstituted 
Suspension 
 
3.1 Introduction 
 Drug products are expected to maintain their potency throughout the period of 
storage and use (shelf-life). The stability of the formulation is critical since a loss in 
potency could lead to under dosing, associated with ineffective therapy. Furthermore, the 
formation of toxic degradation products could make the product toxic and unsafe for 
patient administration.
76
  The International Conference on Harmonization (ICH), the 
World Health Organization (WHO), and other regulatory authorities recommend 
conditions for stability studies.
78
 Generally, the product should be packaged in the final 
container which is intended for the market and tested under conditions similar to those 
which prevail in the potential region of use.    The climatic conditions in sub-Saharan 
Africa, especially Nigeria, the intended market, are hot and humid (zone IVA)
76, 77
 and 
the recommended accelerated stability conditions are 40 
o
C / 75 % RH for 6 months and 
long-term stability conditions are 30 
o
C / 65 % RH for a minimum of 12 months.
78
 
  In addition to the strength and purity, the product should maintain its 
antimicrobial integrity. The content of antimicrobial preservatives in a formulation 
should be greater than the minimum inhibitory concentration (MIC). The recommended 
usage levels (above MIC) for methylparaben and propylparaben in per oral liquid 
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formulations are 0.015-0.2% w/v and 0.01-0.02 % w/v respectively.
101
 Although the 
preservatives show synergistic activity within a wide pH range of 4-8, the activity 
reduces above this range. This stems from the fact the two preservatives have pKa of 8.4 
and above pH 8, the fraction of the ionized phenolate anion is increased. Since charged 
ions penetrate membranes poorly, the activity of the parabens is reduced at pH above 8. 
In addition, at higher pH, parabens undergo hydrolysis to form p-hydroxybenzoic acid, 
which has no antimicrobial activity. Hence, it is essential to monitor the pH of the 
reconstituted suspension during stability studies to ensure that the preservatives maintain 
their activity. 
The data obtained from stability studies under ICH guidelines for long-term 
storage conditions may be used to establish the shelf-life of the product. This is done by 
extrapolating the kinetics of the degradation obtained under the long-term storage 
conditions, based on the principles of chemical kinetics. For granules, the quality 
attributes to be evaluated include potency, dissolution, and antimicrobial preservative 
content. In the case of suspension, the quality attributes to be monitored are potency, pH, 
and viscosity. For a fixed-dose combination product, several analytes made up of the 
active pharmaceutical ingredients and the preservatives have to be monitored.
49, 102
 
The objectives for the stability studies were (i) to determine the stability of the 
granules for reconstitution under accelerated and long-term storage conditions, and (ii) to 
determine the stability of the reconstituted suspension under long-term stability 
conditions. 
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3.2 Experimental 
3.2.1 Stability of Granules for Reconstitution 
Stability Conditions: The stability of the granules was determined by placing granules in 
amber plastic bottles in a VWR 9000L stability chamber (VWR International, Bridgeport, 
NJ) at 40 
o
C/75 %RH and LH-1.5 stability chamber (Associate Environmental Systems, 
Ayer, MA) at 30 
o
C/65 %RH for six months. The granules were sampled at monthly 
intervals for potency, moisture uptake, and dissolution tests.  
 
Potency and Antimicrobial Preservative Content: 2.33 g of granules (equivalent to 5 mL 
dose) was weighed into a 200 mL flask. 100 mL of 40 % v/v acetonitrile/water solution 
was added and sonicated for 30 min. 1 mL of this solution was diluted with 5 mL of 30 % 
v/v acetonitrile/water. The solution was filtered through 0.45 micron nylon filter and 
analyzed by the validated HPLC in triplicate.  The potency and the antimicrobial 
preservative content were determined from the peak area response of the chromatogram. 
 
Moisture Uptake: The moisture uptake was determined by weighing the bottles 
containing the final granules for reconstitution at pre-determined times. The weight gain 
was calculated as the percent moisture uptake. 
 
Dissolution: A weighed sample (2.33 g) of granules was added to each of six dissolution 
vessels containing deaerated 0.01N HCl at 37 
o
C. The USP apparatus II (paddle method) 
was run at 100 rpm for 60 minutes. Samples were collected at 0, 5, 10, 15, 30, 45 and 60 
min, filtered through 0.45 micron nylon filter and analyzed on HPLC.   
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3.2.2 Stability of Reconstituted Suspension 
Reconstituting the Suspension: Sufficient amount of water was added to 93.01g of 
granules to make 200 mL, and shaken to form a suspension. The constituted suspension 
was equivalent to 6mg/mL of lamivudine, 10mg/mL of nevirapine, and 12 mg/ml of 
zidovudine. The suspension was reconstituted in amber plastic bottles. 
 
Stability Conditions: The stability of the reconstituted suspension was determined by 
placing the plastic amber bottles containing the suspension in the stability chamber at 
long-term storage conditions (30 
o
C/65 %RH) for four weeks. The samples were stored at 
long-term storage conditions to simulate in-use conditions. Samples were withdrawn after 
adequate shaking of the bottles at intervals for potency, antimicrobial preservative 
content, pH, and viscosity tests.  
 
Potency and Antimicrobial Preservative Content: A volume of 5 mL was weighed into a 
200 mL flask. 100 mL of 40 % v/v acetonitrile/water solution was added and sonicated 
for 30 min. 1 mL of this solution was diluted with 5 mL of 30 % v/v acetonitrile/water. 
The solution was filtered through 0.45 micron nylon filter and analyzed on HPLC in 
triplicate. 
 
pH, Sedimentation Fraction and Viscosity: The electrode of a pH meter was placed in the 
reconstituted suspension and pH reading recorded. Triplicate measurements were made, 
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the average calculated and compared with the range. The viscosity was measured at 
intervals according to the procedure described in section 2.2.3.5.  
In addition, alternating freeze-thaw cycles, each cycle lasting 24 hours was performed for 
two weeks. The samples for freeze-thaw testing were stored in a refrigerator (4 
o
C) or at 
room temperature (25 
o
C). The viscosity, pH, and redispersion were studied to determine 
the effect of freeze-thaw cycle on the physical stability of the suspension. 
 
3.3 Results and Discussion 
3.3.1 Stability of Granules 
3.3.1.1 Potency of Drugs from Development Batch of Granules 
The potency of the granules was evaluated at accelerated stability conditions (40 
o
C/75 %RH) and long-term stability conditions (30 
o
C/65 %RH) for hot humid tropical 
climate. The potency of the drugs should be within the 90 to 110 % range during the 
shelf-life of the product according USP specifications. The potency was normalized to 
the intial drug content, and not the label claim. Also, the long-term stability at 30 
o
C/65 
%RH was studied for six months in view of experimental constraints. 
It was observed that, the potencies of the three drugs were within this range 
during the six-month study period indicating that the granules for reconstitution were 
stable. After six months at 30 
o
C/65 %RH (Fig 3.1A), the potencies of drugs varied 
between 98.10 – 99.78 % for lamivudine, 98.03 – 99.45 % for zidovudine, and 99.05 – 
100.4% for nevirapine. 
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Fig 3.1 Chromatograms of stability samples of granules from the development batch (A) 
and the clinical batch (B) after storage at 30 
o
C/ 665 %RH for 6 months. [3TC – 
lamivudine, AZT – zidovudine, NEV- nevirapine, MP – methylparaben, PP- 
propylparaben] 
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Similarly, the potencies of the preservatives were within 90 to 110 % range during 
the study period.  After six months at 40 
o
C/75 %RH, the potency of propylparaben was 
greater than 91.13 % while the potency of methylparaben was greater than 93.92 %. At 
30 
o
C/65 %RH, the percent recoveries for methylparaben and propylparaben ranged 
97.60 – 99.15 % and 97.48 – 100.34 % respectively. These percent recoveries represent 
approximately 0.15 %w/v and 0.015% w/v of methylparaben and propylparaben 
respectively. The amounts recovered at 30 
o
C/65 %RH remained within the effective 
inhibitory concentration of 0.015-0.2 % w/v and 0.01-0.02 % w/v for methylparaben and 
propylparaben respectively.
101
  Hence, the granules for reconstitution could be described 
as stable. 
 
3.3.1.2  Potency of Drugs from Clinical Batch of Granules 
The potency of the drugs in the granules from the clinical batch was assessed 
before and after 6 months storage at 30 
o
C /65 %RH (Fig. 3.1B). The potency of 
lamivudine before and after stability studies were 97.49±0.46 % and 99.56±0.81 % 
respectively (Table 3.1). The potency of zidovudine before and after stability studies 
were 101.55±0.56 % and 99.75±0.72% respectively.  Similarly, the recoveries of 
nevirapine before and after stability test were 100.82±0.54 and 99.34±1.10% 
respectively. The differences in potency after stability testing for all three were negligible 
indicating the formulation was stable for at least six months. Therefore, the granules were 
stable and suitable for use in the clinical studies. 
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Table 3.1 Potency of the clinical batch before and after 6 months storage at 30 
o
C /65 
%RH 
Compound Recovery (%) SD (%) 
Initial Time    
            Lamivudine 97.49 0.46 
            Zidovudine 101.55 0.56 
            Nevirapine 100.82 0.54 
After 6 months at 30
o
C/65 % RH   
            Lamivudine 99.56 0.81 
            Zidovudine 99.75 0.72 
            Nevirapine 99.34 1.10 
 
 
3.3.1.3 Degradation Kinetics of Drugs from Development Batch of Granules 
The principles of chemical kinetics were used to obtain the degradation rate 
constant. Although several researchers have assessed the stability of lamivudine, 
zidovudine and nevirapine combination in pharmaceutical dosage forms, the degradation 
kinetics are often not reported. However, the degradation kinetics of the three drugs in 
acids or bases follow pseudo-first order kinetics.
103-105
  Hence first-order degradation 
kinetics were applied to all the drugs using the linearized first-order reaction equation 
(Eq. 3.1) 
KtAA ot  lnln     (Eq. 3.1) 
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where K is the first-order rate constant and Ao and At refer to the initial 
amount of drug and the amount of drug remaining at time t respectively (Fig. 3.2).  
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Fig 3.2A First-order degradation kinetics of development batch (1) of granules stored at 
40 
o
C /75 %RH. Three determinations were made at each time point. [lamivudine (lam), 
zidovudine (zid), and nevirapine (nev)]  
N2 = -0.0088x + 4.6269
R2 = 0.3952
Z2 = -0.0128x + 4.6383
R2 = 0.6375
L2 = -0.0116x + 4.6179
R2 = 0.6266
4.00
4.10
4.20
4.30
4.40
4.50
4.60
4.70
4.80
4.90
5.00
0 1 2 3 4 5 6 7
Lam
Zid
Nev
 
Fig 3.2B First-order degradation kinetics of development batch (2) of granules stored at 
40 
o
C /75 %RH. Three determinations were made at each time point. [lamivudine (lam), 
zidovudine (zid), and nevirapine (nev)]  
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Fig 3.2C First-order degradation kinetics of development batch (3) of granules stored at 
40 
o
C /75 %RH. Three determinations were made at each time point. [lamivudine (lam), 
zidovudine (zid), and nevirapine (nev)]  
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Fig 3.2D First-order degradation kinetics of development batch (1) of granules stored at 
30 
o
C /65 %RH. Three determinations were made at each time point. [lamivudine (lam), 
zidovudine (zid), and nevirapine (nev)]  
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Fig 3.2E First-order degradation kinetics of development batch (2) of granules stored at 
30 
o
C /65 %RH. Three determinations were made at each time point. [lamivudine (lam), 
zidovudine (zid), and nevirapine (nev)]  
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Fig 3.2F First-order degradation kinetics of development batch (3) of granules stored at 
30 
o
C /65 %RH. Three determinations were made at each time point. [lamivudine (lam), 
zidovudine (zid), and nevirapine (nev)]  
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The degradation kinetics of the drugs in granules are summarized in Table 3.2. As 
expected, the degradation rate was faster at the accelerated stability conditions (40 
o
C/75 
%RH) compared to the degradation at the long-term stability conditions (30 
o
C/65 %RH). 
This is due to the fact that reaction rate increases with temperature and moisture. This 
trend was common to all the three drugs studied during the six-month period.  
 
Table 3.2 Degradation kinetics of the FDC granules for reconstitution obtained using 
first-order kinetics.  
 Rate constant k (1/day) 
 40 
o
C/75 %RH 30 
o
C/65 %RH 
Batch 1   
Lamivudine 0.0124±0.0030 0.0032±0.0030 
Zidovudine 0.0104±0.0043 0.0033±0.0040 
Nevirapine 0.0091±0.0029 0.0021±0.0056 
Batch 2   
Lamivudine 0.0116±0.0043 0.0043±0.0037 
Zidovudine 0.0128±0.0046 0.0044±0.0051 
Nevirapine 0.0088±0.0052 0.0013±0.0039 
Batch 3   
Lamivudine 0.0121±0.0062 0.0035±0.0138 
Zidovudine 0.0106±0.0037 0.0032±0.0028 
Nevirapine 0.0082±0.0043 0.0016±0.0045 
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During the development of the HPLC-UV method, the analysis of stressed 
solutions of the drugs showed peaks for the degradation products for nevirapine, 
lamivudine (cytosine and uracil) and zidovudine (thymine). During the stability studies of 
the granules in solid-state, peaks for the degradation products were not detected, although 
potency had reduced. Peak purity testing also revealed that all the peaks observed in the 
chromatograms were pure; that is, the peaks were due to single parent compounds. The 
degradation products might not have been detected due to the fact that volatile 
degradation products might have been formed, or the products formed were not 
detectable at the wavelengths used to monitor the chromatogram. 
 
3.3.1.4 Moisture Uptake of Drugs from Development Batch of Granules 
 The moisture gained after six months ranged from 2.08±0.05% to 2.19±0.05% at 
40 
o
C/75 %RH and 0.53±0.31% to 0.79±0.41% at 30 
o
C/65 %RH.  High moisture content 
usually causes formation of lumps in the powder. The granules stored at 30 
o
C/65 %RH 
were devoid of lumps after six months and were free flowing. In contrast, the samples 
stored at 40 
o
C/75 %RH contained loose lumps, but were easily broken up by gentle 
agitation. The granules were packaged in amber plastic bottles to protect the product from 
light as well as to limit the adsorption of moisture. Since the moisture gained was low at 
both storage conditions, it can be inferred that the amber plastic packing bottle was 
effective at minimizing the entry of moisture into the product. 
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3.3.1.5 Dissolution of Drugs from Development Batch of Granules 
 The dissolution profiles of the products stored at 40 
o
C/75 %RH and 30 
o
C/65 
%RH were assessed at specified intervals during the six months study period. The percent 
released was normalized to the initial potency of the drug. The maximum percent of 
lamivudine released from granules (Fig. 3.3) after six months at 40 
o
C/75 %RH was less 
than that for samples stored 30 
o
C/65 %RH due to the faster degradation at the higher 
temperature. However, more than 85 % of lamivudine was released within 10 min which 
met the USP criterion of not less than 80 % released in 30 min. The same trend was 
observed for all the three batches. Due to the rapid drug release, the f2 similarity factor 
was not calculated. In computing the f2 similarity factor, the regulatory guidelines 
recommend that dissolution points greater than 85% should not be used. 
 The maximum percent of zidovudine released from the granules (Fig. 3.4) after 
six months at 40 
o
C/75 %RH was also less than the drug released from the sample stored 
at 30 
o
C/65 %RH. This is validated by the greater drug degradation at 40 
o
C/75 %RH. 
More than 85 % of zidovudine was released within 10 min which also met the USP 
criterion of not less than 80 % released in 30 min. In the case of nevirapine, there were no 
differences in the dissolution profiles between samples stored at 40 
o
C/75 %RH and 
samples stored 30 
o
C/65 %RH (Fig. 3.5). This could be due to the fact less than 100 % of 
the drug was released from the granules. More than 80 % of nevirapine was released 
within 10 min which satisfied the USP criterion of not less than 75 % released in 60 min. 
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 The quality and purity attributes of the granules evaluated during the stability 
studies remained within the acceptable limit. Hence, the granule for reconstitution will be 
expected to retain potency and dissolution profiles during the product shelf-life.  
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Fig. 3.3 Dissolution of development batch of granules (batch 1) showing the profiles of 
lamivudine at time zero (T0), after six months at 40 
o
C/75 %RH (T6_40/75) and 30 
o
C/65%RH (T6_30/65). 
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Fig. 3.4 Dissolution of development batch of granules (batch 2) showing the profiles of 
zidovudine at time zero (T0), after six months at 40 
o
C/75 %RH (T6_40/75) and 30 
o
C/65%RH (T6_30/65). 
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Fig. 3.5 Dissolution of development batch of granules (batch 3) showing the profiles of 
nevirapine at time zero (T0), after six months at 40 
o
C/75 %RH (T6_40/75) and 30 
o
C/65%RH (T6_30/65). 
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3.3.1.6 Dissolution of Clinical Batch of Granules 
The dissolution of the clinical batch of granules for reconstitution was evaluated 
after six months at 30 
o
C/65%RH. For lamivudine and zidovudine, the time required for 
percent dissolved to reach 80% did not change upon stability testing (Table 3.3). In the 
case of nevirapine, the time required for 75 % to dissolve increased from 5 min to 15 min 
after stability testing. However, this slowing down of dissolution was still within the USP 
specification of not less than 75 % in 60 min. Hence the clinical batch showed acceptable 
dissolution profile after stability testing.  
 
 
 
 
Table 3.3 Dissolution of the clinical batch showing the time taken for percent dissolved 
to meet USP specifications.   
 Initial After 6 months at 30 
o
C/65%RH 
 Time for 80 % of drug to dissolve (min) 
Lamivudine 5 5 
Zidovudine 5 5 
 Time for 75 % of drug to dissolve (min) 
Nevirapine 5 15 
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3.3.2 Stability of Reconstituted Suspension    
3.3.2.1 Potency 
 The potency of the reconstituted suspension was evaluated for four weeks at 30 
o
C/65%RH. The recommendation is for reconstituted suspension to be used for a two-
week period and then discarded. Hence the four-week study was adequate for assessing 
the stability of the suspension. The variance in the initial and final potencies was 
statistically tested utilizing analysis of variance (ANOVA) test (p-value < 0.05).  The 
mean percent recoveries of the drugs from the suspension are summarized in Table 3.4. 
ANOVA of potency of lamivudine from the three batches at initial time and after four 
weeks showed no significant differences with p = 0.1466 and the Fcal (3.8949) less than 
Fcrit (9.5521). At four weeks, the potency of zidovudine for the three batches ranged 
from 97.84 % to 99.15%. ANOVA of the initial and final potencies across the three 
batches showed no significant differences between the batches with p = 0.5448 and Fcal 
was less than the Fcrit. Equally, the potency of nevirapine ranged from 98.11% to 98.32 
% across the three batches. ANOVA of initial and final potency of nevirapine across the 
three batches did not show any significant difference. In addition, the potencies of the 
preservatives, methylparaben and propylparaben remained unchanged after four weeks. 
Thus, the potency of the drugs and the antimicrobial preservative content in the 
suspension remained unchanged after four weeks indicating that the formulation was 
chemically stable.  
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Table 3.4. Percent recoveries of drugs from reconstituted suspension at 30 
o
C/65 %RH 
for 4 weeks (within-use period). N=3, SD = standard deviation.  
 Batch 1 Batch 2 Batch 3 ANOVA 
Time (weeks) Ave (SD) % Ave (SD) % Ave (SD) % P-value Fcal Fcrit 
Lamivudine        
0 104.44 (4.65) 102.75 (3.66) 98.80 (0.73) 0.1466 3.8949 9.5521 
4 100.90 (1.57) 100.85 (1.97) 95.47 (1.13)    
Zidovudine       
0 102.06 (1.27) 99.62 (2.55) 100.68 (0.71) 0.5448 0.7488 9.5521 
4 99.15 (1.52) 97.84 (1.91) 99.04 (0.67)    
Nevirapine       
0 100.67 (0.29) 100.10 (1.66) 100.17 (0.49) 0.9617 
 
0.0395 
 
9.5521 
 
4 98.32 (0.20) 98.11 (1.29) 98.13 (1.42)    
 
 
3.3.2.2 pH and Sedimentation Fraction 
The pH at time 0 and 4-weeks ranged from 7.01 to 7.06 among the three batches. 
ANOVA of the pH showed no significant differences (p = 0.2841) between the pH values 
at the initial and final time points.  This indicated that the formulation was stable and 
there was an absence of reaction products that could alter the pH of the formulation. 
Furthermore, an absence of sedimentation was observed among the three batches: the 
sedimentation fraction was 1.  
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3.3.2.3 Rheology of the Reconstituted Suspension 
Apparent Viscosity: The rheological properties of the reconstituted suspension were 
determined using a cone and plate Brookfield rheometer. The viscosity was measured at a 
shear rate of 0.76 to 114 s
-1
. The apparent viscosity of the suspension was consistent 
within batches and across batches during long-term storage at 30 
o
C/65 %RH for 4 weeks 
(Table 3.5). ANOVA test on the viscosity of the suspension showed no significant 
differences (p-value = 0.4464) between initial and final time points and across batches. In 
view of the fact the viscosity of the suspension is partly affected by pH, the lack of 
change of viscosity further confirms that pH has not changed, an indication that the 
formulation is stable.  
The viscosity of the down-curve was displaced to the left of the up-curve, a 
phenomenon consistent with thixotropic behavior (Fig 3.6). When shear is applied to a 
system and the viscosity decreases with increasing shear, the system is described as 
shear- thinning. If on removal of the shear, the viscosity does not immediately return to 
original value, but recovers gradually over time to the original viscosity, the system is 
said to be thixotropic. When increasing shear rate was applied to the suspension and 
subsequently removed, the viscosity on decreasing the shear rate was lower (Fig 3.6) 
indicating that the system had not regained the original structure. Thus the suspension 
was thixotropic. Thixotropic behavior is of advantage in suspension formulations because 
upon agitation, the viscosity reduces to enhance flow (pourability) and continues to be so 
for a uniform dose to be dispensed. On standing, the system gradually returns to the 
original viscosity by reforming the interparticle interactions of the dispersed system. 
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Table 3.5 Apparent viscosity of suspension measured at a shear rate of 57 s
-1
. 
 Average viscosity mPa.s (RSD) 
Time (weeks) Batch 1 Batch 2 Batch 3 
0 262.0 (4.9) 282.7(3.2) 252.0 (9.4) 
4 224.4 (13.4) 260.3 (10.2) 272.8 (9.1) 
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Fig 3.6  Rheogram of the suspension showing thixotropic behavior. 
 
The Hershel Bulkley and the Casson models: The viscosity data was fitted to the Hershel 
Bulkley model (Fig. 3.7) and the Casson model (Fig. 3.8).
73
 The goodness of model fit 
(CoF) for the Casson model ranged between 86.30 to 95.20 %, while the CoF of the 
Herschel Bulkley model was 85.20 to 99.00 %, indicating that both of the models could 
adequately describe the viscosity of the suspension. The Herschel Bulkley model defines 
the rheological properties
72
 of shear thinning systems as consistency index, k>0 and the 
flow index, 0<n<1 and for shear thickening systems, k>0 and n >1. The observed 
consistency index was greater than zero and flow indices were consistent with this 
definition of shear thinning.  
   120 
 
 
                 
Fig. 3.7 A plot of the Herschel Bulkley model (blue line) and the raw viscosity data (red 
line). 
 
The flow index n, obtained from Herschel Bulkey model describes the rheological 
behavior of the suspension. When n < 1, the suspension exhibits shear thinning behavior 
and as n approaches 1, the suspension becomes more Newtonian. When aggregation 
occurs due to increased interparticle interaction, suspensions exhibit more shear thinning 
behavior as greater shear will be required to break the interparticle interactions. 
Subsequently, the value of the flow index, n decreases with increasing aggregation.
106
 
Therefore if aggregation of the suspended nevirapine particles occurs on storage, it would 
be expected that flow index n will decrease. However, comparing the flow index at the 
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initial and the final time points, there is a marginal increase in n for all three batches. 
This shows that particles did not aggregate on standing, further validating the absence of 
any apparent visible sedimentation.  ANOVA of the mean flow index did not show any 
significant differences (p = 0.7482) between the flow indices at initial time point and 
after four weeks.  In addition, the yield stress and consistency index are inversely related 
to the flow index.
106
 Therefore as flow index increases, yield stress and consistency index 
decrease, corresponding to the trend observed in Table 3.6. The Casson model also 
showed a decrease in yield stress with time while plastic viscosity increased (Table 3.7). 
This could mean that if the reconstituted suspension is stored for a long period, the yield 
stress could decrease sufficiently to result in particle sedimentation. However for the 
purposes of reconstituting the suspension and using within two weeks, this observation 
should have no effect on the formulation and the ability to dispense a uniform dose. 
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Table 3.6. The Herschel Bulkley parameters for the suspension before and after 
stability studies 
Time Consistency Index Flow Index Yield Stress CoF 
 Batch 1    
0 1713.3 (478.8) 0.44 (0.05) 42.7 (6.9) 91.4 (2.9) 
4 1150.3 (560.2) 0.56 (0.09) 23.03 (9.7) 98.4 (1.0) 
 Batch 2    
0 3326.5 (615.7) 0.33 (0.06) 40.7 (10.9) 80.2 (5.4) 
4 1286.0 (176.0) 0.54 (0.03) 26.9 (13.5) 95.3 (1.0) 
 Batch 3    
0 1938.0 (220.6) 0.35 (0.08) 31.3 (6.0) 87.2 (1.7) 
4 2281.5 (33.23) 0.49 (0.11)  26.4 (8.0)  96.4 (1.2) 
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Fig. 3.8 A plot of the Casson model (blue line) and the raw viscosity data (red line). 
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Table 3.7. The Casson parameters for the suspension before and after stability studies 
 
Time Plastic Viscosity Yield Stress CoF 
 Batch 1   
0 35.4 (2.4) 54.0 (2.5) 93.8 (1.4) 
4 60.1 (10.5) 28.1 (4.5) 95.6 (0.3) 
 Batch 2   
0 31.3 (6.0) 59.6 (4.7) 90.8 (0.3) 
4 62.1 (6.0) 32.7(10.7) 92.9 (2.1) 
 Batch 3   
0 30.1 (0.6) 54.4 (7.8) 93.1 (0.3) 
4 57.2 (3.8) 38.7 (5.1) 94.7 (0.5) 
 
 
Freeze-Thaw Stability: The reconstituted suspension was subjected to freeze-thaw 
cycling to determine the effect of temperature on the physical stability of the suspension. 
The apparent viscosity was monitored over the two week period and there were no 
significant changes in the apparent viscosity. Thus intermittently taking the suspension 
out of a refrigerator to dispense a dose will not negatively affect the physical stability of 
the suspension. Similarly, the pH of the suspension remained unchanged. 
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3.4 Conclusions 
 The stability of the development batches of granules for reconstitution was 
evaluated at accelerated and long-term storage conditions. Lamivudine, zidovudine, and 
nevirapine were stable in the formulation during the six month period showing minimal 
degradation. The dissolution profiles of the drugs before and after stability studies did not 
show any significant changes. The potency and dissolution profiles met the USP criteria. 
In addition, after the stability testing of the clinical batch at long-term stability 
conditions, the potency and dissolution attributes met the USP specifications. 
The reconstituted suspension retained its potency throughout the study period. 
The pH and apparent viscosity of the suspension did not change with time. In addition, 
the Herschel Bulkley model adequately described the shear thinning parameters of the 
suspension. The flow index obtained from the Herschel Bulkley showed small increments 
with time while the yield stress and consistency index showed marginal reductions. To 
conclude, the granules for reconstitution and the reconstituted suspension exhibited both 
physical and chemical stability.  
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Chapter 4. Pilot Bioequivalence Study between Generic and 
Reference Products of Lamivudine 150 mg/Zidovudine 300 mg 
Tablets  
  
4.1 Introduction 
The design and conduct of clinical studies if not properly controlled can 
negatively affect the outcome of the study. For instance the local facilities available for 
housing the subjects could influence the decision to keep subject in-house over night 
prior to dosing as well the ability to take frequent samples within the first 24 hr of dosing. 
Further, the ability to estimate the local intrasubject variability could influence the 
number of subject enrolled in the study to avoid the unacceptable conclusion of 
bioinequivalence. To overcome these limitations, it is critical to perform a pilot study 
prior to the pivotal clinical study to evaluate some of these variable parameters. 
Therefore, the pilot bioavailability/bioequivalence clinical study was designed to assess 
the suitability of the proposed clinical site in Lagos, Nigeria for the study. The objective 
of the pilot study was to determine the pharmacokinetic bioequivalence between generic 
and reference fixed-dose combination products of lamivudine 150 mg/zidovudine 300 mg 
tablets.  
Although more than 25 antiretroviral compounds have been approved for 
marketing and clinical use in the treatment of HIV AIDS
7
 in adults, 14 compounds are 
approved for use in children and 13 of these are available in acceptable pediatric 
formulations.
9
 Most of the newer protease inhibitor ARV class of drugs has not been 
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licensed by the FDA for use in children either due to safety concerns or a lack of clinical 
data on the use of the drugs in children. There is thus a limited number of age-appropriate 
pediatric formulations, particularly in resource limited settings. Therefore, scored fixed-
dose combination ARV tablets for adults are frequently administered to children. The 
administration of the scored tablets to children could lead to sub therapeutic doses with 
an increase in the development of resistance.
2, 3, 107
 Further, it may lead to lower 
adherence to medication in children.
9
 Added to this, children often have higher viral 
loads compared to adults
9
 and there is the need to ensure accurate dosing to suppress viral 
replication to reduce the viral RNA load in the blood. Hence, the second objective of this 
chapter of the research was to assess the in vivo quality of the FDC ARV adult tablets 
through a bioavailability and bioequivalence study. The in vitro quality of the tablets was 
evaluated in previous research by this laboratory. 
 
4.2 Experimental 
4.2.1 Materials 
Ammonium acetate, potassium dihydrogen phosphate (KH2PO4), triethylamine (TEA), 
HPLC grade methanol and acetonitrile, heparinized BD vacutainer tubes, cryogenic vials 
(Fisher Scientific, Hanover Park, IL); Aprobarbital (Alltech, Deerfield, IL); Drug free 
human plasma (Plasmacare Inc., Pittsburgh, PA); 2ml micro-centrifuge tubes (VWR, 
West Chester, PA). Lamivudine 150 mg/zidovudine 300 mg test tablets (generic) and 
reference tablets (innovator) were obtained from the National Institute for Pharmaceutical 
Research and Development (NIPRD) and local drug stores in Nigeria.  
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4.2.2  Bioanalytical Assay 
HPLC Chromatographic Condition:  Chromatographic separation was performed on 
Shimazdu HPLC SCL-10A controller with SIL-10A auto injector linked with UV-VIS 
detector SPD-10A; Luna C18 150mm × 4.6mm, 5µm column (Phenomenex, Torrance, 
CA); solvent system comprised of 25mM KH2PO4 (65%v/v) pH adjusted to 6.5 with 
triethylamine and methanol (35%v/v); injection volume was 50 µl;  isocratic elution at a 
flow rate maintained at 1.0 ml/min; detection wavelength was 245nm using EZChrome
TM 
Software (Version 2.1). 
 
 
Preparation of Standard Solutions: Solutions containing 1mg/mL of the lamivudine or 
zidovudine was prepared by dissolving the weighed samples in deionized water. Solvent 
for aprobarbital was methanol:water 50/50 %v/v.  Further dilutions were made using 25 
mM potassium dihydrogen phosphate buffer.  The aprobarbital was used as internal 
standard. 
 
Liquid-Liquid Extraction: A volume of 376 μL of thawed plasma was added to micro 
centrifuge tube followed by 24 μL of the internal standard (aprobarbital) and 576 μL of 
chilled acetonitrile. The tube was vortexed for 3 min and centrifuged at 11000 RPM for 
10 min at 4 
o
C. 800 μL of the supernatant was evaporated under nitrogen at 37 oC. The 
dry residue was reconstituted with 800 μL of the buffer component of the mobile phase 
(25 mM  KH2PO4) and analyzed by HPLC-UV method. 
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Calibration Curves: The appropriate volumes of the standard solutions of lamivudine, 
zidovudine, nevirapine and aprobarbital were added together in a micro-centrifuge tube 
containing 376 μL of drug free plasma and extracted using the extraction procedure 
above. Quality control (QC) samples at three levels were also prepared by spiking blank 
plasma with the working drug and internal standard solutions. The spiked samples were 
then extracted using liquid-liquid extraction method. 
 
Validation: To establish the linearity and the range, replicate samples were used to 
construct a six-point calibration curve. The range was estimated based on the literature 
values for plasma analysis of the three drugs. Linearity was examined over the 
concentration range for lamivudine (50-2400ng/mL) and zidovudine (50-2000ng/mL). 
The data was fitted using the least sum of squares method. Precision and accuracy were 
determined by analyzing replicate samples at low, medium and high levels of the 
calibration curve. Precision was computed as percent relative standard deviation (RSD) 
and accuracy was computed as percent relative recovery.  Inter-day reproducibility was 
examined by repeating the procedure using independent samples on three separate days. 
The data was analyzed using two-way ANOVA. 
 
 
Short- and Long-term Stability: To monitor the stability of the extracted samples during 
running on the HPLC, spiked plasma samples at three different concentrations were kept 
at room temperature for 12, 24 and 48 hr. After the set time period, the plasma samples 
were subjected to liquid-liquid extraction procedure and the extracted drug samples were 
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analyzed using HPLV-UV method. Spiked plasma samples kept under the refrigeration 
condition – 200C for 30 days were assessed for long term stability studies.  
 
4.2.3 Research Protocol Approval and Study Design 
Institutional Review Board (IRB) protocol was submitted to the Duquesne 
University IRB for approval: the approved protocol was assigned the number 05/103 (See 
appendix 3). Similar submission was made to the University of Lagos, Nigeria, the 
clinical site for approval.    
The criteria for enrolling subjects into the study were (a) Adult males determined 
to be healthy on the basis of a pre-trial physical examination, medical history and the 
results of blood biochemistry and hematology tests; (b) subject competent and willing to 
sign informed consent form voluntarily after being given all the detailed information 
about the study; and (c) willingness to be hospitalized for a 24-hour intensive sampling 
period. The subjects were excluded if (a) hypersensitive to study drugs; (b) drinking 
alcohol, smokers; (c) anemic or exhibited abnormal laboratory test, (d) if there were any 
clinically significant diseases or findings during the screening, medical history or 
physical examination that, in the opinion of the investigator, may interfere with the study; 
and (e) exposure to experimental or prescribed drugs within 30 days prior to the 
beginning of the study. Subjects who met the eligibility criteria were administered the 
consent form (see appendix 4). 
Study Design: The study was designed as a single-dose, two-sequence two-treatment 
crossover design. The subjects were randomly assigned to the two arms of the study. The 
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two sequences were (a) test product during period one and reference product during 
period two or (b) reference product during period one and test product during period two.   
 
Dosing: Following an overnight fast, 12 subjects were administered 150/300mg 
3TC/AZT tablets with 240 ml of water. Volunteers were fed with regular diet after 4 
hours of dosing. The test product was 150/300mg 3TC/AZT Duovir® tablets (Cipla 
India) and the innovator product was 150/300mg Combivir® tablets (GSK, UK). 
Nevirapine 200 mg tablets provided for simultaneous administration was inadvertently 
not given to the subjects. 
 
Blood Sampling and Analysis: Blood samples were collected before dosing and at pre-
determined intervals of 0.25, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4, 6, 8 hrs post dosing. All the 
samples were centrifuged and the plasma samples were kept frozen at - 80°C until 
assayed using a validated isocratic HPLC-UV method.  
 
Evaluation of Pharmacokinetic Parameters and Statistical Analysis: The peak area ratio 
for the drug/internal standard was obtained and used to determine the drug concentration 
in the plasma. Non-compartmental pharmacokinetic analysis (NCA) was used to 
determine pharmacokinetic (PK) parameters for each subject. Area under curve from zero 
to the last measurable time point (AUC0-t) and the area under curve from time zero to 
infinity (AUC0-∞) was computed by non-compartmental model with extravascular input 
using WinNonlin Professional
®
 (version 5.2) software (Pharsight Corporation, Mountain 
View, CA). The maximum plasma concentration (Cmax) and the time to attain the 
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maximum plasma concentration (tmax) were determined from the concentration-time 
profile curves. The AUCs and Cmax were log transformed. The geometric mean ratios of 
test/reference of Cmax, AUC0-t and AUC0-∞ for 3TC and AZT were used to determine the 
average bioequivalence of the drug. The 90% confidence intervals (CI) for the ratios were 
determined. The Food and Drug Administration guidelines for average bioequivalence 
requires that the 90% CI for the ratio of mean Cmax, AUC0-t and AUC0-∞ of test to 
reference  lies within the specified interval of 80-125%. 
 
4.3 Results and Discussion 
4.3.1 Validation of HPLC-UV Method 
 The chromatogram showed well resolved peaks indicating specificity of the 
method. The linear dynamic range for lamivudine was 50 – 2400 ng/mL (r2 = 0.9980) and 
the linear range for zidovudine was 50-2000 ng/mL (r
2
=0.9994). The intra-day accuracy 
and precision for lamivudine were 100.04 % and 0.86% respectively. The inter-day 
accuracy and intermediate precision for lamivudine were 100.10 % and 0.65% 
respectively. In the case of zidovudine, the intra-day accuracy and precision were 98.57 
% and 2.74% respectively. The inter-day accuracy and intermediate precision for 
zidovudine were 99.96 % and 1.39 % respectively. Two-way analysis of variance of the 
accuracy and precision within days and between days did not show any significant 
differences (p > 0.05 and Fcalculated < Fcritical) indicating that the method was suitable 
for the intended purpose. 
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4.3.2 Pharmacokinetic Analysis 
 The ratio of the peak area of the drug to the peak area of the internal standard 
(aprobarbital) was used to construct a calibration curve. The calibration curve was used to 
determine the concentration of the plasma drug concentration. Initial inspection of the 
data showed that the data for two subjects was very different from that from the rest of 
the cohort. The data for the two subjects was treated as outliers and eliminated from 
further analysis. Therefore, subsequent data analysis was performed for the remaining 10 
subjects.  
Non-compartmental pharmacokinetic analysis was performed to obtain the area 
under the curve from time zero to time t (AUC0-t) and the area under the curve from time 
zero to time infinity (AUC0-∞). The linear-log trapezoidal rule was used for the 
calculation of AUC, assuming the drug disposition followed first-order kinetics. The 
maximum plasma concentration (Cmax) and the time to achieve the maximum plasma 
concentration (tmax) were obtained from the graph. The tmax for lamivudine in the test and 
reference products was 0.93±0.15 min and 0.75±0.16 min respectively (Fig 4.1). 
Similarly, the tmax for zidovudine in the test and reference products was 0.73±0.11 min 
and 0.63±0.07 min respectively (Fig 4.2).   
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Fig 4.1 Plasma concentration-time profiles for lamivudine from the test and reference 
products. The data represents the mean (± standard error) for 10 subjects.  
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Fig 4.2 Plasma concentration-time profiles for zidovudine from the test and reference 
products. The data represents the mean (± standard error) for 10 subjects.  
   135 
 
 
 
4.3.3 Statistical Analysis for Bioequivalence Assessment 
 Bioequivalence is characterized by three pharmacokinetic parameters: Cmax, 
AUC0-t and AUC0-∞. Therefore these pharmacokinetic parameters were log transformed 
and the ratio of the test to reference PK parameters as well as the 90 % confidence 
interval determined. The analysis was done using WinNonlin 5.2. ANOVA test was 
performed to determine the effect of the model parameters. The model parameters were 
sequence, subject nested in sequence, period and formulation. ANOVA test revealed that 
the effect of subject nested in sequence was significant (p-value = 0.00552) for 
lamivudine (Table 4.1).  This implies that for the two formulations to be bioequivalent, 
the distribution of the subject within the sequence will have to be taken into account. A 
probable cause of this is a carryover effect from the previous dose. However, the washout 
period was long enough to ensure complete elimination of lamivudine before the second 
dose. Besides, the plasma samples collected just before the second dosing did not contain 
any drug. A more plausible cause of this is a large intra-subject variability compared to 
the small sample of 10 subjects. In particular, the mean plasma concentration-time 
profiles for the test product (Fig 4.1 and 4.2) exhibited larger variability (larger standard 
error bars) compared to the reference product. This implies that the drug disposition in 
the subject during period 1 and period 2 were different. 
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Table 4.1 Analysis of variance of the model parameters for lamivudine 
Hypothesis DF SS MS F_stat P_value 
Sequence 1 0.00825 0.00825 0.01718 0.89896 
Subject (Sequence) 8 3.84175 0.48022 7.27077 0.00552 
Formulation 1 0.14793 0.14793 2.23968 0.17288 
Period 1 0.03466 0.03466 0.52479 0.48945 
Error 8 0.52838 0.06605     
 
 
 The FDA specification for bioequivalence requires that the ratio of the test to 
reference pharmacokinetic parameters should be within the 80 – 125 % limits of the 90 % 
confidence interval. For lamivudine, the confidence intervals for Cmax, AUC0-t, and 
AUC0-∞ all extended across the lower limits (Table 4.2) of the bioequivalence limits 
indicating that lamivudine in the two formulations were bioinequivalent. In the case of 
zidovudine, the 90 % confidence interval for AUC0-∞ was 80.07 – 120.39 % which was 
within the bioequivalence limits (Table 4.3). However, the confidence intervals for the 
Cmax and AUC0-t extended across the lower limits of the bioequivalence boundary. 
Therefore, zidovudine in the test and reference products was bioinequivalent. Thus the 
test and innovator fixed-dose combination tablets of lamivudine/zidovudine were not 
bioequivalent. The observance of bioinequivalence could be due to the small sample size 
used in the pilot clinical study and a larger intra-subject variability. The larger variability, 
especially in lamivudine test product (Fig 4.1) produced an apparent higher 
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bioavailability of the test product. However, in vitro dissolution and potency tests on the 
tablets showed consistent results.
108
  
 
Table 4.2. Geometric least square mean values of pharmacokinetic parameters, ratio, and 
90 % confidence interval for lamivudine 
Parameters Test Ref Test/Ref 90 % Confidence Interval 
Cmax (ng/mL) 721.57 792.92 91.00 73.52 – 112.64 
AUC0-t (ng*h/mL) 1688.53 1971.64 85.64 68.85 – 106.52 
AUC0-∞  (ng*h/mL) 2092.72 2740.39 76.37 53.32 -109.37 
 
 
Table 4.3. Geometric least square mean values of pharmacokinetic parameters, ratio, and 
90 % confidence interval for zidovudine 
Parameters Test Ref Test/Ref 90 % Confidence Interval  
Cmax (ng/mL) 516.71 662.36 78.01 63.48 – 95.87 
AUC0-t (ng*h/mL) 1420.52 1607.23 88.38 68.02 – 114.84 
AUC0-∞  (ng*h/mL) 2002.39 2039.45 98.18 80.07 – 120.39 
 
 
4.4 Conclusions 
The validated HPLC-UV method had the requisite accuracy and precision for the 
analysis of the plasma samples. The test and reference fixed-dose combination 
lamivudine 150 mg/zidovudine 300 mg antiretroviral tablets were not bioequivalent. The 
   138 
 
sample size for the pivotal bioequivalence studies should be increased to enhance the 
likelihood of a bioequivalence outcome. Finally, due to some administrative 
inconvenience and logistic problems, the clinical site in Lagos, Nigeria could not be used 
for the Phase I clinical study. Hence an alternate location should be identified for the 
Phase1 bioequivalence clinical trial. Lessons learned from this pilot study formed the 
basis for the development of protocols for the clinical study (chapter 5). 
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Chapter 5. Bioavailability/Bioequivalence Phase 1 Clinical Studies 
of Granules for Reconstitution   
 
5.1 Introduction 
 The bioavailability and bioequivalence of a new formulation should be assessed 
to determine the rate and extent of drug release from the dosage form and the subsequent 
absorption into the plasma. The intricacies of bioequivalence clinical trials are 
underscored by the science-driven guidances that are established by the regulatory 
agencies.  Bioequivalence is defined as the absence of a significant difference in the rate 
and extent to which the active ingredient or active moiety in pharmaceutical equivalents 
or pharmaceutical alternatives becomes available at the site of drug action when 
administered at the same molar dose under similar conditions in an appropriately 
designed study.
79
 Two bioequivalent products are fundamentally assumed to offer 
therapeutic equivalence in terms of formulation performance, efficacy and safety.
81, 85
 
The statistical criterion for bioequivalence as issued by the Food and Drug 
Administration (FDA) requires that the 90 % confidence interval of the ratio of the 
average response for the test to the reference three-fold pharmacokinetic (PK) parameters 
on a log-transformed scale should fall within 80 % to 125 %.
79, 83
 The statistical test for 
the determination of the 90 % confidence interval is the two one-sided t-test. The t-test 
assesses whether (i) the test product is clinically significantly less bioavailable compared 
to the reference listed product and (ii) the reference product is significantly less 
bioavailable compared to the test product.
81
 The three-fold PK parameters that qualify 
   140 
 
bioequivalence are (i) the maximum plasma concentration (Cmax); (ii) the area under the 
plasma concentration-time curve from time zero to time t (AUC0-t); and (iii) the area 
under the plasma concentration-time curve from time zero to time infinity (AUC0-∞ ).  
Other bioavailability PK parameters of interest are the time required to reach the 
maximum plasma concentration (tmax), the elimination half-life, and the terminal 
elimination rate constant.   
To assure the safety, rights and well-being of human subjects, clinical trials are 
performed according to the Helsinki Declaration
89
 on ethical principles in medical 
research as required by the local Institutional Review Board (IRB). Such principles 
include informed consent, subject confidentiality, adverse events reporting, and trained 
personnel should conduct the study. The regulatory guidances by the Food and Drug 
Administration (FDA) and the International Conference on Harmonization (ICH) are 
established to safeguard the rights and safety of subjects, and ensure Good Clinical 
Practice (GCP) or quality standards for ethical and scientific means of conducting clinical 
studies in human subjects. 
79, 90
  Hence, a clinical study protocol designed to follow ICH-
GCP will be developed and submitted for approval. The goal is to test the hypothesis that 
lab-developed fixed-dose combination granules for reconstitution comprising lamivudine, 
zidovudine and nevirapine will be bioequivalent to the co-administered single entities of 
the reference products.  
To test the hypothesis, the following specific aims were proposed.  
Specific Aim 1: To develop a clinical research proposal and submit for approval from the 
Institutional Review Board. Approval from the other regulatory authorities with 
jurisdiction over the study will be obtained. 
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Specific Aim 2: To assess the bioavailability and bioequivalence of the granules for 
reconstitution in adult cohorts. The clinical batch will be used for the clinical study in 
adult cohorts at the Bowen University Teaching Hospital (BUTH) in Nigeria. 
 
5.2 Experimental  
Materials: Ammonium acetate, potassium dihydrogen phosphate (KH2PO4), 
triethylamine (TEA), HPLC grade methanol and acetonitrile, heparinized BD vacutainer 
tubes, cryogenic vials (Fisher Scientific, Hanover Park, IL); Aprobarbital (Alltech, 
Deerfield, IL); Drug free human plasma (Plasmacare Inc., Pittsburgh, PA); 2ml micro-
centrifuge tubes (VWR, West Chester, PA).  
 
5.2.1 Clinical Research Protocol  
A clinical research proposal designed under Good Clinical Principles guidances 
and justifying the significance of the study was submitted to the following institutions for 
approval: (i) Institutional review Board – Duquesne University, Pittsburgh PA, protocol  
number 09-56.  
(ii) Institutional review Board – Roosevelt University, Schaumburg, IL, protocol  
number 2010-73. 
(iii) Ethics Board – Bowen University Teaching Hospital, Ogbomosho, Nigeria.  
The submission included (i) Transmittal form, (ii) Advertisement for subject recruitment, 
(iii) Informed consent; and (iv) National Institute of Health (NIH) training certificate for 
the conduct of studies in human subjects. See Appendices 5 and 6 for IRB approval letter 
and sample of the informed consent form.   
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In partnership and under Cooperative Research Agreement (CRDA) with a start-
up company, Elim Pediatric Pharmaceuticals Inc, Investigational New Drug (IND) 
application was submitted to the FDA on FDA Form 1571.  The rationale for the IND 
submission was that although all the three drugs being investigated in the study have been 
approved by the FDA for marketing, the granules for reconstitution is a new formulation 
without prior exposure in humans. Hence, an IND was required prior to testing. The IND 
consisted of (i) the protocols which had been approved by the IRB, (ii) investigator's 
brochure, (iii) chemistry, manufacturing, and control information (iv) pharmacology and 
toxicology information, and (v) previous human experience with the investigational 
drugs.  Similar submission was made to the National Agency for Food and Drug 
Administration and Control (NAFDAC) in Nigeria.  
Other research instruments developed were Case Report Form (CRF), 
Medical/Laboratory/Technical Procedures /Tests, Certificates of Analysis of 
Investigational Products, Master Randomization List, and Monitoring Visit Reports. 
Based on the lessons learned from the pilot study (chapter 4), several protocols were 
developed detailing every step. For instance, there were protocols for reconstituting the 
granules with water, product administration using oral syringe, centrifugation of blood 
and storage of plasma. 
 
5.2.3 Bioavailability and Bioequivalence Clinical Trials 
5.2.3.1 Study Design 
 The clinical phase was conducted as a joint project with Ms Anjali Joshi. The 
study protocol titled ―Three-way Crossover Bioequivalence Study of Pediatric 
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Formulations of Lamivudine/Zidovudine/Nevirapine‖ was designed and submitted to the 
regulatory authorities. The three-way crossover was designed such that it could be split 
into two two-way crossover designs. The products under investigation in the three arms 
of the study were (i) AZT/3TC/Nev 60/30/50 mg per 5 mL granules for reconstitution. 
(ii) AZT/3TC/Nev 60/30/50 mg per tablet for oral disintegration. (iii) Per-oral liquid 
formulations containing single entities of AZT, 3TC or Nev. The same drugs at the same 
doses were investigated; therefore teasing out the results into two two-way crossover 
design did not have a negative impact on the results. Hereafter, the clinical study will be 
referred to as two-way crossover study. 
 
Two-way Crossover Study Design: The study was designed as an open label two-
sequence two-period crossover design. The sequences were Test-Reference (TR) or 
Reference-Test (RT) and the dosing periods were I and II. Of the three drugs, nevirapine 
had the longest half-life of 45 hr for a single dose. Therefore a washout period of 14 days 
was included to account for over 7 half-lives. The 7 half-lives will ensure that at least 
99% of the drug is eliminated before the dose is administered during period II.  
 
 
 
5.2.3.2 Enrollment of Subjects 
Announcement for Study: Advertisements announcing the study were posted at the 
Bowen University Teaching Hospital (BUTH) for two months prior to the 
commencement of the study to invite volunteers. The ICH guidance document E11 on 
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clinical investigation of medicinal products in the pediatric population suggests that for 
relative bioavailability comparison of pediatric formulations, adult subjects may be 
used.
91
 The use of adults permits the initial assessment of pharmacokinetic parameters as 
well as the safety profile of the new formulation. Hence, healthy adult volunteers were 
invited to participate in the study.   
 
Eligibility Criteria: The eligibility criteria included adults between 22 and 55 years; 
Healthy, determined on the basis of a pre-trial physical examination, medical history, 
electrocardiogram and the results of blood biochemistry and hematology tests; Subject is 
competent and willing to sign informed consent form voluntarily after being given all the 
detailed information about the study; Willing to be hospitalized for 24-hour intensive 
sampling period.  
 
Exclusion Criteria: The exclusion criteria was hypersensitivity to study drugs; Abnormal 
laboratory biochemistry values; Smokers;  Any clinically significant diseases or findings 
during the screening, medical history or physical examination that in the opinion of the 
investigator, may interfere with the study; Treatment with experimental drugs within 30 
days prior to study entry.  
Based on the above protocol, 44 adult cohorts were screened, and 11 subjects 
were disqualified from further continuation in the study. Twenty-four subjects were 
dosed and donated samples.  
 
5.2.3.3 Dosing and Sample Collection  
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Following an overnight fast, the volunteers were dosed with either the reference 
drugs or test suspension. All test suspensions were freshly prepared and administered 
without being stored for dosing during the subsequent periods. The reference drug 
regimen consists of 12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of 
Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 
10 mg/mL suspension. The test drug was 20 mL of reconstituted granules for suspension 
containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of 
suspension. The doses were dispensed with oral syringes. The subjects were administered 
the doses together with 240 ml of water. The registered nurse in-charge of dosing 
checked the oral cavity of the volunteers to ensure the dose had been swallowed. 
One venipuncture was made just before the dosing and an in-dwelling catheter 
inserted for blood sample collection during hospitalization for 24 hours. Fresh 
venipunctures were made for each ambulatory sample collection. The total number of 
venipunctures during the study period were 10 (5 venipunctures X 2 doses). 5 mL of 
blood samples were collected before dosing and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 12, 24, 
48, 72, 96 hours after dosing. The total blood sample collection from each patient for the 
duration of the study was 150 mL (5 mL X 15 samples X 2 doses).  
The blood samples collected in heparinized labeled tubes were centrifuged at 
room temperature for 15 minutes at 2700RPM and the plasma was transferred to labeled 
cryogenic vials and stored at -80 
o
C. The frozen plasma was shipped on dry ice from 
BUTH, the clinical site, to Duquesne University for HPLC-UV analysis. 
 
5.2.3.4  Bioanalytical Assay 
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Preparation of Standard Solutions: Solutions containing 1mg/mL of the lamivudine or 
zidovudine was prepared by dissolving the weighed samples in deionized water. Solvent 
for nevirapine and aprobarbital (internal standard) was methanol:water 50/50 %v/v.  
Further dilutions were made using 25 mM potassium dihydrogen phosphate buffer.  The 
aprobarbital was used as internal standard. 
 
Liquid-Liquid Extraction: 200 μL of chilled acetonitrile was added to a micro-centrifuge 
tube. 376 μL of thawed plasma was added followed by 24 μL of the internal standard 
(aprobarbital) and 576 μL of chilled acetonitrile. The tube was vortexed for 3 min and 
centrifuged at 1200 g for 12 min at 4 
o
C. 800 μL of the supernatant was evaporated under 
nitrogen at 37 
o
C. The dry residue was reconstituted with 800 μL of the buffer component 
of the mobile phase (25 mM  KH2PO4) and analyzed by HPLC-UV method. 
 
Calibration Curves: The appropriate volumes of the standard solutions of lamivudine, 
zidovudine, nevirapine and aprobarbital were added together in a micro-centrifuge tube 
containing 376 μL of drug free plasma and extracted using the extraction procedure 
above. 
 
Chromatographic Conditions: An isocratic HPLC method at a flow rate of 1 mL/min was 
used for the plasma analysis. The chromatographic system consisted of Waters 2695 
Separations module, 996 PDA detector, and Empower 2 chromatographic software 
(Waters Corporation, Milford, MA). The chromatogram was monitored at 245 nm.  The 
solvent system comprised of 25mM KH2PO4 (65%v/v) pH adjusted to 6.5 with 
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triethylamine and methanol (35%v/v) and Column used was Luna-C18 5μm 150 x 4.6 
mm column (Phenomenex, Torrance, CA). The injection volume was 100 μL. 
    
Validation: To establish the linearity and the range, replicate samples were used to 
construct a six-point calibration curve. The range was estimated based on the literature 
values for plasma analysis of the three drugs. Linearity was examined over the 
concentration range of lamivudine (100-2400ng/mL), zidovudine (100-2000ng/mL), and 
nevirapine (100-3000µg/mL). The data was fitted using the least sum of squares method. 
Precision and accuracy were determined by analyzing replicate samples at low, medium 
and high levels of the calibration curve. Precision was computed as percent relative 
standard deviation (RSD) and accuracy was computed as percent relative recovery.  Inter-
day reproducibility was examined by repeating the procedure using independent samples 
on three separate days. The data was analyzed using two-way ANOVA. 
 
5.2.3.5 Pharmacokinetic and Statistical Analysis 
 The peak areas obtained from the chromatograms were used to construct plasma 
concentration time profiles. The pharmacokinetic parameters were the primary study 
endpoints and these were determined by non-compartmental analysis using WinNonlin 
software (Pharsight Corporation, Sunnyvale, CA). The maximum plasma concentration 
(Cmax,) and the time to attain maximum concentration (tmax) were obtained directly from 
the graphs. The area under curve of plasma concentration-time curves (AUCo-t, AUCo-∞) 
were obtained by applying trapezoidal rule. The bioequivalence comparison between the 
tests and reference drugs was performed using the two one-sided test. The FDA statistical 
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criterion for bioequivalence requires that the 90 % confidence interval of the ratio of the 
average response for the test to the reference three-fold pharmacokinetic parameters 
(Cmax, AUC0-t, AUC0-∞) on a log-transformed scale should fall within 80 % to 125 %.
79, 83
 
 
5.3 Results and Discussion 
5.3.2 Bioanalytical Assay 
 The chromatogram obtained showed well resolved peaks of lamivudine, 
zidovudine, nevirapine and the internal standard (Fig 5.3). This indicated the specificity 
of the isocratic HPLC-UV method. However, there were two large peaks from the blank 
plasma, probably due to heparinized vacutainer tubes used to collect the blood to prevent 
clotting. The HPLC-UV method was validated for range, precision, and accuracy. The 
linear range for lamivudine was 100 – 2400 ng/mL with an R2 value of 0.9959±0.0028 
(Table 5.1). The linear range for zidovudine and nevirapine were established over the 
ranges of 100 – 2000 ng/mL and 100 – 3000 ng/ml respectively with the corresponding 
R
2
 values of 0.9945±0.0020 and 0.9946±0.0044 respectively. The linear ranges examined 
covered the estimated ranges of the plasma concentrations of the three drugs. 
 The intraday accuracy ranged from 97.86±2.41% to 100.71±0.47% and the 
intraday precision ranged from 0.47 5 to 2.46%. The interday accuracy and intermediate 
precision were evaluated using two-way ANOVA to determine whether the recoveries 
from the different concentration levels or the different days were significantly different. 
The significance level  was set at 0.05.  The interday accuracy and intermediate 
precision for lamivudine were 98.87±1.88% and 1.90% respectively. The p-value was 
0.0931, and Fcal (4.5560) was less than Fcrit (6.9443) indicating that there were no 
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significant differences between the assay values on different days. The interday accuracy 
and intermediate precision for zidovudine were 98.38±1.61% and 1.63% respectively. 
The p-value was 0.6474, and Fcal (0.4856) was less than Fcrit (6.9443) indicating that 
there were no significant differences between the assay values on different days. 
Similarly, the interday accuracy and intermediate precision for nevirapine were 
97.57±1.88% and 1.93% respectively. The p-value was 0.9271, and Fcal (0.0772) was 
less than Fcrit (6.9443) indicating that there were no significant differences between the 
assay values on different days. The validated method was stable and produced consistent 
results within different concentration levels and between days and thus was suitable for 
application to the analysis of the plasma. Analysis of plasma samples stored at room 
temperature (mimicking HPLC run conditions) and at -20 
o
C (Chapter 4) showed that the 
drugs were stable in the plasma. 
 
Table 5.1 Validation parameters for the isocratic HLPC-UV method for plasma analysis 
 Parameter  Lam Zid Nev 
Range (ng/mL) 100 - 2400 100 - 2000 100 - 3000 
R
2
 0.9959 (0.0028) 0.9945 (0.0020) 0.9946 (0.0044) 
Intraday    
      Accuracy (%) 100.71 (0.47) 99.27 (1.81) 97.86 (2.41) 
      Precision (%) 0.47 1.82 2.46 
Interday    
     Accuracy (%) 98.87 (1.88) 98.38 (1.61) 97.57 (1.88) 
     Int. Precision (%) 1.90 1.63 1.93 
LOD (ng/mL) 22.20 29.20 12.35 
LOQ (ng/mL) 66.59 87.61 37.06 
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Fig 5.3 Chromatogram showing the peaks of a calibration curve standard. [Lamivudine 
(lam), zidovudine (zid), nevirapine (nev), aprobarbital (IS), and unknown (X)] 
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Fig 5.4 Chromatogram of (A) sample of plasma from a subject and (B) blank plasma. 
[Lamivudine (lam), zidovudine (zid), nevirapine (nev), aprobarbital (IS), and unknown 
(X)] 
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5.3.3 Demographics and Safety Results 
 The study population was made up of 24 healthy adults: all the subjects were of 
black race. Forty-four adults aged 22-55 years were screened, 11 were disqualified based 
on the exclusion criteria. Of the eligible 33 cohort, 24 subjects were dosed and blood 
samples were collected from all the 24 subjects (Table 5.2). All the 24 subjects completed 
the study and did not miss any samples. Therefore all the 24 subjects were protocol 
compliant and data from these subjects was included in the pharmacokinetic and 
statistical analysis. There were no reports of severe adverse events by any of the study 
subjects indicating that the drugs were safe. 
 
Table 5.2 Demographics of the study population. 
 Parameter Group A Group B 
Males 12 6 
Females 4 2 
Weight (kg) 61.4 63.9 
Age (yr) 31.7 33.5 
 
5.3.4 Pharmacokinetic Analysis 
The plasma samples were analyzed using the validated HPLC-UV method. The 
peak areas obtained from the chromatograms were converted to the ratio of the peak area 
of the drug to the peak area of the internal standard. The external calibration curves were 
then used to convert the peak area ratio into the concentration of the drugs. Thus plasma 
concentration time profiles were obtained. These data points were plotted as plasma 
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concentration-time curves using Phoenix WinNonlin 6.1 (Pharsight Corporation, 
Sunnyvale, CA). The non-compartmental pharmacokinetic analysis was performed using 
the log trapezoidal method to yield the area under the curve (AUC). The linear terminal 
portion of the curve was used to obtain the elimination rate constant and the elimination 
half-life. The maximum plasma concentration (Cmax) and time to attain maximum plasma 
concentration (tmax) were read directly from the graphs.  The mean plasma concentration 
profiles of the reference product and the test suspension were compared for lamivudine, 
zidovudine, and nevirapine. 
  
Time to Maximum Plasma Concentration and Elimination Half-Life: The mean plasma 
concentration-time profiles for lamivudine in the test and reference products looked 
similar (Fig 5.5). The median (range) of tmax for lamivudine for test and reference 
products were the same 0.75 (0.5-1.5) hours. The elimination half-lives for the test and 
reference products were 5.14 h and 5.95 h respectively. With respect to zidovudine, the 
mean plasma concentration-time profiles for the test and reference products also looked 
similar (Fig 5.6). The median (range) of tmax for zidovudine for test and reference 
products were 0.75 (0.25-1.5) h and 0.5 (0.25-1.5) h respectively. The elimination half-
life (t1/2) was 3.01 h and 3.38 h for the test and reference products respectively. In the 
case of nevirapine, the mean plasma concentration-time profiles for the test and reference 
products also looked similar (Fig 5.7). The median (range) of tmax for nevirapine for test 
and reference products were 4.5 (0.75-12.0) h and 3.0 (1.5-6.0) h respectively. The t1/2 
was 58.4 h and 54.7 h for the test and reference products respectively. See the section on 
drug disposition below for the discussion.  
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Fig 5.5 Mean (± standard error) plasma concentration-time profiles of lamivudine for the 
reference product (ref) and the test suspension (n=24).  
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Fig 5.6 Mean (± standard error) plasma concentration-time profiles of zidovudine for the 
reference product (ref) and the test suspension (n=24).  
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Fig 5.7 Mean (± standard error) plasma concentration-time profiles of nevirapine for the 
reference product (ref) and the test suspension (n=24).  
 
Maximum Plasma Concentration and Area Under the Curve: The maximum plasma 
concentration (Cmax) and the area under the curve (AUC) describe the exposure levels of 
the drugs in the blood. The Cmax for lamivudine ranged 600.81-1146.99 ng/mL and 
601.97-1304.99 ng/mL for the test and reference products respectively. The 
corresponding AUC0-t for the test and reference lamivudine ranged 2322.56-3991.81 
ng*h/mL and 1986.02-4045.76 ng*h/mL respectively. In the case of zidovudine, test and 
reference Cmax ranged 411.65-856.41 ng/mL and 275.14-958.95 ng/mL respectively with 
the corresponding AUC0-t 2040.03-3941.85 ng*h/mL and 1693.32-4121.39 ng*h/mL. 
With respect to nevirapine, the Cmax for the test and reference product were 230.61-
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704.53 ng/mL and 258.33-629.44 ng/mL respectively. The AUC0-t ranged 13448.92-
31218.68 ng*h/mL and 14260.02-29541.48 ng*h/mL for the test and reference 
nevirapine products respectively. 
 
Drug Disposition and Special Patient Populations:  The Cmax for lamivudine and 
zidovudine were relatively lower compared to results from other studies due to the fact 
that the test dose administered (3TC=120 mg, AZT = 240 mg) was lower compared to the 
other doses studied elsewhere (3TC=150 mg, AZT = 300 mg).
13, 108, 108
  The dose of the 
formulation was 3TC/AZT/Nev 30/60/50 mg/5mL, but this was scaled-up (3TC=120 mg/ 
AZT = 240 mg/ Nev = 200 mg) four times to the corresponding adult dose in order to 
increase the plasma concentration in adults and thereby increase the peak area detected 
by  HPLC-UV method. Of the three drugs, nevirapine is the most toxic; therefore 
nevirapine dose was used as the upper limit. Since the ratio of the doses is fixed for the 
FDC granules (test product), the doses of lamivudine and zidovudine were lower than the 
typical adult doses.   
The tmax and the elimination half-lives for the three drugs were comparable to data 
in the prescribing information for the innovator products
17, 109
 or the results from other 
studies
13
, although t1/2 for nevirapine was slightly higher. The blood sampling was 
truncated at 96 h, but the half-life of single dose of nevirapine is 45 h.
109
 The sampling 
was not extended long enough to capture up to three half-lives of nevirapine elimination. 
Thus the elimination rate constant captured for nevirapine could have been 
underestimated and this would have overestimated the half-life of nevirapine since half-
life (t1/2) is an inverse function (Eq 5.1) of the elimination rate constant (k).  
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k
t
693.0
21
         Eq. 5.1 
 
Nevirapine Disposition: The pharmacokinetic parameters of nevirapine in children 3 
months and older and adults are the same. Although the prescribing information for 
nevirapine (Viramune®)
109
 indicates an absence of racial differences in the disposition of 
nevirapine, other studies state otherwise. Differences in nevirapine exposure levels in 
adults may be due to drug metabolism enzyme differences. Nevirapine is subject 
oxidative metabolism by CYP2B6 and CYP3A.
20
 Cytochrome CYP2B6 516TT 
polymorphism has been shown to influence the plasma and intracellular concentrations 
and toxicity of NNRTIs (nevirapine and efavirenz) in HIV-infected patients.
110
 
Furthermore, Wyen et al demonstrated that CYP2B6 983T>C genotype leads to lower 
nevirapine metabolism in Black patients with an associated elevated plasma 
concentration.
20
 The Black population has an increased variant allele frequency in this 
gene, which results in lower metabolic activity and higher nevirapine exposure. Similarly, 
higher nevirapine exposure level in Black children has also been reported.
107
 However to 
facilitate accurate dosing by healthcare providers and caregivers, the manufacturers of 
nevirapine products, the World Health Organization, and other regulatory bodies do not 
emphasize this in dosing regimen. This has implications on the safety and toxicity in this 
sub-population. Hence there is a need for comparison of pharmacokinetic data from 
different Black populations (i.e. adults and children) to provide a basis for the 
development of pharmacogenomic database and prescribing information for nevirapine. 
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Drug Disposition in Paediatrics and HIV Patients: Lamivudine plus zidovudine plus 
nevirapine is recommended as a preferred first-line of antiretroviral therapy for treatment 
naïve infants (less than 12 months) and children 12 to 36 months.
1
 Older treatment naïve 
children may also receive this combination. The dose of the FDC granules for 
reconstitution formulation was 3TC/AZT/Nev 30/60/50 mg/5mL. This ratio was 
recommended by the Paediatric Antiretroviral Working Group (PAWG) of World Health 
Organization recommended as an ideal dosing strength for priority antiretroviral 
product.
16, 111
  This ratio based on body surface area (BSA) was developed by considering 
the clinical data from pediatric HIV/AIDS patients. This recommended dose was 
specifically for pediatric patients and does not require dose adjustment before 
administration to pediatric HIV/AIDS patients. In particular, the dose of nevirapine was 
increased, since the apparent clearance is higher in children due to a larger body surface 
area.
124,125
 In this fixed-dose combination, the ratio of lamivudine to zidovudine to 
nevirapine is 30:60:50, whereas in adults, the ratio is 30:60:40 (150:300 mg:200 mg). 
This formulation is not recommended for adults since it will lead to nevirapine 
overexposure and toxicity.    Hence, it can be concluded that this FDC granules for 
reconstitution is age-appropriate for pediatrics compared to the scored pediatric ARV 
tablets administered to children. The impact of under-dosing using adult FDC 
formulations cannot be over emphasized. 
 
Drug-drug interactions: Nevirapine is principally metabolized by the liver via the 
cytochrome P450 isoenzymes CYP2B6 and CYP3A4, which it induces and is thus prone 
to numerous drug-drug interactions. Co-administration of drugs that are metabolized by 
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these enzyme systems may yield lower plasma concentrations. 
109
   Drugs that induce 
these enzymes in turn can cause low plasma level of nevirapine. For instance, rifampin 
co-administered for tuberculosis, an opportunistic infection in HIV, may reduce the 
plasma concentration of nevirapine and reduce efficacy. On the other hand, enzyme 
inhibitors may cause increased plasma concentration of nevirapine and result in toxicity.  
  Lamivudine is excreted mainly unchanged in the urine and plasma levels are not 
affected by other drugs. However, zalcitabine may inhibit the intracellular 
phosphorylation of lamivudine into lamivudine triphosphate, and thus reduce efficacy.
17
 
In the case of zidovudine, stavudine and doxorubicin may antagonize the drug and reduce 
efficacy.
17
 However, during this study, there were no reports of adverse events or drug-
drug interactions since the subjects did not co- administer these drugs.  
 
5.3.5 Statistical Analysis 
Analysis of Variance: Analysis of variance test was performed on the Cmax, AUC0-t, 
AUC0-∞  to determine whether the model parameters had effect on the observed 
pharmacokinetic parameters. The ANOVA model (Eq. 5.2) tested was  
 
           
          Eq. 5.2 
 
where Yijk = pharmacokinetic response of the ith subject in the kth sequence at the jth  
period 
μ = overall mean 
ijkkjkjkiijk eQFPSY  )(
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Pj = fixed effect of the jth period; j=1, 2 
Qk = fixed effect of the sequence, k=1, 2  
Fjk = fixed effect of formulation in the kth sequence which is administered in the 
jth period 
Sik = random effect of the ith subject nested in kth sequence  
eijk = the within subject random error in observing Yijk 
 
With the exception of subject with random variability, all the other parameters had fixed 
effects. The observed PK parameters were assumed normally distributed, independent, 
and the variance was homogeneous. The desirable result was that, all the model 
parameters will have no effect of the observed PK parameters. For the AUC0-t for 
lamivudine, the ANOVA showed that the sequence (p-value= 0.6668), subject 
(p=0.8676), period (p=0.2289) and formulation (p=0.7303) were all not significant (Table 
5.3). ANOVA of the Cmax and AUC0-∞ for lamivudine revealed that all the parameters 
were not significant. Similar ANOVA for zidovudine and nevirapine showed that the 
model effects were not significant. It could be inferred that the observed differences in 
the PK parameters between test and reference products did not depend on the model 
parameters. 
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Table 5.3 ANOVA of the model parameters for AUC for lamivudine 
Source DF SS MS F_stat P_value 
Sequence 1 0.0044 0.0044 0.1904 0.6668 
Subject (Sequence) 22 0.5063 0.023 0.6168 0.8676 
Formulation 1 0.0571 0.0571 1.5316 0.2289 
Period 1 0.0045 0.0045 0.1219 0.7303 
Error 22 0.8208 0.0373   
 
 
Two One-sided t-Tests of Bioequivalence:   The bioequivalence between test and 
reference products were statistically tested using the two one-sided t-tests. The two one-
sided tests hypotheses were  
LRTH  :01     vs.   LRTaH  :1    Eq. 5.3 
and 
URTH  :02  vs.   URTaH  :2   Eq. 5.4 
The first null hypothesis H01 (Eq. 5.3) was used to test whether the difference between 
the mean test (μT) and the reference (μR) PK parameter was less than the lower limit (θL) 
of the bioequivalence limit. In effect, H01 the tests if the test product was less bioavailable 
compared to the reference product. By rejecting H01, it could be inferred that the 
difference between mean test and reference parameters was greater than the lower limit 
of the bioequivalence limit.  The second null hypothesis H02 (Eq 5.4) tested whether the 
difference between the test and the reference PK parameter was greater than the upper 
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limit (θU) of the bioequivalence limit. This tests whether the test product was more 
bioavailable compared to the reference product. By rejecting H02, then it can be inferred 
that the difference between the test and the reference PK parameters is less than the upper 
limit of the bioequivalence limit. In rejecting H01 and H02, it is concluded the difference 
between the test and the reference products is greater than the lower limit of the 
bioequivalence limit, but less than the upper limit of the bioequivalence limit (Eq. 5.5), 
hence the products are bioequivalent. 
URTL      Eq. 5.5 
 
The Phoenix WinNonlin 6.1 software package uses the Anderson-Hauck test 
statistic (tAH)
84
 procedure to test the null hypotheses (Eq. 5.3 and Eq. 5.4) using Eq. 5.6 
where n1 and n2 are the sample sizes of the test and reference products.  
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tAH follows a non-central t-distribution with the non-centrality
84
 parameter δ is given by  
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   Eq. 5.7 
 
The 90 % confidence interval at a significance level of 0.05 was used to establish the 
bioequivalence intervals for the drugs. The lower and upper limits of the bioequivalence 
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limits are 80 – 125 %.83 The Cmax, AUC0-t, and AUC0-∞ for lamivudine, zidovudine, and 
nevirapine were transformed using natural log (ln), and the above steps used to calculate 
the bioequivalence interval for each parameter. Subsequently, the power of the analysis 
for each bioequivalence calculation was also calculated. The power is the probability of 
detecting at least 20 % difference between the least square means of the test and 
reference PK parameters. 
 Power = 1 – (probability of a type II error) 
  = probability of rejecting H0 when Ha is true. 
 
 The 90 % confidence interval and the power of analysis for the PK parameters for 
lamivudine were calculated (Table 5.4). The 90 % confidence interval for Cmax, AUC0-t, 
and AUC0-∞ were 85.69 -102.54 %, 96.13 – 117.79 % and 82.63 – 106.72 % respectively. 
All these intervals within the 80 – 125 % bioequivalence limit. Therefore, lamivudine in 
the FDC granules for reconstitution and the reference lamivudine solution were 
bioequivalent.   
The power of the analysis for Cmax, AUC0-t, and AUC0-∞ were 99.09 %, 97.41 % 
and 89.29% respectively.  With respect to zidovudine, the 90 % confidence interval 
(power) for Cmax, AUC0-t, and AUC0-∞  were 83.33-109.15 % (86.32%), 99.94-124.54 % 
(95.43 %) and 98.22-122.43 % (92.90) respectively (Table 5.5). All these intervals were 
within the 80 – 125 % bioequivalence limit. Therefore, zidovudine in the test FDC 
granules and reference zidovudine syrup were bioequivalent. In the case of nevirapine, 
the 90 % confidence interval (power) for Cmax, AUC0-t, and AUC0-∞ were 87.71-109.20 % 
(95.55%), 89.31-106.26 % (99.34 %) and 85.95-102.82 % (99.10) respectively (Table 
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5.6). The observed bioequivalence intervals for the PK parameters of nevirapine were 
within the 80 – 125 % bioequivalence limits. Hence, nevirapine in the FDC granules for 
reconstitution was bioequivalent with the nevirapine in the innovator suspension.  
Therefore, combining the data for the three drugs, it is concluded that the fixed-
dose combination granules for reconstitution was bioequivalent to the co-administered 
single component innovator products. The power for detecting at least 20 % difference 
between the test and reference products was greater than 86.32 %.  
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Table 5.4 Pharmacokinetic parameters, ratio, and 90 % confidence interval for lamivudine 
Parameter Test [T] Ref [R] Ratio[T/R] 90 % CI
a
 Power 
Cmax (ng/mL)
b
 828.13 883.47 93.74 85.69 -102.54 0.9909 
AUC0-t (ng*h/mL)
b
 3019.39 2837.52 106.41 96.13 – 117.79 0.9741 
AUC0-∞ (ng*h/mL)
b
 3831.97 4080.57 93.91 82.63 – 106.72 0.8929 
tmax (h)
c
 0.75 (0.50-1.50) 0.75 (0.50-1.50)    
a. CI: Confidence interval 
b. Geometric least square mean 
c. Median (range) 
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Table 5.5 Pharmacokinetic parameters, ratio, and 90 % confidence interval for zidovudine 
Parameter Test [T] Ref [R] Ratio[T/R] 90 % CI
a
 Power 
Cmax (ng/mL)
b
 575.44 603.38 95.37 83.33-109.15 0.8632 
AUC0-t (ng*h/mL)
b
 2935.26 2631.04 111.56 99.94-124.54 0.9543 
AUC0-∞  (ng*h/mL)
b
 3941.48 3565.23 110.55 98.22-122.43 0.9290 
tmax (h)
c
 0.75 (0.25-1.50) 0.50 (0.25-1.50)    
a. CI: Confidence interval 
b. Geometric least square mean 
c. Median (range) 
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Table 5.6 Pharmacokinetic parameters, ratio, and 90 % confidence interval for nevirapine 
Parameter Test [T] Ref [R] Ratio[T/R] 90 % CI
a
 Power 
Cmax (ng/mL)
b
 373.90 382.05 97.87 87.71-109.20 0.9555 
AUC0-t (ng*h/mL)
b
 19813.18 20338.82 97.42 89.31-106.26 0.9934 
AUC0-∞  (ng*h/mL)
b
 30693.62 32649.68 94.01 85.95-102.82 0.9910 
tmax (h)
c
 4.50 (0.75-12.0) 3.0 (1.5-6.0)    
a. CI: Confidence interval 
b. Geometric least square mean 
c. Median (range) 
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5.4 CONCLUSIONS 
The validated HPLC-UV method for the bioanalytical assay had the requisite 
accuracy and precision for analyzing the plasma samples. Twenty-four healthy adults 
were enrolled and completed the clinical study. There were no reports of severe adverse 
events by any of the subjects enrolled in the study.  The ANOVA tests showed that the 
model parameters – sequence, subject, period, and formulation – had no significant effect 
(p>0.05) on the observed mean Cmax, AUC0-t, and AUC0-∞ for lamivudine, zidovudine and 
nevirapine. The observed 90 % confidence intervals for Cmax, AUC0-t, and AUC0-∞ for 
lamivudine, zidovudine and nevirapine were within the 80 – 125 % bioequivalence limits. 
Therefore, the fixed-dose granules for reconstitution and the co-administered reference 
products were bioequivalent. 
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APPENDIX 1 
 
SUMMARY 
 
Granules and Suspension Formulation Development 
The gradient high performance liquid chromatography method was validated for the 
pharmaceutical analysis of the drugs and the preservatives in the formulation. The 
method was suitable for the analysis of the fixed-dose combination granules and 
suspension without any interference from the formulation matrix.  
There were no drug-drug interactions among the drugs and there were no drug-
excipient interactions in the developed formulation. Sucralose was stable and compatible 
with the drug and suspending agent; therefore it could be used as high-intensity 
sweetener in oral powders for reconstitution into suspension.  Furthermore, sucralose, the 
high intensity sweetener was preferred to neotame due to the lack of chromophores in the 
molecule and thus non-interference in HPLC-UV analysis.   
 The roller compaction process was suitable for producing granules of uniform 
potency as indicated by the results of content uniformity. Powder X-ray diffraction 
analysis showed that the roller compaction process did not induce any polymorphic 
transformations in the drugs. The roller compaction process parameters were optimized 
for ribbon strength, particle size distribution and granule flow. In addition, the 
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formulation optimization revealed that the Avicel RC591 and Aerosil 200 were important 
determinants of the viscosity of the suspension and the sedimentation rate.  
 The drugs and preservatives met the acceptance criteria for potency, and the 
granules had the desirable product characteristics. Dissolution conditions of 0.01N HCL 
medium and USP apparatus II at 100 rpm were identified to be discriminatory between 
granule formulations containing nevirapine anhydrous or nevirapine hemihydrate.  The 
percent drug released for lamivudine, zidovudine, and nevirapine from all the three 
development batches and the clinical batch met the USP specifications for dissolution. 
The development batches and the GMP batch had the requisite potency and dissolution 
profiles. 
 
Stability of the Granules for Reconstitution and the Reconstituted Suspension 
The stability of the development batches of granules for reconstitution was 
evaluated at accelerated (40 
o
C/75 %RH) and long-term (30 
o
C/65 %RH) storage 
conditions. Lamivudine, zidovudine, and nevirapine were stable in the formulation during 
the six month period showing minimal degradation. The dissolution profiles of the drugs 
before and after stability studies did not show any significant changes. The potency and 
dissolution profiles met the USP criteria. In addition, after the stability testing of the 
clinical batch at long-term stability conditions, the potency and dissolution attributes met 
the USP specifications. 
The reconstituted suspension retained its potency throughout the study period. 
The pH and apparent viscosity of the suspension did not change with time. In addition, 
the Herschel Bulkley model adequately described the shear thinning parameters of the 
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suspension. The flow index obtained from the Herschel Bulkley small increments with 
time while the yield stress and consistency index showed marginal reductions. To 
conclude, the granules for reconstitution and the reconstituted suspension exhibited both 
physical and chemical stability.  
 
Pilot Bioequivalence Clinical Study of Fixed-Dose Combination Tablets 
The validated HPLC-UV method had the requisite accuracy and precision for the analysis 
of the plasma samples. The marketed test and reference fixed-dose combination 
lamivudine 150 mg/zidovudine 300 mg antiretroviral tablets were not bioequivalent. The 
sample size for the pivotal bioequivalence studies should be increased to enhance the 
likelihood of a bioequivalence outcome. Finally, due to some administrative 
inconvenience and logistic problems, the clinical site in Lagos, Nigeria could not be used 
for the Phase I clinical study. Hence an alternate location was identified for the Phase1 
bioequivalence clinical trial. 
 
Bioequivalence Phase I Clinical Study of Fixed-Dose Combination Granules for 
Reconstitution 
The validated HPLC-UV method for the bioanalytical assay had the requisite accuracy 
and precision for analyzing the plasma samples. Twenty-four healthy adults were 
enrolled and completed the clinical study. There were no reports of severe adverse events 
by any of the subjects enrolled in the study.  The ANOVA tests showed that the model 
parameters – sequence, subject, period, and formulation – had no significant effect 
(p>0.05) on the observed mean Cmax, AUC0-t, and AUC0-∞ for lamivudine, zidovudine and 
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nevirapine. The observed 90 % confidence intervals for Cmax, AUC0-t, and AUC0-∞ for 
lamivudine, zidovudine and nevirapine were within the 80 – 125 % bioequivalence limits. 
Therefore, the fixed-dose granules for reconstitution and the co-administered reference 
products were bioequivalent. 
 
Effect of overencapsulation of Tablets of a BCS class I and class II drugs  
While encapsulation resulted in a lag time of 2-3 min in disintegration compared to the 
unencapsulated tablets, the disintegration and dissolution of propranolol and rofecoxib 
was the same whether tablets were encapsulated in DB capsules or standard gelatin 
capsules. It can thus be expected that in vitro drug release will not be influenced by the 
type of capsule used for overencapsulation in the double blind clinical study.    
DB capsules was not used in the bioequivalence studies of the ARV drugs 
because it was determined by the clinical research team that on-site packing or 
overencapsulation (instead at the clinical batch manufacturing site) violates GMP and 
GCP requirements. The bioequivalence between the unencapsulated and encapsulated 
tablet is not inferred in this study, however, the in vivo disintegration data of 
unencapsulated and overencapsulated tablets reported by Wilding et al. suggest that the in 
vitro disintegration lag time is negligible in vivo (2).  Nevertheless, it is important to use 
DB capsules for test and comparator dosage forms to correlate in vitro data especially for 
the high soluble drugs (BCS class I). Similarly, the presence or absence of backfill had no 
significant effect on either disintegration or dissolution.  In effect, capsules offer an easy 
and inexpensive way of blinding clinical trials while posing no threat to studies where the 
performance of two drugs is compared.  The use of DB-type capsules offers the added 
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value of an advanced design that allows for overencapsulation of tablets with larger 
diameter and makes blind breaking in clinical trial virtually impossible.  
 
FUTURE DIRECTIONS 
 
The FDC formulation of lamivudine, zidovudine and nevirapine was stable at 40 
o
C/75 RH and 30 
o
C/65 %RH for six months.  Although potency reduced during the 
stability studies, the peaks due to the degradation products were not detectable. To 
resolve this anomaly, HPLC instrument coupled to a mass spectrometer detector could be 
used for the detection of the degradation products formed. The mass spectrometer has 
much higher sensitivity than the UV detector and will facilitate the detection and 
identification of the possible degradation products formed in the solid state. 
Alternatively, if the degradation product is evolved as a gas, then gas chromatography 
linked to a mass detector could be used for identification. In addition, long-term stability 
studies should be continued for the determination of the actual shelf-life of the product. 
The Phase 1 bioequivalence study assessed the pharmacokinetics parameters of 
the FDC granules in adults. The next step is to assess the bioavailability and 
bioequivalence in pediatric subjects. This study in pediatric subjects can be designed to 
evaluate pharmacokinetic parameters and safety. In addition, formulation acceptability in 
pediatric subjects should be assessed. Since pediatric patients dislike unpleasant tasting 
medicine, there is a need to conduct a taste test prior to the bioavailability and 
bioequivalence study in children. The taste test may require training of the investigators 
as well as the volunteers.  
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APPENDIX 2 
 
THE EFFECT OF OVERENCAPSULATION ON 
DISSOLUTION AND DISINTEGRATION 
The objective is to evaluate the effect of overencapsulation on in vitro 
disintegration and dissolution of BCS class I and II drugs. Overencapsulation was 
proposed earlier in the project as a method of blinding the tablets for the Phase I clinical 
study. 
 
A2.1 Overencapsulating Dosage Forms for Clinical Trials 
In the past decade, the number of comparative clinical trials has increased 
considerably. To meet the challenging time lines for the provision of clinical material, 
encapsulating tablets in hard gelatin capsules or overencapsulation is used as a quick and 
low cost technique to blind investigators and volunteers in a clinical study. 
Overencapsulation is a process of enclosing a capsule or a tablet in a larger capsule, and 
frequently backfilling with a pellets, granules, or powder to minimize or prevent rattling. 
It eliminates the need to outsource a matching placebo and complex double dummy study 
design. While standard hard gelatin capsules are widely used for overencapsulation of 
double blind clinical trials, they might not always provide the features required for the 
broad variety of clinical trial designs and comparator products. To overcome these 
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limitations for certain trials, specific double blind capsules (DB capsule) have been 
developed. These DB capsules are two-piece hard gelatin capsules uniquely designed for 
double-blind clinical trials, in which the capsule body is completely covered by the 
elongated design of the cap. This makes it virtually impossible to open the capsule 
without causing clearly visible damage, and thus alerting investigators of blind breaking, 
and bias. The wider diameter of DB capsules offers an advantage of relative ease of 
containment of several shapes and sizes of tablets while the shorter length facilitates ease 
of swallowing. Whole tablets can be directly filled into DB capsules and no breaking or 
grinding of tablets is needed, eliminating the concern for inaccurate dosage or 
modification of intended performance of drug. Standard two-piece hard gelatin capsules 
can also be used for blinding tablets for clinical trials; however, in this case, the smaller 
diameter (compared to DB capsules) limits the size of tablet that can be filled into the 
capsule.   
In studies involving overencapsulation, the questions can be asked; will the 
overencapsulation affect parameters such as dissolution, absorption or bioavailability. In 
comparative pharmacokinetic trials, the encapsulation of esomeprazole multiple-unit-
pellet-system, 40 mg tablets using hard gelatin capsules did not influence the rate (Cmax) 
and extent (AUC) of absorption in a study involving 49 volunteers.
112
 Other in vivo 
studies have shown the equivalence of in-vivo disintegration time using gamma 
scintigraphy and therapeutic effect onset time between encapsulated and nonencapsulated 
sumatriptan tablets.
113
 Although some studies have shown that encapsulation may not 
affect in vitro dissolution studies, it could delay absorption and in vivo efficacy of drugs 
that are intended for fast onset of action such as demonstrated in an open trial design with 
 187 
 
patient scoring the headache pain response to a migraine drug.
114
 Dissolution could also 
be affected by low capsule fill weight,
115
 type of filler and the solubility of the drug.
116
  
Using the right capsule size and excipients (backfill) similar to those in the tablet 
formulation could reduce the effect on dissolution.  The solubility of the drug should be 
factored into the blinding process. 
The antiretroviral drugs lamivudine and zidovudine are BCS Class 1 compounds 
whereas nevirapine is a BCS class II compound. Propranolol, a highly soluble highly 
permeable BCS class I chiral drug marketed in the racemic mixture exists as polymorph 
forms I and II. Crystallization solvent, grinding and compression have been reported to 
cause changes of the crystalline state, causing differences in dissolution performance.
117, 
118
 Although propranolol is not hygroscopic, presence of moisture in the backfill could 
cause interparticle surface interaction that could somewhat affect performance of the 
encapsulated tablet.  Rofecoxib, a low solubility and high permeability BCS class II drug 
is susceptible to oxidation and photolysis.
119
 The influence of moisture on the 
disintegration and dissolution of the encapsulated tablets has not been studied for either 
class of drugs.   
The model independent similarity factor (f2) may be used to compare the 
dissolution profiles of two drug products (Eq. A1). This is a measurement of the 
similarity in the percent dissolution between the two curves. An f2 greater than 50 implies 
two dissolution profiles are similar in the percent of drug dissolved per time (9). The 
FDA recommends using only one sample beyond 85% dissolution because the value of f2 
is sensitive to the number of sampling points used in the computation.
120, 121
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Rt and Tt are dissolution values of the reference and test batches respectively at time t, 
and n is the number of points.  The dissolution profiles can be determined using the 
traditional approach of high performance liquid chromatography (HPLC) method or the 
data can be acquired in ―real time‖ using a fiber optic diode array probes or system 
(FOPS).  The latter method was used by Bijlani and Adeyeye in the monitoring of 
dissolution of a multiparticulate ibuprofen system.
122
  They reported that it was much 
faster and accurate than the HPLC method.  
The objective of the study was to investigate the effect of overencapsulation of 
tablets of a BCS class I drug (propranolol) or class II drug (rofecoxib) on in-vitro 
disintegration and dissolution. DB
®
 capsules were compared with Coni-Snap capsules in 
the presence or absence of backfill.  The dissolution was carried out using the Delphian 
FOPS method.  The long-term stability of the overencapsulated products was examined. 
 
A2.2 Experimental 
A2.2.1 Materials 
Propranolol hydrochloride USP tablets (blue color), 20mg, and rofecoxib (VIOXX
®
) 
tablets (yellow color), 25mg, were purchased from Pliva Inc., East Hanover, NJ and 
Merck & Co. Inc., Whitehouse Station, NJ respectively.  DB capsules (DBcaps® Size B) 
and standard gelatin capsules (Coni-Snap® size 00) were supplied by CAPSUGEL 
(Greenwood, SC). Microcrystalline cellulose (Avicel
®
 PH102) was donated by FMC 
Biopolymer (Philadelphia, PA), while Foremost Farms (Baraboo, WI) supplied 
anhydrous lactose. Vankel dissolution apparatus and Delphian
®
 fiber optic dissolution 
monitoring system from Delphian Inc. (Woburn, MA) were used.  
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A2.2.2. Experimental Design  
Two blocks of 2 x 2 x 2 randomized full factorial design were used to determine the 
effect of three independent parameters (Table A2.1). Two levels i.e. 2 drug types 
(propranolol and rofecoxib), 2 capsule types (DBcaps® and Coni-Snap®); 2 filler levels 
(microcrystalline cellulose/lactose 1:1 mixture and no filler) were used in the design. 
 
A2.2.3 Capsule Backfilling 
A predetermined weight of a 1:1 physical mixture of anhydrous lactose:microcrystalline 
cellulose was filled into the capsule body. The tablet was placed on the backfill and the 
capsule cap was snapped on to lock. In cases where backfill was not required, only the 
tablet was filled into the capsule.  
 
A2.2.4 Weight Variation  
Twenty capsules from each batch were weighed and the average weight, standard 
deviation and %RSD computed. To remove bias, the hand filling of the capsules was 
blinded from the analyst who conducted the weight variation experiment. The samples 
were also coded. 
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Table A2.1 Blocks of 2 x 2 x 2 randomized full factorial design 
Run Batch Drug Capsule Filler 
1 1a  R DB None 
2 2a  R ConiS MCC:Lactose 
3 3a  P ConiS MCC:Lactose 
4 4a  P DB None 
5 5a  P DB MCC:Lactose 
6 6a  R DB MCC:Lactose 
7 7a  R ConiS None 
8 8a  P ConiS None 
9 1b  P ConiS None 
10 2b  R ConiS MCC:Lactose 
11 3b  R DB MCC:Lactose 
12 4b  R ConiS None 
13 5b  R DB None 
14 6b  P DB None 
15 7b  P DB MCC:Lactose 
16 8b  P ConiS MCC:Lactose 
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A2.2.5 Disintegration Test  
Vankel disintegration apparatus, running at 30 dips per minute (dpm) and simulated 
gastric fluid (pH 1.2) without pepsin was used for disintegration test. Two randomly 
selected capsules from a batch were tested at a time. This was repeated three times, 
making a total of six capsules from each batch.  The average D-time was then computed. 
Two capsules were run at a time to allow video recorder camera (Kodak MDS 100) to 
capture the process of capsule disintegration. 
 
A2.2.6 Dissolution Analysis 
The Vankel dissolution apparatus and Delphian RAINBOW
TM
 Dynamic Dissolution 
Monitor System consisting of six photodiode array (PDA) probes, cell length 10mm, 
were used. Simulated gastric fluid (pH 1.2) without pepsin, degassed at 40
o
C was used as 
the medium at 37
o
C.  
 
Linearity: A spectrophotometric linearity test was performed to test each individual probe 
for both linearity and reproducibility. Using the blank dissolution medium, the fiber optic 
system first acquired the 100% transmittance. This was followed by calibration involving 
collecting the transmittance from three replicates of six respective standard solutions. 
Percent difference and %RSD were calculated, and linearity determined. 
The dissolution of propranolol was determined using the USP Apparatus I (basket 
method) at 50 rpm in 900mL of simulated gastric fluid. A filtered solution of 20mg 
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propranolol in 900ml simulated gastric fluid was used as the standard. Peak absorbance 
wavelength and baseline correction wavelength were 288nm and 370nm respectively.  
In the case of rofecoxib, the USP Apparatus II (paddle method), at 50 rpm, in 
900mL of simulated gastric fluid was used. A filtered solution of 25 mg rofecoxib in 
900ml simulated gastric fluid was used as the standard. Peak absorbance wavelength and 
baseline correction wavelength were 268 nm and 370 nm respectively. Replicates of eight 
batches were tested making a total of 16 runs.  
 
A2.2.7 Statistical Analysis 
The f2 similarity factor (Eq. 1) was used to compare the dissolution profiles. Six and 16 
time points were used for propranolol and rofecoxib respectively, due to differences in 
the dissolution rates of the two drugs. In comparing the dissolution profiles for 
encapsulated and unencapsulated tablets, the data was normalized for a lag time of 2 min 
(13). The significance of effects of individual parameters and their interaction on 
disintegration time and dissolution were determined using least squares regression model 
(p-value < 0.05).  
 
A2.3 Results and Discussion 
A2.3.1 Weight Variation 
The weights of the samples showed no randomness, the reason being that the 
contributors to the total sample weight (drug weight, capsule weight, and filler weight) 
were fixed with fairly little variation from the mean of the individual parameters.  This 
uniformity was reflected by the low %RSD (0.49 – 1.31%), indicating the process of 
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encapsulation was accurate and efficient.  Rofecoxib had a higher overall weight because 
the original average weight (200 mg) of the tablets was higher than that of propranolol 
(110 mg). 
   
A2.3.2 Disintegration 
Review of the video of the process of capsule disintegration did not reveal any 
differences between DB and standard gelatin capsules. There was an average time lag of 
60 s before the capsules ruptured and the range was 34 s to 70 s. Some capsules did not 
rupture, instead the capsule cap separated from the body, exposing the content to the 
medium. The individual parameters, i.e., capsule type, drug type and filler showed no 
effect on disintegration D-time (Table A2.2).  The effects due to interactions among 
parameters on disintegration time were also not significant.   
The D-time for rofecoxib was slightly higher than for propranolol, possibly due to 
its lower solubility; the average D-times were 3.82 ± 0.28 and 3.69 ± 0.44 min 
respectively.  Comparing the capsule effect, the average D-times were 3.85 ± 0.28 and 
3.67 ± 0.43 min for DB and standard gelatin capsules respectively. However, these 
differences were not statistically significant (p = 0.05). In the case of the filler, average 
D-times were 3.75 ± 0.36 and 3.77 ± 0.39 min for presence and absence of filler 
respectively, an indication that the filler had no effect on disintegration time.   
As expected, the D-time for encapsulated tablets was greater than that for plain 
tablets. D-times for unencapsulated tablets were 1.80 min and 1.93 min compared to 3.69 
and 3.82 min for the overencapsulated propranolol and rofecoxib tablets respectively.  
This is due to time lag required for capsules to rupture and expose content to 
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disintegration medium.  All the samples passed USP specification of D-time of less than 
30min.  The residual plot (Fig A2.1) was random without any trend indicating that the 
parameters had no effect on disintegration time.  
 
Fig A2.1 Residual plot of observed and predicted disintegration time 
 
Table A2.2. Significance of effects of individual parameters and the interaction on 
disintegration time, irrespective of capsule type. 
Source Nparm DF Sum of Squares F Ratio Prob>F 
Drug 1 1 0.072900 0.4382 0.5246 
Capsule 1 1 0.119025 0.7155 0.4195 
Drug*Capsule 1 1 0.297025 1.7856 0.2143 
Filler 1 1 0.000225 0.0014 0.9715 
Drug*Filler 1 1 0.030625 0.1841 0.6780 
Capsule*Filler 1 1 0.000900 0.0054 0.9430 
―DF is degrees of freedom, F Ratio is F-statistic for testing that the effect is zero, and 
Nparm is the number of parameters associated with the effect‖. 
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A2.3.3 Calibration of Fiber-Optic Probes 
All the six Delphian fiber optic probes had good linearity (coefficient of 
determination R
2
 0.9991±0.0004) for propranolol and rofecoxib (Fig A2.2).  The % RSD 
of each probe was less than 2.0 % indicating reproducibility for the different 
concentration levels. The probes passed the percent difference between six probes. 
 
 
 
 
 
 
 
 
 
Fig A2.2 Linear range of the six probes.  
 
A2.3.4 Dissolution 
The time taken for 80 % of the drug to dissolve (T80) was also used to statistically 
compare the results of dissolution profiles. From the significance of effects table (Table 
A2.3), it was observed that the drug used had an effect on T80 (p <0.0001). Although the 
interaction between drug and capsule appeared significant (p = 0.0219), this is of no 
formulation consequence considering the fact that the drugs belong to two different BCS 
classes.  
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The effects due to filler (p = 0.5716) and type of capsule (p = 0.7614) were not 
significant.  The average T80 times were 14.39 and 13.80 min for presence and absence of 
filler respectively.  The differences were not statistically significant. The same weight of 
backfill was used for all capsule types although the DBcaps size B capsules were smaller 
in volume than Coni-Snap size 00 capsules. Differences in T80 for the two capsules types 
were not significant, thus the volume of fill did not have an effect on dissolution profile. 
 
Table A2.3 Significance of effects of individual parameters and their interaction on 
dissolution T80, irrespective of capsule type. 
Source Nparm DF Sum of Squares F Ratio Prob > F 
Filler 1 1 1.3631 0.3447 0.5716 
Capsule 1 1 0.3875 0.098 0.7614 
Drug 1 1 838.8264 212.1287 <0.0001 
Drug*Capsule 1 1 30.2775 7.6568 0.0219 
Capsule*Filler 1 1 6.4643 1.6347 0.2330 
Drug*Filler 1 1 0.5006 0.1266 0.7302 
―DF is degrees of freedom, F Ratio is F-statistic for testing that the effect is zero, and 
Nparm is the number of parameters associated with the effect‖. 
 
 
 
A2.3.5  F2 Similarity Factor 
The dissolution profiles were also compared using the f2 similarity factor. A lag 
time of 2 min was observed for the dissolution profiles of encapsulated and 
unencapsulated tablets, and this was incorporated into f2 computations.
123
 An f2 greater 
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than 50 is an indication that two dissolution profiles are similar. Propranolol attained 
dissolution plateau faster than rofecoxib due to differences in solubility of the drugs in 
the dissolution medium. For propranolol tablets, the f2 between standard gelatin and DB 
capsules was 60.67 indicating that the dissolution curves of the two were similar (Fig 
A2.3). The f2 between unencapsulated propranolol tablets and DB capsules or standard 
gelatin capsules were 59.48 and 53.94 respectively.  The similarity factor between 
rofecoxib tablets encapsulated in DB and CS capsules was 62.48 (Fig A2.4).  The f2 
between unencapsulated rofecoxib tablets and DB capsules or unencapsulated rofecoxib 
tablets and standard gelatin capsules were 56.97 and 54.92 respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig A2.3 Dissolution profiles of propranolol tablets (prop), in Coni-Snap capsule (prop in 
CS) and in DBcaps (prop in DB). 
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Fig A2.4  Dissolution profiles of rofecoxib tablets (Rof), in Coni-Snap capsule (Rof in 
CS) and in DBcaps (Rof in DB). 
   
 
A2.3.6 Long-term Stability  
On storing the encapsulated tablets at room temperature and humidity conditions 
for one year, there were no differences in the dissolution profiles of propranolol and 
rofecoxib tablets encapsulated using DB or standard gelatin capsules. This implies that 
the double walled DB capsules could be used for blinding drug candidates for a clinical 
study. 
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A2.4 Conclusions 
While encapsulation resulted in a lag time of 2-3 min in disintegration compared to the 
unencapsulated tablets, the disintegration and dissolution of propranolol and rofecoxib 
was the same whether tablets were encapsulated in DB capsules or standard gelatin 
capsules. It can thus be expected that in vitro drug release will not be influenced by the 
type of capsule used for overencapsulation in the double blind clinical study.   The 
bioequivalence between the unencapsulated and encapsulated tablet is not inferred in this 
study, however, the in vivo disintegration data of unencapsulated and overencapsulated 
tablets reported by Wilding et al. suggest that the in vitro disintegration lag time is 
negligible in vivo (2).  Nevertheless, it is important to use DB capsules for test and 
comparator dosage forms to correlate in vitro data especially for the high soluble drugs 
(BCS class I). Similarly, the presence or absence of backfill had no significant effect on 
either disintegration or dissolution.  In effect, capsules offer an easy and inexpensive way 
of blinding clinical trials while posing no threat to studies where the performance of two 
drugs is compared.  The use of DB-type capsules offers the added value of an advanced 
design that allows for overencapsulation of tablets with larger diameter and makes blind 
breaking in clinical trial virtually impossible.  
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